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Major depressive disorder (MDD) is a common psychiatric disorder associated 
with considerable morbidity and mortality. The World Health Organization (WHO) 
anticipates that by the year 2020 depression is one of the most disabling conditions, 
both among psychiatric and somatic disorders. MDD puts a high burden on 
individuals and families and, in terms of health care costs, also on society worldwide 
(Gilbody, 2004).
Since ancient times, depression has been recognized as a psychopathological 
condition. This started with the notion that the liability to depression differed from 
person to person and, later on, that the liability to depression varied between families. 
The symptoms defining depression have remained remarkably stable during the 
years; however, the beliefs about their causes have not. Back in time, individuals 
with a depressed mood were said to be ‘melancholic’, due to an excess of black 
bile according to the humoral pathology theory of Hippocrates (460-370 BC). Later 
on, depression was thought to be caused by slow circulation of blood in the brain. 
During the last few years, the focus of research on psychiatric disorders has shifted to 
the biological substrates of these disorders and the role of environmental factors in 
the interplay with genetic factors. Using neuroimaging (both functional and structural 
magnetic resonance imaging (MRI) studies), neurochemical, neuroendocrinological, 
neurocognitive and pharmacological studies, attempts have been made to unravel the 
neurobiological substrates of psychiatric disorders. The knowledge that depression 
is a familial disorder provided the rationale to perform genetic studies of depression. 
While research into the genetics of MDD has been expanding over the last years and 
has identified promising candidate genes and genetic regions of interest, it has also 
given rise to additional questions. An important issue is how to define the phenotype 
of MDD in a way that is relevant for genetic studies and how to reduce the clinical 
heterogeneity of depression.
Before the aims and the outline of this thesis are presented, an introduction is given 
of the clinical characteristics and the epidemiology and etiology of MDD, with a focus 
on genetic studies and gene by environment interaction studies. Specific attention is 
paid to the challenges in genetic studies of multifactorial disorders such as MDD and 
to the concept of endophenotypes (or intermediate phenotypes) in MDD research.
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Major depressive disorder as a clinical disorder
MDD is a psychiatric disorder that aggregates in families. Core symptoms of MDD 
are a depressed mood most of the day and a loss of interest or pleasure in (almost) 
all activities. For a diagnosis of MDD, these core symptoms accompanied by other 
depression-related symptoms have to be continuously present for at least two weeks. 
Table 1a presents an overview of the diagnostic criteria for depressive disorders 
according to the Diagnostic and Statistical Manual of Mental Disorders, 4th edition 
(DSM-IV; American Psychiatric Association, 1994). These symptoms should cause 
clinical distress or impairment of functioning in one or more domains of daily life. 
These impairments might act on social, interpersonal activities and on emotional, 
physical and occupational functioning.
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Table 1a  Diagnostic criteria for major depressive episodes (DSM-IV)
A. Five (or more) of the following symptoms have been present during the 
 same 2-week period and represent a change from previous functioning; 
 at least one of the symptoms is either (1) depressed mood or (2) loss of 
 interest or pleasure.
(1) Depressed mood most of the day, nearly every day, as indicated by 
 either subjective report (e.g., feels sad or empty) or observation made by 
 others (e.g., appears tearful).
 NOTE: In children and adolescents, irritability may be observed.
(2) Markedly diminished interest or pleasure in all, or almost all, activities 
 most of the day, nearly every day (as indicated by either subjective 
 account or observation made by others).
(3) Significant weight loss when not dieting or weight gain (e.g., a change 
 of more than 5% of body weight in a month), or decrease or increase in 
 appetite nearly every day.
 NOTE: In children, consider failure to make expected weight gains.
(4) Insomnia or hypersomnia nearly every day.
(5) Psychomotor agitation or retardation nearly every day (observable by 
 others, not merely subjective feelings of restlessness or being slowed down).
(6) Fatigue or loss of energy nearly every day.
(7) Feelings of worthlessness or excessive or inappropriate guilt (which 
 may be delusional) nearly every day (not merely self-reproach or guilt 
 about being sick).
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Individuals affected with MDD can differ markedly in symptom profiles, age of onset, 
severity, course of disease and their response to antidepressant treatment. In DSM-
IV (American Psychiatric Association, 1994), specifications to describe subtypes 
and characteristics of MDD are used (see also Table 1b). These specifiers define 
the type of symptoms (catatonic, melancholic or atypical), the severity of MDD (mild, 
moderate, severe with or without psychotic features), the course of the disorder 
(single episode/recurrent episodes, chronicity, partial or full remission, seasonal 
pattern, rapid-cycling, with or without full inter-episode recovery) and the onset of the 
disorder (e.g. postpartum onset).
Epidemiology
The lifetime prevalence of depression is estimated to be 15-17% in Caucasians (Bijl 
et al., 1998a; Kessler et al., 1993; Kessler et al., 1994; WHO International Consortium 
in Psychiatric Epidemiology, 2000), and the one-year prevalence is around 5-10% 
(Bijl et al., 1998a; Kessler et al., 2005b; WHO International Consortium in Psychiatric 
Epidemiology, 2000). Prevalence rates of MDD differ substantially for males and 
females, with the latter gender being approximately twice as often affected with 
MDD (ratio 1.7: 1; Kessler et al., 1993). The National Comorbidity Survey-Replication 
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(8) Diminished ability to think or concentrate, or indecisiveness, nearly every 
 day (either by subjective account or as observed by others).
(9) Recurrent thoughts of death (not just fear of dying), recurrent suicidal 
 ideation without a specific plan, or a suicide attempt or a specific plan 
 for committing suicide.
B. The symptoms do not meet criteria for a Mixed Episode.
C. The symptoms cause clinically significant distress or impairment in 
 social, occupational, or other important areas of functioning.
D. The symptoms are not due to the direct physiological effects of a 
 substance (e.g., a drug of abuse, a medication) or a general medical 
 condition (e.g., hypothyroidism).
E. The symptoms are not better accounted for by Bereavement, i.e., after 
 the loss of a loved one, the symptoms persist for longer than 
 2 months or  are characterized by marked functional impairment, morbid 
 preoccupation with worthlessness, suicidal ideation, psychotic 
 symptoms, or psychomotor retardation.
14
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Table 1b  Specifiers associated with mood disorders according to DSM-IV
Mild: A few symptoms, if any, are present beyond what is needed to make a 
 diagnosis, and a person can function normally although with extra effort.
Moderate: The severity of symptoms is between mild and severe.
 Severe Without Psychotic Features: Most symptoms are present and a 
 person  clearly has little or no ability to function.
Severe With Psychotic Features: A person experiences hallucinations or 
 delusions. Psychoses may develop in about 15% of those with major 
 depressive disorder. The presence of delusions and hallucinations often
 interferes with a person's ability to make sound judgments about 
 consequences of their actions and this may put them at risk for harming 
 themselves. Psychotic symptoms are serious  and a person in this condition 
 needs immediate medical attention and  possibly hospitalization.
Single Episode/Recurrent: A first episode is considered "single," 
 subsequent episodes are "recurrent."
In Partial/Full Remission: There is full remission when there is an absence 
 of symptoms for at least two months. For partial remission, full criteria for a 
 major depressive episode are  no longer met, or there are no substantial 
 symptoms but two months have not yet passed.
Chronic: For at least two years a person's symptoms have met criteria for a 
 major depressive episode.
Catatonic Features: Unusual behaviors or movements such as immobility, 
 excessive activity that is purposeless, rigid or peculiar posturing, 
 mimicking others' words or behaviors.
Melancholic Features: A loss of pleasure in most activities or an inability to 
 feel better, even for a short time when something pleasurable happens. 
 Also, at least three of following is  present: the depressed mood is
 distinct (i.e., unlike feelings of bereavement), it is worse in the morning, a 
 person wakes too early in the morning, there is distinct agitation or 
 movements are slowed down,  substantial weight loss, or extreme feelings 
 of guilt. Melancholic features are associated with a person experiencing 
 a specific precursor to the illness and having a better response to 
 antidepressants. Men and women may equally have these features, 
 although they are more common in older people. They may also be more 
 likely to occur in more severe depressive episodes, particularly ones with 
 psychotic features.
Atypical Features: During the last two weeks of major depression or bipolar 
 disorder (depressive episode) or the last two years of dysthymia, a person 
 is able to experience brightened mood when good things happen. 
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(NCS-R) in 9,892 inhabitants of the United States (Kessler et al., 2003) and the 
Netherlands Mental Health Survey and Incidence Study (NEMESIS), held in 7,076 
Dutch adults (Bijl et al., 1998a), observed similar lifetime prevalence differences of 
MDD between genders; 20.1-21.3% in females and 10.9-12.7% in males (Bijl et al., 
1997; Bijl et al., 1998a; Kessler et al., 1993). The gender difference in depression is 
minimal in childhood, increases sharply in adolescence and decreases again in the 
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 Also,  at least two of the following must be present: substantial gain in 
 weight or  appetite, sleeping to much (at nighttime or daytime napping that 
 is at least 10 hours total or two hours beyond normal), body feels heavy or 
 weighted  down, or persistent sensitivity to rejection by others that is related 
 to personal or social difficulties. The sensitivity to rejection tends to be a 
 more long-standing problem. The presence of depression may increase 
 the  sensitivity, although it is often still present when the person is not 
 depressed. Atypical features occur two to three times more often in 
 women. They are also associated with depression beginning at an earlier 
 age (e.g., teens) and possibly more chronic depressive episodes. 
 Personality and anxiety disorders may also be more common.
Postpartum Onset: The depressive episode begins within four weeks of 
 giving birth.
With/Without Full Interepisode Recovery: Describes a long-term course of 
 recurrent major depression or bipolar disorder. The specifiers indicate 
 whether a person recovered from his/her symptoms between the two latest 
 episodes.
Seasonal Pattern: Describes a pattern of depressive episodes in recurrent 
 major depression or bipolar disorder. The symptoms tend to begin (usually 
 fall or winter) and end (usually spring) at particular times of the year.
Rapid-Cycling: Describes a recurrent pattern of depressive and manic 
 episodes in bipolar disorder. A person has had at least four mood episodes 
 during the last 12 months. There is either a general absence of symptoms 
 between episodes or a clear switch from one to its opposite, such as from 
 depression to mania. Rapid-cycling may affect5% to 15% of those with 
 bipolar disorder, and women account for 70%-90% of those with this 
 pattern. Certain medical conditions may be related to rapid-cycling such as
 neurological problems, hypothyroidism, head injury, and mental 
 retardation, as well as treatment with antidepressants. Those who develop 
 a pattern of rapid-cycling may have a less favorable prognosis.
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post-menopausal years because of a decline in the prevalence in females (Hankin & 
Abramson, 1999; Rutter et al., 2003). This gender difference seems to be a universal 
phenomenon across different cultures and treatment settings (Weissman & Klerman, 
1977). Marked differences, however, exist in the overall prevalence of MDD between 
ethnic groups. Cross-national epidemiological surveys have indicated that the lifetime 
prevalence of MDD is very low in some Asian populations with reported prevalences 
of only 1.5% in Taiwanese and 2.9% in Korean populations (Weissman et al., 1996).
There are several factors that might contribute to gender differences in rates of 
psychopathology. First, there are the natural genetic differences between the sexes 
defining the biological differences between males and females (Rutter et al., 2003). 
This involves more than the possession of XY or XX sex chromosomes. Among 
others, processes such as X chromosome inactivation, genomic imprinting and 
gender-specific meiotic events may underlie the gender differences in the prevalence 
of disorders (Rutter et al., 2003). The second factor is the consequence of being male 
or female, including differences in prenatal hormone programming influencing brain 
development, slower rates of biological maturation in males, experiences that are 
restricted to one gender (such as being pregnant) and lifestyle differences that are 
socially and culturally defined. The third factor regards possible gender differences in 
exposure to environmental risks or protective factors, or differences in susceptibility to 
stress or adversity. It has been shown that males and females differ in hypothalamus-
pituitary-adrenal (HPA) axis responsivity in reaction to stress (for review see Kudielka 
& Kirschbaum, 2005). Furthermore, personality traits and cognitive and affective 
coping styles can differ between the genders (Rutter et al., 2003). All these factors 
may be involved in mediating the gender differences in psychopathology.
Comorbid disorders in MDD
Comorbidity seems to be the rule rather than the exception in patients with lifetime 
MDD (de Graaf et al., 2002b; Kessler et al., 2003). More than two-thirds (72.1%) of 
subjects with lifetime MDD experience more than one axis I disorder (de Graaf et al., 
2002b; Kessler et al., 2003) and only in 19% of males and 30% of females diagnosed 
with lifetime MDD, no other psychiatric disorder is reported (Kessler et al., 1996). 
Especially generalized anxiety disorder (GAD), several additional anxiety disorders 
(Middeldorp et al., 2005b) and alcohol abuse and dependence (Merikangas et al., 
1994; Merikangas et al., 1996) are common comorbid disorders in MDD. Dysthymia 
occurs frequently as a comorbid condition as well (Keller, 1994), though the question 
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remains whether dysthymia is a separate, co-occurring disorder or whether it lies on 
the continuum of depressive disorders (Donaldson et al., 1997).
Several models have been described to explain comorbidity between psychiatric 
disorders (Klein & Riso, 1993; Neale & Kendler, 1995). The first and most prominent 
model explains the co-occurrence of two disorders by shared genetic factors 
(common etiology). In a second model, disorder A is seen as a risk factor for the 
development of disorder B. A third model explains comorbidity by disorder A 
generating symptoms of disorder B in an individual being invulnerable to disorder 
B itself (epiphenomenon). A fourth model describes that above a certain threshold, 
symptoms of disorder B occur in disorder A (extreme multiformity). A fifth model 
explains comorbidity as disorders A and B having independent distributions and the 
comorbid disorder being an independent disorder (disorder AB). A further possible 
explanation for the occurrence of comorbidity is that disorders A and B are presenting 
together due to artefactual causes (chance, sampling bias, population stratification 
or classification system issues) (Klein & Riso, 1993; Middeldorp et al., 2005b; Neale 
& Kendler, 1995).
Besides the gender difference in the prevalence of MDD as discussed above, 
gender differences exist in the prevalence of MDD comorbid axis I disorders, as 
well. Comorbid simple phobias and bulimia nervosa are more prevalent in females, 
whereas substance abuse and substance dependence are more prevalent in males 
(Fava et al., 1996; Carter et al., 1999). In general, females are more likely than males 
to have three or more comorbid disorders (Kessler et al., 1994).
Etiology
Depression is a multifactorial disorder with multiple genetic as well as environmental 
factors influencing the development of the disease. For example, biological and 
psychosocial factors might affect gene expression; psychosocial and genetic factors 
might affect other biological factors; and biological factors might affect the response 
to psychosocial factors (Kaplan & Sadock, 1998). The involvement of multiple factors 
in the development of MDD and the interaction between them may lead to the clinically 
heterogeneous expression of the disorder. The presence of comorbid disorders adds 
to the heterogeneity of MDD. In addition, the genetic contribution to MDD is through 
multiple genes of small effect, rather than through a few genes of major effect. These 
1
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factors are leading to challenges in etiologic studies of MDD, and in genetic studies in 
particular. Below, quantitative genetic studies of the epidemiology of MDD, a number 
of genetic linkage and association studies, environmental risk factor and gene by 
environment interaction (G x E) studies in MDD are described. Subsequently, the 
challenges in etiologic studies of MDD are discussed.
Quantitative genetics of MDD
Family and twin studies have shown that MDD is a familial disorder: an average 
risk ratio of 2.8 for major depression has been observed in first-degree relatives 
of MDD subjects compared to relatives of controls, indicating a moderate level of 
familial aggregation (for review see Sullivan et al., 2000). Twin studies have shown a 
concordance rate of 50% for MDD in monozygotic twins (who are identical in their 
genetic information and share most of their environment). For dizygotic twins (who 
share on average 50% of genetic information, but also most of their environment), the 
concordance rate is lower, around 10-34% (Sullivan et al., 2000), substantiating the 
role of genetic factors in causing the disorder. Heritability estimates in the range of 
35%-40% have been retrieved for MDD from twin studies (Kendler et al., 2006b; Shih 
et al., 2004; Sullivan et al., 2000).
The gender difference in the prevalence of MDD has led researchers to examine 
whether the etiologic constellation of MDD differs by gender. Studies of gender 
differences in the type (different genes) and strength of genetic risk factors (different 
magnitude of effects) of MDD have shown inconsistent results. Some studies did 
not observe gender differences in the heritability of MDD (Kendler & Prescott, 
1999; McGuffin et al., 1996; Sullivan et al., 2000), whereas a twin study observed 
substantially higher correlations for liability to lifetime depression in female-female 
pairs than in male-male pairs (Kendler et al., 2006b). This twin study together with 
some others concluded that gender differences exist in the heritability of MDD, with 
a significantly higher heritability in females (40-42%) than in males (29-31%) (Bierut 
et al., 1999; Kendler et al., 2001; Kendler et al., 2006b). Nevertheless, the genetic risk 
factors for MDD appear to be moderately correlated in males and females (0.55-
0.63), which suggests that some genetic influences are shared between genders, 
but also that a substantial proportion of the genetic risk factors are gender-specific in 
their effect (Kendler et al., 2006b).
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Molecular genetic studies
Two ways of studying the molecular genetic aspects of MDD are genome-wide 
linkage and association approaches, both strategies having their pros and cons.
Genome-wide linkage analysis is a hypothesis-free approach based on the co-
segregation of a marker allele with a disease allele within families (Eley & Rijsdijk, 
2005). In general, the more proximal two genes or markers are on the genome, the 
less likely that crossover and recombination will occur between them during meiosis 
and the more likely that the two genes/markers will be transmitted together to the next 
generation (co-inheritance). If a certain genetic marker is more commonly shared in 
relative pairs concordant for disease than in discordant relative pairs, the disease 
and marker are said to be linked (Sham & McGuffin, 2002). The marker itself might 
not be of etiologic importance, but may be inherited along with a nearby located 
disease-causing locus (Eley & Rijsdijk, 2005). The linked locus can be narrowed 
down by examining additional markers. A limitation of linkage designs (in addition to 
their suitability for identification of large gene effects only) is the need of a sufficient 
amount of suitable pedigrees to keep statistical power (Sham & McGuffin, 2002). 
Furthermore, genetic loci identified by linkage analysis are generally quite large, 
encompassing up to hundreds of genes, from which it can still be very difficult to 
extract the true disease gene.
A more powerful and straightforward approach for the identification of disease genes 
in multifactorial disorders is association, which can be applied in a candidate gene-
based or genome-wide manner (Eley & Rijsdijk, 2005). In genetic association studies, 
case-control designs are often used to investigate whether a particular allele occurs 
at a significantly different (higher or lower) frequency in affected individuals compared 
to unaffected individuals (Eley & Rijsdijk, 2005). A typical association approach is to 
select candidate genes or regions based on earlier genome-wide linkage results, 
studies in animal models or from pharmacological studies (hypothesis-driven) 
(Strachan & Reid, 2004). In candidate gene association studies, one tries to identify 
polymorphisms with (functional) significance to the trait. However, since theories 
regarding the etiology of the disorder might not be (entirely) correct or complete, 
candidate gene studies are unlikely to discover all genetic risk factors for disease.
Relatively new in the field of discovering genes for multifactorial disorders are 
genome-wide association studies (GWAS). GWA analyses are hypothesis-free, the 
entire genome is examined and subjects are genotyped for 315,000 to 1,000,000 
1
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single nucleotide polymorphisms (SNPs). If certain genetic markers are significantly 
more (or less) frequent in subjects with the particular trait, the marker is said to be 
associated with that trait. The associated markers point out a region in which a gene 
for the trait or phenotype is located. GWAS make use of linkage disequilibrium (LD). 
LD describes the correlation between two alleles at different loci. Alleles that are tightly 
linked on the same chromosome are unlikely to be separated through recombination 
in meiosis, even through many generations, causing some combinations of alleles 
or genetic markers to occur more frequently than expected in the population by 
chance. In GWAS, due to the LD-based selection of polymorphisms, the apparently 
associated allele might therefore not have a direct effect on disease risk, but is likely 
to be in LD with another allele at a nearby locus that is the actual risk factor (Sham 
& McGuffin, 2002). Due to the necessity of investigating so many markers, the costs 
of GWAS are still extremely high, the statistical power is often relatively poor (due 
to limited sample size) and the chance of false-positive results is high if correction 
for multiple testing is not rigorously applied (Baker, 2008; McCarthy et al., 2008; 
McCarthy & Hirschhorn, 2008). A further general limitation of case-control association 
approaches is the chance of population substructure being present. Population 
substructure or stratification implies that genetically distinct subsets are present in 
the population, possibly having variation in both the allele and disease frequency, 
which might cause spurious association. However, stratification can be minimized 
using family-controlled designs or applying genomic control (Eley & Rijsdijk, 2005; 
Sham & McGuffin, 2002).
Genome-wide linkage and association studies in MDD
Genome-wide linkage analyses in MDD patients have identified a considerable 
number of regions of interest, but only some of these have been replicated in at least 
one study, so far (see Table 2) (Camp et al., 2005; Holmans et al., 2004; Holmans et 
al., 2007; Levinson et al., 2007; McGuffin et al., 2005; Zubenko et al., 2002b; Zubenko 
et al., 2003b; Zubenko et al., 2003a; Zubenko et al., 2004). In genetic linkage studies 
in families with recurrent, early-onset MDD, a number of significant results were 
observed. Interestingly, some regions were only significant among female affected 
relative pairs, but not among male affected pairs (Zubenko et al., 2002b; Zubenko 
et al., 2003b), like a linkage region on chromosome 2q which was only observed in 
females (Zubenko et al., 2002b; Zubenko et al., 2003a). Chromosome 8p appeared 
to be related to several MDD-related phenotypes (Zubenko et al., 2004) and had a 
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gender-specific effect in males (Holmans et al., 2004). As Table 2 shows, more (but 
still unreplicated) male-specific regions with suggestive or statistical evidence for 
linkage have been described (Abkevich et al., 2003; Camp et al., 2005; Holmans et 
al., 2004; Holmans et al., 2007; Zubenko et al., 2003b). Differences in study design, 
sample recruitment, sample size, analytic methods and heterogeneity of phenotype 
might all contribute to inconsistencies in the reported linkage results.
1
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Table 2  Overview of genome-wide linkage studies of MDD
Study Sample  Statistical Female- Male-
 selection significant  specific specific
  or suggestive  loci loci
  loci 
Zubenko Recurrent early- 1p, 1q, 2q, 4q, 2q, 4q, 5q, 5q
et al. 2003b onset MDD 5q, 8p, 10p,  Xq
  10q, 11p, 11q, 
  15q, 18q, 19p, 
  19centr, Xq   
Abkevich  Families with >3 12q  12q
et al. 2003 members affected 
 with MDD   
Holmans  Families with one 15q  6q, 8p, 
et al. 2004 affected sibling pair    17p
 with recurrent MDD 
Zubenko  Recurrent early- 2p, 5q, 6q, 8p, NA NA
et al. 2004 onset MDD with a 11q, Xq   
 history of suicide 
Camp  Families with >2 3centr, 7p, 18q  4q, 15q
et al. 2005 members affected 
 with MDD   
McGuffin  Sibling pairs with 12q, 13q, 15q 1p
et al. 2005 recurrent unipolar 
 depression   
Holmans  Families with one 15q  8p, 17p
et al. 2007 affected sibling pair 
 with recurrent MDD   
Regions indicated in bold have been replicated.
NA = not analyzed. 
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Genome-wide association studies of depression have not been published so far, but 
are currently in preparation (e.g. Boomsma et al., 2008). However, GWA studies of 
neuroticism, a vulnerability trait for depression and sharing genetic determinants with 
MDD, have revealed new candidate genes of neuroticism (Shifman et al., 2008; van 
den Oord et al., 2008: for an overview, see chapter 6).
Candidate gene association studies: the 5-HTT and BDNF genes
Multiple candidate genes have been studied for their role in MDD, among others 
the genes encoding the brain-derived neurotrophic factor (BDNF), the serotonin 
transporter gene (5-HTT), the serotonin receptor 1A and 2A (5-HTR1A and 
5-HTR2A), tryptophan hydroxylase 1 (TPH1), catechol-O-methyl transferase (COMT), 
phospholipase A2 (PLA2) and the glucocorticoid receptor (NR3C1) (Levinson, 2006; 
Lopez-Leon et al., 2008; Mill & Petronis, 2007). The candidate gene studies have 
provided rather inconclusive results, so far. The most prominent candidate genes in 
MDD research are the 5-HTT and BDNF genes.
The serotonin neurotransmitter system is directly implicated in the pathophysiology 
of mood disorders (Kaplan & Sadock, 1998). Serotonergic dysfunction has been 
reported in several brain regions in individuals with MDD (Arango et al., 2002). The 
5-HTT gene (official name SLC6A4) is located on 17q11.1-q12 (Heils et al., 1996; Lesch 
et al., 1996) and the protein product of this gene is the target of selective serotonin 
reuptake inhibitors (SSRIs). This gene is comprised of 14 exons. An insertion/deletion 
polymorphism with a short allele (s-allele; 14 copies of a 20-23 base pair repeat unit) 
and a long allele (l-allele; 16 copies) has been described in the promoter of the gene 
(Heils et al., 1996; Lesch et al., 1996). This variant, denoted 5-HTTLPR, is a functional 
polymorphism in which the short variant is associated with lower 5-HTT transcription 
and function compared to the long variant (Lesch et al., 1996). This results in lower 
serotonin reuptake from the synaptic cleft in s-allele carriers compared to subjects 
homozygous for the l-allele (Collier et al., 1996). The serotonin transcription efficiency 
influences mood tone, circadian and neuroendocrine functions such as sleep, 
appetite, sexual behavior, and motor function (Lesch & Mossner, 1998). These 
features are often disturbed in depression.
Multiple association studies of the 5-HTTLPR in MDD have been performed. Three 
meta-analyses (Furlong et al., 1998; Lopez-Leon et al., 2008; Lotrich & Pollock, 2004) 
described a small but significant effect of s-allele carriership and the s/s genotype on 
increased risk of depression. However, another meta-analysis (Lasky-Su et al., 2005) 
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did not observe a significant association between the 5-HTTLPR variant and MDD.
Another gene of interest to MDD is the BDNF gene, located on chromosome 11p13 
(Maisonpierre et al., 1990). The BDNF gene codes for a neurotrophin which is highly 
expressed in the central nervous system, especially in the hippocampus (Martinowich 
et al., 2007; Willis-Owen et al., 2005), and plays a role in the proliferation, differentiation 
and survival of neuronal cells (Bath & Lee, 2006; Duman, 2004; Schumacher et al., 
2005). Furthermore, BDNF regulates synaptic plasticity and connectivity in the adult 
brain (Angelucci et al., 2005; Bath & Lee, 2006). According to the ‘neurotrophic 
hypothesis’ of depression (Duman, 2004), stress leads to a reduction of BDNF 
expression which, in turn, causes atrophy and cell loss in brain regions controlling 
mood and depression, such as the hippocampus and cerebral cortex. Further 
evidence of involvement of BDNF in depression comes from pharmacological studies 
which have shown that the use of antidepressants leads to an upregulation of BDNF 
in the hippocampus of depressed subjects (Angelucci et al., 2005; Duman, 2004; 
Duman & Monteggia, 2006; Shimizu et al., 2003). In a study by Chen et al. (2001), 
increased BDNF expression was found in humans with antidepressant medication at 
the time of death, compared to depressed individuals untreated at the time of death. 
Therefore, it has been suggested that BDNF is involved in the pathophysiology of 
MDD (Angelucci et al., 2005; Duman, 2004; Karege et al., 2002; Lang et al., 2005; 
Schumacher et al., 2005). Several candidate gene studies of the BDNF gene have 
been performed, investigating a SNP (rs6265) in exon 11 of the BDNF gene resulting 
in an amino acid substitution from valine to methionine at codon 66 (Val66Met) in 
the prodomain of the BDNF gene (Schumacher et al., 2005). The BDNF risk allele for 
depression and depression-related traits has not been clearly defined, however. A 
number of studies did not observe an association of the Val66Met polymorphism with 
MDD (Cohen et al., 2004; Oswald et al., 2005; Schumacher et al., 2005; Surtees et 
al., 2007), whereas other studies suggested the Met allele to be associated with MDD 
and MDD-related phenotypes or traits (Chen et al., 2006; Egan et al., 2003; Hariri et 
al., 2003; Hwang et al., 2006; Ribeiro et al., 2007). This is coherent with the finding that 
the Met allele of this polymorphism is associated with abnormal intracellular sorting of 
BDNF and altered hippocampal structure and function (Egan et al., 2003). However, 
in other studies the Val allele has been found associated with the development of 
depression (Lang et al., 2005; Sen et al., 2003) and a family-based study showed 
the Val allele to be associated with childhood-onset mood disorders (Strauss et al., 
2005). Meta-analyses of the Val66Met polymorphism have not yielded significant 
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associations with MDD, so far (Chen et al., 2008; Gratacos et al., 2007; Lopez-Leon 
et al., 2008).
The 5-HTT and the BDNF genes in comorbid disorders
In general, genetic studies often focus on a particular disease, without taking 
into account the presence of comorbid disorders. However, several studies have 
suggested shared genetic vulnerabilities between disorders (common etiology) 
(Gorwood, 2004; Kendler et al., 1993a; Kendler et al., 2003; Middeldorp et al., 
2005b). Therefore, knowledge of the presence of comorbid disorders in MDD may be 
of importance for MDD research. For the comorbid disorders commonly associated 
with MDD, such as alcohol-related disorders and anxiety disorders, candidate gene 
studies of the 5-HTT and BDNF genes have also been performed. A meta-analysis 
of alcohol use disorders described a significant association of the s-allele of the 
5-HTTLPR polymorphism with alcohol dependence, although the effect was small. It 
appeared that the effect was largest in the presence of comorbid psychopathology 
(Feinn et al., 2005). Regarding anxiety, genetic studies have primarily focused on 
anxiety-related traits (Middeldorp et al., 2007; Osher et al., 2000; Schinka et al., 2004; 
Sen et al., 2004), rather than on specific anxiety disorders. However, a few studies 
of the latter kind are to be mentioned, here. For GAD, a positive association with the 
s-allele of the 5-HTTLPR was observed in a case-control study in Chinese subjects 
(You et al., 2005). In a meta-analysis of panic disorder, no significant association 
with the 5-HTTLPR polymorphism was observed (Blaya et al., 2007), whereas in a 
meta-analytic study of obsessive compulsive disorder (OCD) an association with the 
s-allele of the 5-HTTLPR polymorphism was shown, though this effect was essentially 
accounted for by one study (Lin, 2007). In addition to these studies, one association 
study of the 5-HTTLPR polymorphism has been performed to dysthymia in a 
Brazilian sample (Oliveira et al., 2000). This did not reveal any significant association 
findings.
Studies of the BDNF Val66Met polymorphism in MDD comorbid disorders are limited. 
An association study of alcohol dependence in Japanese males did not show an 
effect for the Val66Met polymorphism (Tsai et al., 2005), nor did a second study 
by Zhang et al. (2006) in a sample of alcohol dependent European Americans. A 
meta-analysis of substance use related disorders (both alcohol and drugs) with 
predominantly Asian samples showed a protective effect against substance use 
related disorders in subjects carrying the Met allele (Gratacos et al., 2007). For 
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the relation of the Val66Met polymorphism with anxiety disorders, the same holds 
as for the 5-HTTLPR polymorphism. Most studies measured anxiety-related traits 
(Hunnerkopf et al., 2007; Jiang et al., 2005; Lang et al., 2005; Willis-Owen et al., 2005), 
rather than DSM-IV anxiety disorders. Studies of panic disorder in Asian subjects 
(Lam et al., 2004; Shimizu et al., 2005) and a study of OCD (Wendland et al., 2007) 
did not report a significant association with the BDNF Val66Met polymorphism.
Environmental factors
As the heritability of depression is around 35-40%, the remaining part of the variance 
should be (mostly) explained by environmental factors. These can be divided into 
shared environmental risk factors (circumstances to which individuals from the same 
family are equally exposed) and individual-specific environmental factors (events and 
circumstances to which individuals from the same family are not equally exposed). 
Studies suggest that individual-specific environmental risk factors are involved in the 
etiology of depression (58-67%), whereas the influence of shared environmental risk 
factors seems negligible (Sullivan et al., 2000).
In twin studies as well as studies in community samples, several environmental 
risk factors for the development of depression have been examined. Childhood 
sexual abuse, parental loss, negative parent-child relationships, lifetime trauma, low 
educational attainment, low social support, marital problems and being divorced, 
financial difficulties and stressful life events were identified as risk factors for MDD 
(Brown & Harris, 1978b; Kendler & Gardner, 2001; Kendler et al., 2002; Kendler et 
al., 2006a; Lewinsohn et al., 1988; Parker, 1979; Weissman et al., 1991). Research 
of environmental factors in depression has shown that the depressogenic effects 
of these factors depend on the level of threat induced by them. This research also 
indicates that so called ‘life events’, a concept used to make the environmental factors 
measurable, are related to the onset of depression and have stronger effects on first 
onset depression than on recurrent depression (Uher & McGuffin, 2008).
It is of importance to determine which environmental factors might increase (or 
decrease) the risk of disease (Hunter, 2005), as this could guide the development of 
preventive treatment programs for high-risk individuals (Mitchell et al., 2003).
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Gene by environment interplay
Gene by environment (G x E) interaction studies investigate whether genes control 
sensitivity to environmental factors (or whether the environment controls the effects 
of genes) (Boomsma & Martin, 2002). The current view in MDD research is that a 
genetic predisposition to MDD will be (co)determined by environmental risk factors 
that might facilitate the development of the disorder (Lesch, 2004).
An influential G x E study in this field, performed by Caspi and colleagues (2003), 
showed a dose-response effect: individuals homozygous for the s-allele of the 
5-HTTLPR polymorphism in the gene encoding the serotonin transporter, described 
above, were significantly more likely to develop depression after experiencing a 
number of stressful life events (such as illness, romantic losses or bereavement) than 
individuals homozygous for the l-allele. The risk for heterozygous individuals was 
intermediate. Building on the findings of Caspi et al. (2003), an interesting finding 
was that mild stressful life events had greater depressogenic effects than the more 
severe life events (Uher & McGuffin, 2008). The findings of the Caspi et al. G x E 
study have been replicated eleven times, also three nonreplications and some partial 
replications (in females only) have been reported (Uher & McGuffin, 2008). For 
positive environmental factors (such as social support) similar associations have been 
described as for negative events (Kaufman et al., 2004; Wilhelm et al., 2006). This 
suggests that the 5-HTTLPR polymorphism renders s-allele carriers more sensitive to 
environmental factors in general (Uher & McGuffin, 2008). Studies in adolescents (Eley 
et al., 2004; Sjoberg et al., 2006) have shown intriguing gender-specific interactions 
for the 5-HTTLPR polymorphism; female s-carriers were significantly more vulnerable 
to depression in the presence of particular environmental factors, whereas in males 
no significant effects (Eley et al., 2004), or even protective effects (Sjoberg et al., 
2006) were observed.
The 5-HTTLPR by environment interaction is not diagnosis-specific, however. 
Positive G x E interactions for this polymorphism in interaction with life events have 
also been described for other phenotypes and traits, such as alcohol and drug use 
(Covault et al., 2007; Uher & McGuffin, 2008). Perhaps this is caused by a feature 
presenting in several phenotypes (such as personality or behavioral traits) that is 
actually responsible for the observed interaction findings.
Regarding the BDNF Val66Met polymorphism, less G x E studies have been performed. 
The first G x E interaction study of the Val66Met polymorphism in a sample of elderly 
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Asian depressed subjects (Kim et al., 2007) showed that the number of experienced 
life events was significantly associated with depression in Met/Met homozygotes and 
Val/Met heterozygotes. A replication study by Wichers et al. (2007) in females only 
found a significant interaction between adverse events and the BDNF Met allele for 
the risk of depression, as well.
Endophenotypes
A strategy to reduce both clinical heterogeneity and genetic complexity of 
multifactorial human disease phenotypes is the use of endophenotypes in genetic 
studies. Endophenotypes (or intermediate phenotypes) are measurable components 
that lie intermediate between genes and the disorder (Gottesman & Gould, 2003). 
Psychiatric diagnoses are often clinically and genetically heterogeneous and could 
be decomposed into better measurable traits with the underlying idea that stronger 
and/or less genetic factors are involved in those traits, and thus the chance of 
discovering the underlying genes is increased (Flint & Munafo, 2007; Gottesman & 
Gould, 2003).
Endophenotypes should ideally meet a number of criteria, such as being related 
to the illness in the population, being heritable and being state-independent. 
Endophenotypes should also co-segregate with the illness within families, and 
lastly, they should be found in a higher rate in unaffected family members than in 
the general population (Gottesman & Gould, 2003). Endophenotypes for psychiatric 
disorders can be found in the field of neuropsychological, cognitive, biochemical, 
endocrinological, neuroanatomical and neurophysiological measures.
Putatively useful endophenotypes for depression are, among others, measures of 
the HPA axis, rapid eye movement (REM) sleep abnormalities and certain personality 
traits, in particular neuroticism (Hasler et al., 2004). The neuroticism trait is known 
to meet the proposed criteria for an MDD endophenotype and has already been 
successfully used as a trait in genetic studies (Sen et al., 2003; Shifman et al., 2008; 
van den Oord et al., 2008) (see chapter 6 for an overview of genetic studies of 
neuroticism).
Despite the endophenotype concept having emerged as a promising strategy 
to dissect the genetics of psychiatric diseases, to identify vulnerability genes of 
downstream features of clinical phenotypes, and to resolve questions about etiologic 
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models, it is not yet entirely clear that the genetics of endophenotypes will be easier 
to dissect than the genetic basis of psychiatric phenotypes. For a critical review 
of the endophenotype approach, illustrated by meta-analyses of the COMT gene 
in relation to executive functions as endophenotypes, see Flint & Munafò (2007). 
Nonetheless, studies in attention-deficit / hyperactivity disorder (ADHD), for example, 
have suggested that endophenotypes may indeed enable more powerful genetic 
studies (Rommelse et al., 2008). Moreover, endophenotype studies could also lead 
to the identification of trait markers for disease susceptibility and biological markers 
of disease (Flint & Munafo, 2007), which could aid in reducing the phenotypic 
heterogeneity of MDD needed to detect vulnerability genes for MDD further (Hasler 
et al., 2004).
Methodological challenges in genetic studies of MDD
A phenomenon (called the ‘winner’s curse’) observed in genetic reserach of 
complex disorders, which includes psychiatric disorders, is that the first published 
genetic studies on a genetic factor involved in a particular disorder describe strong 
findings, which are followed by findings of only marginal or even opposite effects 
in subsequent research (Ioannidis et al., 2001). Overall, for (candidate gene-based) 
association studies, the rate of replication is very low (Colhoun et al., 2003; Ioannidis 
et al., 2001). Some general difficulties in replicating and reporting genetic linkage 
and association findings have been described for complex disorders (Colhoun et al., 
2003; Lander & Kruglyak, 1995). The reasons that might account for inconsistency 
and nonreplication in genetic studies are outlined below. Some problems mainly arise 
from psychopathological or genetic matters, others more from statistical matters.
With regard to psychopathological factors, clinical heterogeneity in MDD and the 
psychobiological complexity of MDD might play a role in the failure to replicate. As 
outlined earlier, the clinical presentation of MDD differs markedly between individuals. 
The diagnosis of MDD encompasses several distinct symptoms and illness-related 
characteristics, such as age of onset and severity of the disorder, which implies that 
different studies examining MDD do not necessarily measure the same phenotype. 
The high rate of comorbid disorders also adds to the clinical heterogeneity in MDD 
and leads to reduced homogeneity of the study groups. A further issue is that it is 
unknown which phenotype should be used in molecular genetic studies (Buitelaar, 
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2005). The clinical MDD diagnosis is mostly assessed by the use of classification 
schemes such as DSM-IV or the International Classification of Diseases-10 (ICD-10) 
and these do not per se reflect underlying neurobiological processes (Lesch, 2004) 
or optimal phenotypes for genetic research (Buitelaar, 2005) and may therefore be 
suboptimal for use in genetic studies.
Another factor complicating the replication of genetic studies is that of genetic 
heterogeneity (different sets of genes being responsible for the risk of a disease) 
(Buitelaar, 2005). In polygenic disorders such as MDD, multiple loci of modest effect 
interacting with each other and with environmental factors most probably produce 
vulnerability to the same disorder (Mill & Petronis, 2007). A further explanation for 
nonreplication related to genetic issues arises through the fact that genetic findings 
might not be replicable due to allelic heterogeneity between ethnic groups. Studies 
of subjects from another ancestry may lead to replication failures due to differences 
in the LD structure between samples from different ethnic backgrounds. Population 
stratification is also a source for nonreplication or inconsistent findings. This type of 
stratification is observed if subpopulations with different allele frequencies or disease 
risks are included in one study sample. This may confound the outcome of interest 
and can lead to false-positive results. In addition, environmental factors that differ 
between studies or study groups might also lead to false-positive findings or the 
nonreplication of association findings.
Inconsistencies in genetic findings can also be based on statistical grounds, through 
the variation in power between studies (Colhoun et al., 2003). Very large samples are 
required for the consistent identification of genes of small effect, but genetic studies 
are frequently underpowered (Colhoun et al., 2003). An additional factor which may 
complicate insights in the field of genetic studies is publication bias. Negative results 
have less chance of getting published compared to positive results. This could lead 
to misleading results when reviewing the studies (Colhoun et al., 2003) or when 
performing meta-analyses.
The inclusion of comorbid disorders in the phenotype, gender-specific analyses and 
the use of (putative) endophenotypes could be of particular interest to solve some of 
the challenges described above in genetic studies of MDD.
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Aims and outline of this thesis
As MDD is a clinically and genetically highly heterogeneous disorder complicating 
its genetic dissection, the overall aim of this thesis was to explore whether molecular 
genetic studies of MDD can be improved by redefining the phenotype of MDD 
and investigating which factors should be taken into account in genetic research 
of MDD. Three samples have been used in the studies included in this thesis: 1) a 
clinical sample with lifetime depression (GenMood), 2) a population-based sample 
with lifetime depression selected from the Netherlands Mental Health Survey and 
Incidence Study (NEMESIS) and 3) a population-based sample with healthy controls 
selected from the Nijmegen Biomedical Study (NBS).
The clinical sample was collected in the context of a study into the genetics of MDD 
(GenMood). Recruitment started in 2004 in the Netherlands. Individuals with a lifetime 
diagnosis of major depression and a familial vulnerability to depression (having at least 
one first-degree relative with a history of MDD) were recruited. Eligible participants 
were phenotyped and endophenotyped on the basis of diagnostic, temperamental, 
cognitive, endocrinological and life-style measures (see chapters 2 and 4).
The population-based sample with lifetime depression was drawn from NEMESIS 
(Bijl et al., 1998b). NEMESIS studies the prevalence, incidence, course and 
determinants of psychiatric disorders in a representative sample of Dutch adults. The 
first measurement phase involved 7,076 individuals (69.7% response) and took place 
in 1996. Data from depressed cases within this population-based sample were used 
for the analyses described in chapters 2 and 3.
The second population-based sample used in this thesis was drawn from NBS. NBS 
is a cross-sectional survey conducted by the Radboud University Nijmegen Medical 
Centre in 2002-2003, with a second assessment in 2006. NBS is based on an age- 
and sex-stratified random sample of the population of Nijmegen. In NBS, subjects 
were questioned for several purposes. Among others, lifestyle information, personality 
assessments, history of depression (and other psychiatric disorders), family history 
of depression, medical history and blood samples were collected. Informed consent 
was obtained for the collection of questionnaire data, blood collection, linkage to 
population and disease registries, collection of additional clinical data from medical 
records and retaining identifying information for the duration of 25 years. From 
the NBS sample, 2,080 individuals were selected for genome-wide genotyping in 
collaboration with deCODE genetics, Reykjavik, Iceland (chapter 6).
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The influence of familiality of MDD on comorbidity and the role of gender
In chapters 2 and 3, the effect of familiality of MDD on the presence of comorbid axis 
I disorders and the role of gender within this relationship was investigated.
The central question in chapter 2 was whether familiality of MDD influenced the 
presence of comorbid axis I disorders in individuals with MDD. More specifically, 
we tested whether population-based familial MDD (f-MDD) and nonfamilial MDD (nf-
MDD) were associated with different patterns of comorbidity. Since more comorbidity 
is expected to be present in clinical samples, the clinical f-MDD sample (GenMood) 
was studied as well. In addition, we investigated whether MDD characteristics, such 
as age of onset, disease course and severity, influenced the association between 
familiality of MDD and comorbidity patterns.
In chapter 3, we aimed at investigating whether gender differences in lifetime 
comorbidity patterns were affected by familiality of MDD. This study was performed 
in the familial and nonfamilial MDD samples from the NEMESIS study. As age of 
onset, disease course and severity of MDD are associated with familial MDD, we 
also investigated whether gender differences in lifetime comorbidity patterns 
were associated with these MDD characteristics, in addition to familiality of MDD. 
In conjunction with chapter 2, this study of the relationship between familiality of 
MDD and gender differences in comorbid disorders was performed to add to our 
knowledge of the clustering and etiology of comorbidity in males and females.
These studies could be expected to create more insight in MDD phenotypes relevant 
for genetic studies. If familiality of MDD and gender would be found associated with 
the presence of specific comorbid disorders, this would be an important factor to take 
into account in research into MDD etiology (as well as possibly in MDD treatment).
The role of the 5-HTTLPR polymorphism in MDD and comorbid disorders
Chapter 4 describes an association study of the 5-HTTLPR polymorphism in the gene 
encoding the serotonin transporter and MDD plus comorbid disorders in the clinical 
GenMood sample with f-MDD cases. Since prevalences of comorbid disorders vary 
between females and males, we also performed the analyses separately for males 
and females to investigate potential gender differences in the relationship of the 
5-HTTLPR polymorphism with a particular phenotype.
As said before, the serotonin transporter gene (5-HTT) is a frequently studied 
candidate gene in MDD research¸ but these studies have revealed inconsistent 
results. This might partly be due to the high prevalence of comorbid disorders in 
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MDD which contributes to the phenotypic heterogeneity of the disorder. For some 
of the MDD comorbid disorders, associations with the 5-HTTLPR polymorphism 
have been described in literature. Therefore, we postulated that taking into account 
MDD comorbidity in candidate gene studies would improve power and consistency 
of these studies. Although carried out in a sample of limited size, this study could 
be expected to provide a proof of principle for the potential usefulness of such an 
approach.
The Val66Met polymorphism of the BDNF gene: a meta-analysis
In chapter 5, a meta-analysis of all available case-control association studies of the 
BDNF Val66Met variant in MDD is described. So far, studies of the BDNF Val66Met 
variant in MDD have shown inconsistent results. As indicated earlier, this might be 
the result of limited statistical power in individual studies of small sample size, MDD 
diagnostic diversity, and of variation across studies in inclusion criteria, such as the 
definition of the psychiatric phenotype. Other issues that might have contributed to 
the inconsistency of association findings are the difference in MDD prevalence across 
genders and ethnicities and/or the ancestry-dependent frequency of the Met allele.
We investigated whether a relationship exists between the Val66Met polymorphism 
and MDD. This has been done before with essentially negative results (Chen et al., 
2008; Gratacos et al., 2007; Lopez-Leon et al., 2008). In the current meta-analysis, 
however, we postulated that risk induced by BDNF might differ by gender and 
ethnicity. In addition, we investigated the effects of age on the relation between the 
Val66Met genetic variant and MDD. As meta-analysis is viewed as a good way to 
circumvent the limitations of statistical power and the effects of phenotype definitions 
in individual studies (Munafo & Flint, 2004; Trikalinos et al., 2008), this study could be 
expected to identify whether an association of the BDNF variant and MDD exists and 
whether associations would be restricted to gender- or ethnicity-dependent groups.
A genome-wide association study of neuroticism
In chapter 6, a genome-wide association study (GWAS) of neuroticism in a large Dutch 
sample from NBS is described. Neuroticism is a personality trait with an estimated 
heritability between 30% and 60% (Jang et al., 1996; Lake et al., 2000; Tambs et al., 
1991). It is a vulnerability factor for psychopathology and is in particular associated 
with depressive and anxiety disorders (Jacobs et al., 2006; Levinson, 2006; Sen et 
al., 2003). In general, females score higher on this trait than males, both in healthy 
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populations as in MDD cases (Costa, Jr. et al., 2001; Francis, 1993; Goodwin & 
Gotlib, 2004; Greenberg et al., 2000; Lang et al., 2005; Maier et al., 1992), which 
could suggest gender differences in the heritability of neuroticism. The neuroticism 
personality trait meets the proposed criteria for an endophenotype for MDD and has 
been regularly studied in genetic linkage and candidate gene studies (Du et al., 2000; 
Fullerton et al., 2003; Munafo et al., 2003; Nash et al., 2004; Sen et al., 2003). So far, 
two GWAS of neuroticism have been performed (Shifman et al., 2008; van den Oord 
et al., 2008), reporting different sets of genes to be associated with neuroticism.
In this study, we aimed at identifying new genes for neuroticism in a hypothesis-free 
manner in a large, well-powered study. Given the gender difference in neuroticism 
scores, we postulated a priori that gender differences in the SNPs associated with 
neuroticism will be apparent. Subjects were evaluated with the short version of 
the Eysenck Personality Questionnaire (EPQ-RSS) and genotyped for more than 
300,000 single nucleotide polymorphisms (SNPs). This GWAS of neuroticism could 
be expected to aid in the identification of MDD susceptibility genes.
Lastly, a summary and a discussion of the results are presented in chapters 7 and 8.
1
general introduction

M. Verhagen, A. van der Meij, B. Franke, W.A.M. Vollebergh, R. de Graaf,  
J.K. Buitelaar & J.G.E. Janzing
European Archives of Psychiatry and Clinical Neuroscience, 2008, 258, 505-512.
Chapter 2 
Familiality of major depressive disorder and patterns 
of lifetime comorbidity
The NEMESIS and GenMood studies; a comparison 
of three samples
36
Abstract
Background Major depressive disorder (MDD) aggregates in families and is 
associated with high rates of lifetime axis I comorbidity. This study examined whether 
familiality of MDD is associated with the presence of specific comorbid disorders, 
which might be an important factor to be taken into account in MDD treatment and 
research into MDD etiology.
Methods A population sample was divided into subjects with familial (f-MDD; n=432) 
and nonfamilial MDD (nf-MDD; n=454). Since more comorbidity was expected in 
clinical cases, a clinical sample with f-MDD (n=120) was also studied. Subjects 
were assessed with the Composite International Diagnostic Interview and family 
history methods. Binary logistic regression analyses were carried out to examine the 
influence of familiality of MDD on comorbidity. Analyses were adjusted for potential 
confounders, including MDD characteristics such as severity and age of onset.
Results Dysthymia, anxiety disorders, and alcohol use disorders were significantly 
more prevalent in subjects with f-MDD than in subjects with nf-MDD. Clinical f-MDD 
was associated with more anxiety disorders and fewer alcohol use disorders than 
population f-MDD. After adjustment for MDD characteristics including age of onset, 
severity, and disease course, comorbid disorders remained more prevalent in f-MDD 
than in nf-MDD.
Limitations The instruments used in the population and the clinical samples were not 
identical, however, they were comparable to a substantial degree.
Conclusions F-MDD, especially in clinical cases, appears to increase the risk of 
development of comorbid disorders, regardless of MDD characteristics. The 
link between familiality and comorbidity is important because it will aid a better 
understanding of the MDD phenotype, and it contributes to planning of effective 
treatment and to molecular genetic studies.
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Background
Major depressive disorder (MDD) is one of the most common psychiatric disorders 
and causes impairment in several areas. The lifetime prevalence of MDD is estimated 
at 15-17% (Bijl et al., 1998a; Kessler et al., 1993; Kessler et al., 1994). Family studies 
have shown an average risk ratio of 2.8 for major depression among the first-degree 
relatives of probands with major depression compared with the relatives of controls, 
indicating moderate familial aggregation of unipolar mood disorders (Sullivan et al., 
2000). MDD characteristics, such as age of onset and recurrence of episodes, each 
increase the risk of the disorder in relatives (Kupfer et al., 1989; Marazita et al., 1997; 
Weissman et al., 1984; Weissman et al., 1986; Zubenko et al., 2001). Twin studies 
estimate the heritability of MDD to be moderate, in the range of 35%-40% (Shih et al., 
2004; Sullivan et al., 2000).
In most studies MDD is treated as a homogeneous disorder even though there are 
considerable differences in syndrome characteristics and in MDD subtypes. Moreover, 
MDD is associated with high rates of lifetime psychiatric comorbidity, which also 
contributes to heterogeneity in expression of MDD. MDD with comorbid disorders 
causes more functional disabilities than pure MDD (Bijl et al., 1998a; Kessler et al., 
1996; Ravelli et al., 1998; Kessler et al., 2003). The National Comorbidity Survey-
Replication (NCS-R) observed that 72.1% of subjects with lifetime MDD had more 
than one axis I disorder (Kessler et al., 2003), with anxiety disorders, in particular 
generalized anxiety disorder (GAD), and dysthymia being found to frequently occur 
with MDD (Middeldorp et al., 2005b; Ravelli et al., 1998). Although twin and family 
studies indicate that MDD and anxiety disorders are distinct entities and not alternative 
phases of one disease (Middeldorp et al., 2005b), common genetic risk factors might 
explain the high rate of comorbidity. Most epidemiological studies, except for the 
Netherlands Mental Health Survey and Incidence Study (NEMESIS), found MDD to 
be associated with alcohol use disorders (Kendler et al., 1993a; Ravelli et al., 1998).
Factor analytic studies focusing on the clustering of axis I disorders have repeatedly 
revealed a three-factor model of disorders. This model is composed of two internalizing 
factors, ‘anxious-misery’ (MDD, dysthymia, and GAD) and ‘fear’ (panic disorder, 
agoraphobia, social and simple phobias), and an externalizing cluster, composed of 
alcohol dependence, drug dependence, and antisocial personality (Krueger, 1999; 
Vollebergh et al., 2001; Kendler et al., 2003). This three-factor division is observed 
in both males and females (Krueger, 1999; Kendler et al., 2003). Interestingly, GAD 
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coincides more frequently with depression and dysthymia than with other anxiety 
disorders (Krueger, 1999; Vollebergh et al., 2001). Apparently, these three latent 
dimensions reflect core psychopathological processes underlying different mental 
disorders over time (Vollebergh et al., 2001), with the common psychopathological 
variance being possibly due to shared genetic factors (Krueger, 1999). The finding 
of this three-factor model is supported by findings from studies investigating genetic 
factors for axis I disorders. In a female-twin study by Kendler et al. (1995), MDD and 
GAD loaded on the same genetic factor, whereas other anxiety disorders clustered 
together on another genetic factor. This suggests that GAD and MDD are different 
manifestations of the same underlying genetic vulnerability. The genetic influences 
on alcohol dependence were largely disorder-specific and independent of those 
influencing susceptibility to major depression (Kendler et al., 1995).
Despite the frequent presence of comorbid disorders in MDD, the observed axis 
I clusters in factor analytic studies, and the considerable differences in syndrome 
characteristics, MDD is still often considered a single disorder with regard to 
treatment and studies aiming at identifying the (genetic) etiology of the disorder. This 
might explain the large variability in response to treatment and probably leads to 
underestimation of the heritability of MDD (Beekman & Ormel, 1999; Hasin et al., 
2005). While diagnostic and genetic boundaries between the subtypes of MDD and 
other psychiatric disorders are still unclear (Jones et al., 2002), it may be important 
to recognize the expression of different subtypes and the accompanying comorbid 
lifetime psychiatric disorders.
In this study, we examined the relationship between MDD familiality and patterns of 
comorbid axis I disorders. More specifically, we tested whether familial MDD (f-MDD) 
and nonfamilial MDD (nf-MDD) are associated with different patterns of comorbidity. 
We also investigated whether MDD characteristics, such as age of onset, disease 
course, and severity, influence the association between familiality of MDD and 
comorbidity patterns.
Methods
Samples
Two samples of subjects with lifetime MDD were included in this study. Inclusion 
criteria were age 18-64 years at the time of interview, first episode of MDD between 
12 and 50 years, and being of Dutch descent (participant and both parents born in 
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the Netherlands). Subjects with a lifetime diagnosis of comorbid bipolar disorder or 
schizophrenia were excluded.
The first sample was drawn from a longitudinal prospective study (NEMESIS) of 
the prevalence, incidence, course, and determinants of psychiatric disorders in a 
representative sample of Dutch adults. NEMESIS had three measurement phases. 
The first involved 7,076 individuals (69.7% response) and took place in 1996. 
These data were used in the current study. To select a representative population, 
households in 90 different Dutch municipalities were identified and subjects with the 
most recent birthday were invited for participation. To correct for differing response 
rates in different population groups, poststratification weighting was applied to the 
NEMESIS database (gender, age, marital status, and urbanization). For a more 
detailed description see Bijl et al. (1998b).
The second sample was collected in the context of a clinical study into the genetics of 
MDD. Recruitment started in 2004 in the Netherlands and is still continuing (GenMood 
study). The Dutch central medical ethics review board and local ethics boards 
approved the study. Individuals with major depression and a familial vulnerability 
to depression (having at least one first-degree relative with a history of MDD) were 
recruited through psychiatric treatment settings and advertisements on Internet, 
in local newspapers, and in popular magazines. After providing written informed 
consent, eligible participants were (endo)phenotyped on the basis of diagnostic, 
temperamental, cognitive, endocrinological, and life-style measures. The clinical 
GenMood sample used in this study consisted of 120 subjects.
Diagnostic assessment and procedures
The Composite International Diagnostic Interview (CIDI) was used for diagnostic 
assessment. The CIDI is a structured interview developed by the World Health 
Organization (WHO) that can be administered by trained interviewers who are not 
clinicians. The CIDI has acceptable interrater reliability and test-retest reliability for 
most diagnoses including major depression (Wittchen, 1994). DSM-III-R lifetime 
diagnostic reliability was found to be acceptable to good with kappa values well 
above 0.5. Although few studies have validated the CIDI, it is considered to have 
acceptable validity (Wittchen, 1994).
Subjects in the population sample (NEMESIS study) were interviewed at home 
using the computerized CIDI 1.1 (DSM-III-R) (Smeets & Dingemans, 1993; World 
Health Organization, 1990), and those in the clinical sample (GenMood study) were 
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interviewed when in remission at the Department of Psychiatry of the Radboud 
University Nijmegen Medical Centre or at home, by means of the computerized CIDI 
2.1 (DSM-IV) (WHO-CIDI, 1998). For the current study, the following CIDI sections were 
of interest: the lifetime presence of mood disorders (dysthymia, major depression, 
bipolar disorder), anxiety disorders (panic disorder, agoraphobia, generalized 
anxiety disorder (GAD), obsessive compulsive disorder (OCD), social phobias, 
simple phobias), schizophrenia and other non-affective psychotic disorders, and 
alcohol abuse and dependence. We used the CIDI diagnostic information to estimate 
comorbidity and to exclude subjects with lifetime bipolar or schizophrenic disorder.
In the population sample, information on family history was obtained by questioning 
subjects about the presence of axis I disorders in first-degree relatives: had 
relatives ever been hospitalized in a psychiatric setting, ever received medical care 
for psychiatric disorders, or ever had a psychiatric disorder? If, based on a single 
question, participants reported major depression in a first-degree relative, they were 
classified as f-MDD (positive family history for MDD, n=432); otherwise, they were 
classified as nf-MDD (negative family history, n=454, see Figure 1). In a subsample 
consisting of 323 relatives of 51 clinical subjects, a high level of agreement was found 
between this single question and a more elaborate family history method based on 
the Family Interview for Genetic Studies (FIGS; Maxwell, 1992) and the Family History 
Research Diagnostic Criteria (FH-RDC; Endicott et al., 1975) (kappa= 0.78).
In the clinical sample, a family history method based on a combination of the FIGS 
(Maxwell, 1992) and the FH-RDC (Endicott et al., 1975) was used. With the use of 
a drawn family tree showing all first-degree relatives, the lifetime presence of MDD, 
bipolar disorders, anxiety disorders, and alcohol use disorders was evaluated for 
each first-degree relative individually. A best-estimate diagnosis was made using 
criteria from the FH-RDC. Subjects were positive for f-MDD if the proband reported 
at least one first-degree relative to have been diagnosed with MDD and to have 
received treatment (or to have ever been hospitalized for the disorder). Family 
members positive for lifetime MDD were contacted and asked to participate in the 
GenMood project. To estimate the reliability of this family history method, we checked 
50 random pedigrees. In 50.5% of the relatives we were able to verify MDD status by 
using information obtained from the CIDI or a telephone interview. In 92.2% of the 
relatives depression was confirmed. Unfortunately, we were unable to assess MDD 
status in the remaining 49.5% of the relatives because subjects had died or were 
unwilling/unable to participate in GenMood.
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Dependent variables
As dependent variables we used lifetime comorbid diagnoses of dysthymia, anxiety 
disorders (panic disorder with and without agoraphobia, agoraphobia, social 
phobia, simple phobia, GAD, and OCD), and alcohol use disorders (alcohol abuse 
and dependence). We used the following definition of comorbidity: “Comorbidity is 
the presence of more than one disorder in a person in a defined period of time, 
regardless of the association between those disorders” (Burke et al., 1990). For this 
study the “defined period of time” was lifetime. This means that comorbid disorders 
did not necessarily co-occur with MDD.
Independent variables
Subjects were classified according to MDD characteristics including age of onset 
(early vs. late onset), disease course (single episode vs. recurrent MDD), and disease 
severity (mild vs. severe) on the basis of CIDI diagnostic scores. The age of onset 
dichotomy distinguished early onset MDD (first episode of MDD ≤ 25 years) from 
late onset MDD (first episode of MDD > 25 years) (Maher et al., 2002; Marazita et 
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Figure 1  Flowchart of NEMESIS samples and reasons for exclusion 
 of subjects
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al., 1997; Zubenko et al., 2002a; Zubenko et al., 2001). Single MDD was defined as 
a single episode of MDD during life (DSM classifications 296.20, 296.21, 296.22, 
296.23, 296.24), and recurrent MDD was defined as more than one episode of MDD, 
at least 2 months apart, in which criteria for MDD were not met (DSM classifications: 
296.30, 296.31, 296.32, 296.33, 296.34). Severity of MDD was categorized as mild 
(mild and moderate episodes; DSM classifications 296.21, 296.22, 296.31, and 
296.32) and severe (severe episodes of MDD and MDD with psychotic features; DSM 
classifications 296.23, 296.24, 296.33, and 296.34).
Statistical analyses
Sociodemographic and clinical characteristics of the samples were compared. 
For categorical variables, contingency tables were created and Pearson’s χ2 were 
calculated. For continuous variables, independent T-tests were performed. All tests 
were two-tailed. For each sample, the frequency of overall comorbidity and of each 
single comorbid disorder was calculated. We investigated whether the samples 
differed from each other with respect to the lifetime prevalence of comorbid disorders 
using logistic regression analyses. P-values below 0.05 were considered statistically 
significant.
To study the effect of familiality of MDD on the presence of lifetime comorbid 
disorders, binary logistic regression analyses were performed. Dependent variables 
were comorbid dysthymia, anxiety disorders, and alcohol use disorders (0=absence; 
1= presence). Analyses were adjusted for gender, age at the time of interview, 
and educational attainment. These factors have been found to be associated with 
depression in community samples (Kessler et al., 2005a; Bijl et al., 1998a). In the next 
step, MDD characteristics such as age of onset (early vs. late), course (recurrent vs. 
single), and severity (severe versus mild MDD) were added to the logistic regression 
analyses to see whether apparent differences in comorbid disorders between 
samples were due to familial factors and not actually due to MDD characteristics. 
Covariates were entered simultaneously.
Associations between variables were expressed as odds ratios (ORs) and 95% 
confidence intervals (95% CIs). Differences between odds ratios were considered 
statistically significant if the confidence intervals of a risk factor mutually excluded 
the point estimates in one or both of the other categories (Gardner & Altman, 1986). 
Analyses were performed using SPSS 12.0.
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Results
Descriptive and clinical characteristics of the samples
The demographics of the population (NEMESIS study) and clinical (GenMood study) 
samples are summarized in Table 1. Both samples consisted of about 70% females, 
but the clinical sample was significantly older, on average 5 years, and had a higher 
educational status than the population sample. There were no significant differences 
in marital status.
The nf-MDD sample differed significantly from the f-MDD samples with regard to 
age of onset (there were fewer cases with an early onset), course (there were fewer 
cases with recurrent MDD), and severity (more subjects had mild MDD) (Table 1). 
The clinical f-MDD sample had more recurrent cases than the population f-MDD 
sample.
Comorbid disorders in the samples
Significantly more subjects in the clinical f-MDD sample than in population f-MDD 
sample or in the nf-MDD sample had at least one comorbid disorder (89.2%, 74.3%, 
and 66.7% respectively). The presence of comorbid disorders was significantly 
higher in population f-MDD than in population nf-MDD (OR 1.5, 95% CI 1.1-2.0). In 
the clinical f-MDD sample, comorbid disorders were also significantly more prevalent 
than in population nf-MDD cases (OR 5.1, 95% CI 2.7-9.7: see Table 2 ‘Any disorder’). 
The difference in prevalence of comorbidity between both familial samples was also 
significant, since the confidence intervals mutually excluded the point estimates from 
the other category. Figures 2 and 3 show the rates of the different comorbid disorders 
in each sample. The most frequent comorbid disorders were anxiety disorders, in 
particular GAD and phobias.
Familiality of MDD and prevalence of comorbid disorders
Table 2 (columns labeled with a) presents the results of the binary logistic regression 
analyses examining whether familiality of MDD influenced the presence of comorbid 
disorders. Since the subjects in the population f-MDD and nf-MDD samples were 
significantly younger than the subjects in the clinical f-MDD sample, age was used 
as a covariate. Other covariates were gender and educational status. We found that 
subjects in the population f-MDD sample had significantly more often dysthymia 
and alcohol use disorders than the subjects in the nf-MDD sample. There was no 
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difference in the overall prevalence of anxiety disorders, though, OCD was significantly 
more prevalent in the subjects in the population f-MDD sample (Table 2, population 
f-MDDa). Almost all disorders, except for agoraphobia and alcohol use disorders, 
were more common in the subjects in the clinical f-MDD sample than in the subjects 
in the nf-MDD sample (Table 2, clinical f-MDDa).
Comparison of the population and clinical samples of f-MDD showed that anxiety 
disorders, especially panic disorder, simple phobias, social phobias, GAD, and OCD 
were more often present in the clinical f-MDD sample than in the population f-MDD 
sample, whereas alcohol use disorders were less prevalent in the clinical f-MDD 
sample than in the population f-MDD sample (Table 2; columns labeled with a).
Characteristics of MDD and prevalence of comorbid disorders
Overall, more comorbidity was observed in the subjects with f-MDD (clinical and 
population samples) with early onset compared with late onset MDD (OR 1.7, 
95% CI 1.3-2.3), and in nf-MDD subjects with severe MDD compared with those 
with mild MDD (OR 2.3, 95% CI 1.7-3.1). Disease course influenced the presence 
2
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Figure 2  Lifetime prevalence of comorbid dysthymia, anxiety disorders 
and alcohol use disorders in the samples
Note: Anxiety disorders include simple phobia, social phobia, GAD, OCD, panic disorder with 
and without agoraphobia, and agoraphobia. Alcohol use disorders include alcohol abuse and 
alcohol dependence.
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of comorbidity only at a trend level. Binary logistic regression results showed that 
adjustment for these MDD characteristics did not lead to major changes in the odds 
ratios for comorbidity. Odds ratios for dysthymia and alcohol use disorders remained 
significantly higher in the population f-MDD sample than in the nf-MDD sample 
(Table 2; population f-MDDb), whereas dysthymia and anxiety disorders, especially 
panic disorder, GAD, and OCD, remained significantly more prevalent in the clinical 
f-MDD sample than in the nf-MDD sample (Table 2; Clinical f-MDDb). Minor changes 
were observed for OCD (Table 2; compare population f-MDDa and f-MDDb) and social 
and simple phobias (Table 2; compare clinical f-MDDa and f-MDDb). There were 
significant differences in comorbid disorders between the clinical f-MDD sample and 
the population f-MDD sample after controlling for age of onset, disease course, and 
severity of MDD (Table 2; columns labeled with b). Anxiety disorders, in particular 
panic disorder, simple phobias, and GAD, were significantly more prevalent in the 
clinical f-MDD sample than in the population f-MDD sample, whereas alcohol use 
disorders were significantly more prevalent in the population f-MDD sample.
chapter 2
Figure 3  Lifetime prevalence of comorbid specific anxiety disorders in 
the samples
Note: Panic disorder includes both panic disorder with and without agoraphobia.
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Discussion
The present report is one of the first to investigate the presence of lifetime comorbid 
disorders in f-MDD versus nf-MDD. The findings lend support to our hypothesis that 
the rate of lifetime comorbid dysthymia, anxiety disorders, and alcohol use disorders 
is higher in f-MDD than in nf-MDD. In addition, subjects from the clinical f-MDD 
sample reported significantly more anxiety disorders (especially GAD) and fewer 
comorbid alcohol use disorders than subjects from the population f-MDD sample. 
These effects of familiality on comorbidity patterns largely remained after correcting 
for MDD characteristics, such as age of onset, disease course, and severity. That the 
association between familiality and comorbidity patterns was independent of disease 
severity is contrary to the generally held belief that more severe forms of illness are 
accompanied by more comorbidity. This finding has not been reported earlier.
Comorbid disorders in the samples
In MDD, comorbidity seems to be rule rather than exception (Alpert et al., 1999; de 
Graaf et al., 2003; Lecrubier, 2008), with dysthymia, anxiety disorders, and alcohol 
abuse and dependence frequently co-occurring with MDD (Merikangas & Gelernter, 
1990; Sanderson et al., 1990). This was also the case in our samples, with anxiety 
disorders showing higher comorbidity with MDD than alcohol use disorders. This 
difference in anxiety- and alcohol use disorder comorbidity accompanying MDD 
is consistent with findings from other studies (Angst, 1996; Kessler et al., 1996). 
Epidemiological studies have indicated that of the anxiety disorders, panic disorder 
and GAD are most often comorbid with MDD (Kendler et al., 1995; Merikangas et 
al., 1996). In the population samples, however, panic disorder was less prevalent 
than social and simple phobias. In the clinical sample, panic disorder was as often 
present as social and simple phobias. GAD was most prevalent.
Familiality and comorbidity
That comorbidity is less common in nf-MDD than in f-MDD might indicate that 
familial vulnerability for MDD is expressed as MDD with comorbid disorders rather 
than as pure MDD. This is in accordance with family studies showing that comorbid 
disorders in a proband with MDD significantly increase the risk of MDD in relatives 
(Angst et al., 2005; Grove et al., 1987; Kendler et al., 1994; Weissman et al., 1986). 
However, it is not clear which lifetime comorbid disorders influence the risk of MDD 
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in relatives (Grove et al., 1987; Kendler et al., 1994; Lieb et al., 2002; Weissman et al., 
1986). Weissman et al. (1986) found that comorbid anxiety disorders and secondary 
alcoholism increased the risk of MDD in relatives, whereas Kendler et al. (1994) found 
comorbid panic disorder and bulimia to increase the risk of MDD in the co-twin. 
In the latter study, however, only female twins were included and it is unclear how 
many of them actually had bipolar disorder. The significantly higher prevalence of 
comorbid anxiety disorders in the clinical sample in this study might be explained by 
treatment or referral bias (Galbaud du Fort et al., 1993). This is in line with findings 
that clinical cases of MDD are more socially incapacitated than population cases of 
MDD (Costello, 1990). In the latter study (Costello, 1990), the presence of comorbid 
disorders was not taken into account, which could have made the association even 
stronger.
Contrary to our expectation, alcohol use disorders were not more prevalent in the 
clinical f-MDD sample than in the nf-MDD sample. This is probably due to selection 
bias; the clinical sample had a higher educational attainment. It is also possible that 
subjects with alcohol use disorders are more easily reached in population surveys 
than in psychiatric clinics, since alcohol use disorders are mostly treated in specialized 
treatment settings.
Strengths and limitations
The findings of this study should be interpreted in the light of its strengths and 
limitations. A strength of this study is that we included both population and clinical 
samples of f-MDD and a control sample without f-MDD. In fact, this is one of 
the first studies to investigate the effect of familiality of MDD on comorbidity in a 
large, representative population sample. However, due to differences in samples, 
study design, and methodologies between the population (NEMESIS) and clinical 
(GenMood) studies there are some limitations. CIDI 1.1 (DSM-III-R) was used for 
diagnostic assessment in the population study, whereas CIDI 2.1 (DSM-IV) was used 
in the clinical study. However, the differences between these instruments would not 
affect diagnostic outcomes. Furthermore, the family history method used for the 
assessment of MDD in relatives differed between the two studies. Both studies were 
similar in relying solely on proband knowledge. Although the family history method 
has been criticized because of its susceptibility to bias (Roy et al., 1996), it is known 
that familiarity of the informant with manifestations of psychopathology increased the 
reporting accuracy for relatives, which is also the case in our study. We were able 
2
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to show a relatively high agreement between the single family history question for 
the assessment of familiality of MDD and the more elaborate family history method. 
Further, the reliability of the family history method approach used in the clinical study 
was very high (Verhagen et al., 2008). Altogether, we believe that the different family 
history methods will identify familial cases comparably well.
Another limitation is the use of retrospective reports of axis I disorders. This can be 
subject to recall bias, although studies suggest that it is possible to collect reliable 
lifetime diagnoses (Andreasen et al., 1981; Mannuzza et al., 1989). However, we 
do not think that this has biased our findings in a serious way since this possible 
influence from memory is operating in all three samples.
Implications
The present study shows that it is important to include comorbid disorders in the 
phenotypic description of MDD in addition to MDD characteristics, such as age of 
onset, disease course, and severity of MDD. A better understanding of the phenotype 
of MDD is of importance for the clinical assessment, treatment, and prevention of 
MDD, and for etiological (genetic) studies. Treatment often focuses on one condition, 
thereby possibly neglecting other concurrent conditions (Lecrubier, 2008; Merikangas 
& Gelernter, 1990), whereas all disorders, primary as well as comorbid, should be 
treated. The confirmation in this study that f-MDD is associated with an earlier onset of 
disease, more recurrence, and more severe episodes of MDD should be considered 
with regard to prevention as well. Individuals with these characteristics may be 
particularly vulnerable to the development of comorbid psychiatric disorders.
A better insight into the relevant phenotype of MDD, i.e. the frequent presence of 
comorbid disorders, could lead to more accurate phenotyping in molecular genetic 
studies. This is essential since it may otherwise result in misleading association 
findings, such as an association between a candidate locus and the phenotype 
of interest (i.e. MDD) that may actually be attributable to an association between 
that locus and the comorbid phenotype, or results that are not reproducible in other 
studies.
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Abstract
Objective Gender differences exist in the prevalence and psychiatric comorbidity of 
major depressive disorder (MDD). This study investigates whether familiality of MDD 
contributes to observed gender differences in comorbidity.
Method Familial (f-MDD) and nonfamilial (nf-MDD) MDD cases from a population 
sample were assessed for comorbid dysthymia, anxiety disorders and alcohol-
related disorders using the Composite International Diagnostic Interview (CIDI). 
Logistic regression analyses were performed to examine the effect of f-MDD on 
gender differences in comorbidity, adjusted for confounders.
Results Females with f-MDD reported significantly more comorbid dysthymia and 
generalized anxiety disorder (GAD) than their male counterparts; females with nf-
MDD reported significantly more comorbid simple phobias and agoraphobia than 
their male counterparts. Gender differences in comorbid panic disorder and alcohol-
related disorders occurred independently of the familial load. Adjustment for age of 
onset, severity and recurrence of MDD did not change these results.
Conclusion Models to explain comorbidity patterns of MDD differ by gender. 
Familiality of MDD should be taken into account.
Significant outcomes
-  In females, significantly more lifetime dysthymia and anxiety disorders were 
observed; in males, lifetime alcohol use disorders were significantly more 
prevalent.
-  Some gender differences in comorbidity patterns were dependent on the familiality 
of MDD; other gender differences occurred independently of the familial load.
-  MDD characteristics such as age of onset, course of disease and severity of MDD 
did not affect these results.
Limitations
-  The use of retrospective reports of axis I disorders might have led to recall bias.
-  The family history method relies solely on proband knowledge regarding 
psychopathology in first-degree relatives.
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Introduction
Major depressive disorder (MDD) is one of the most common psychiatric disorders, 
causes impairment in several areas and places a large burden on patients and family 
members (Fadden et al., 1987). The lifetime prevalence of MDD is estimated at 15-
17% (Bijl et al., 1998a; Kessler et al., 1993; Kessler et al., 1994). Twin studies estimate 
the heritability of MDD to be moderate, in the range of 35%-40% (Shih et al., 2004; 
Sullivan et al., 2000). Two large population-based studies, the Netherlands Mental 
Health Survey and Incidence Study (NEMESIS; 7,076 Dutch adults, Bijl et al., 1998a) 
and the National Comorbidity Survey-Replication (NCS-R; 9,892 inhabitants of the 
United States, Kessler et al., 2003), observed a gender difference in the lifetime 
prevalence of MDD of 20.1-21.3% in females and 10.9-12.7% in males (Bijl et al., 
1997; Bijl et al., 1998a; Kessler et al., 1993). Studies regarding gender differences in 
heritability and in genetic risk factors for MDD have yielded inconsistent results; some 
studies did not observe gender differences in the heritability of MDD (Kendler & 
Prescott, 1999; McGuffin et al., 1996), whereas other studies reported a significantly 
higher heritability of MDD in females (40-42%) than in males (29-31%) (Bierut et al., 
1999; Kendler et al., 2001; Kendler et al., 2006b).
Gender differences not only exist in the prevalence of MDD but also in the prevalence 
of comorbid axis I disorders. Studies on psychiatric comorbidity in MDD have shown 
that comorbidity in MDD is the rule rather than the exception; findings from the NCS-R 
indicate that more than two-thirds (72.1%) of subjects with lifetime MDD experience 
more than one axis I disorder (Kessler et al., 2003). Only 30% of females and 19% of 
males diagnosed with lifetime MDD reported no other disorder (Kessler et al., 1996). In 
clinical studies with depressed out-patients, it was observed that simple phobias and 
bulimia nervosa are significantly more prevalent comorbidities in females, whereas 
substance abuse and dependence are more prevalent in males (Fava et al., 1996; 
Carter et al., 1999). Furthermore, females were more likely than males to have three 
or more comorbid disorders (Kessler et al., 1994). In these studies, subjects were 
assessed on comorbid disorders independently of the familiality of MDD, despite 
the high chance of MDD running in the family. An average risk ratio of 2.8 has been 
observed for major depression among the first-degree relatives of subjects with 
MDD compared with the relatives of controls (Sullivan et al., 2000). Moreover, MDD 
characteristics, such as age of onset and recurrence of episodes, are associated 
with familial occurrence of MDD (Kendler et al., 2007; Kupfer et al., 1989; Marazita et 
al., 1997; Weissman et al., 1984; Weissman et al., 1986; Zubenko et al., 2001).
3
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Aims of the study
The first aim of the study was to investigate whether gender differences in lifetime 
comorbidity patterns were affected by familiality of MDD. Furthermore, as age of 
onset, disease course and severity of MDD are associated with familial MDD, the 
second aim was to investigate whether gender differences in lifetime comorbidity 
patterns were associated with these MDD characteristics, in addition to familiality of 
MDD.
Material and methods
Subjects
A sample was drawn from the longitudinal prospective NEMESIS study of the 
prevalence, incidence, course and determinants of psychiatric disorders in Dutch 
adults (aged 18-64 years; Bijl et al., 1998b). To select a representative population, 
households in 90 different Dutch municipalities were identified. The selected 
households were contacted over the telephone or were visited in person by the 
interviewers. The subject with the most recent birthday and having an age between 
18 and 64 years was invited for participation. Respondents provided verbal consent 
after having been informed of the aims of the study. To correct for differing response 
rates in different population groups, poststratification weighting was applied to the 
NEMESIS database (gender, age, marital status and urbanization). NEMESIS started 
in 1996 and had three measurement phases. In the first wave, 7,076 individuals 
(69.7% response) were interviewed (Spijker et al., 2006; de Graaf et al., 2002a). For 
the current study, these data were used.
Subjects with lifetime MDD were included in the current study; subjects with lifetime 
comorbid diagnoses of bipolar disorder or schizophrenia were excluded. Next, the 
sample was divided into participants reporting a positive or negative family history 
of MDD (for details see below). The familial MDD (f-MDD) sample consisted of 499 
subjects; the nonfamilial MDD (nf-MDD) sample consisted of 613 subjects (see 
Figure 1).
Diagnostic assessment
The computerized Composite International Diagnostic Interview (CIDI 1.1; DSM-
III-R; Smeets & Dingemans, 1993; World Health Organization, 1990) was used for 
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diagnostic assessment. The CIDI is a structured interview developed by the World 
Health Organization (WHO) and can be administered by trained interviewers who are 
not clinicians. The CIDI has acceptable inter-rater-reliability and test-retest reliability 
for most diagnoses including major depression (de Graaf et al., 2004; Wittchen, 
1994). DSM-III-R lifetime diagnostic reliability was found to be acceptable to good 
with kappa values well above 0.5 (Wittchen, 1994). Furthermore, good overall 
diagnostic concordance between a clinical checklist and the CIDI diagnosis of 
depressive disorders has been found (κ = 0.83) (Janca et al., 1992; Wittchen, 1994). 
Although few studies have validated the CIDI, it is considered to have acceptable 
validity (Wittchen, 1994).
The participants had a face-to-face interview at their homes by trained interviewers 
experienced in systematic data collection (Bijl et al., 1998b). For this report, the 
following CIDI sections were used for the confirmation of MDD diagnosis and for 
assessing comorbidity: major depression, dysthymia, anxiety disorders (generalized 
anxiety disorder (GAD), panic disorder, agoraphobia, obsessive compulsive disorder 
(OCD), social phobias, simple phobias), alcohol abuse and dependence. Using 
the CIDI diagnostic information, lifetime comorbidity was estimated. We used the 
following definition of comorbidity: “Comorbidity is the presence of more than 
one disorder in a person in a defined period of time, regardless of the association 
between those disorders” (Burke et al., 1990). Bipolar disorders, schizophrenia and 
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Figure 1  Flowchart of NEMESIS population samples and reasons for 
exclusion of subjects
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other non-affective psychotic disorders were assessed to exclude subjects fulfilling 
these criteria. Because the presence of lifetime comorbid disorders was assessed, 
DSM-III-R hierarchical rules were not applied.
The CIDI information was also used to describe MDD characteristics such as age of 
onset, disease course and severity of MDD. The age of onset dichotomy distinguished 
MDD with a first episode of MDD ≤ 25 years from MDD with a first episode of MDD > 
25 years (Maher et al., 2002; Marazita et al., 1997; Zubenko et al., 2002a; Zubenko et 
al., 2001). Recurrent MDD was defined as more than one episode of MDD, at least 2 
months apart in which criteria for MDD were not met; single MDD was defined as a 
single episode of MDD during life. Severity of MDD was categorized as severe (severe 
episodes and MDD with psychotic features) or mild (mild and moderate episodes).
Family history assessment
Besides diagnostic assessment, family history information was obtained. Subjects 
were questioned about the presence of axis I disorders in first-degree relatives. 
They were asked if family members had ever had a psychiatric disorder, had ever 
been hospitalized in a psychiatric setting or had ever received medical care for 
psychiatric disorders. To evaluate the presence of depression in first-degree relatives, 
the following questions were asked: 1) did your father, your mother or both of them 
ever had a depression? 2) did one of your brothers or sisters ever had a depression? 
If any of these questions was positively answered, the family was classified as positive 
for MDD (f-MDD); if not they were classified as nf-MDD. In an independent sample of 
323 relatives of 51 subjects with depression, we estimated the measure of agreement 
between the above-mentioned questions of the family history of depression and the 
Family History Research Diagnostic Criteria (FH-RDC) for depression (Andreasen 
et al., 1977). We found substantial agreement (κ = 0.78). Furthermore, in 97.6 % 
(40 of 41) of the relatives positive for depression according to FH-RDC criteria, the 
CIDI interview confirmed a lifetime diagnosis of depression according to DSM-IV 
criteria.
The family history information was used to determine the Family Loading Score of 
Depression (FLSD). FLSD is the proportion of the first-degree relatives (parents and 
siblings) with a lifetime history of depression. Depression status of children was not 
considered because it is uncertain if pre-pubertal depression shares the same etiology 
as depression with a first incidence in or after puberty (Harrington et al., 1997).
In earlier publications on the NEMESIS study, a positive psychiatric family history was 
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significantly associated with psychiatric morbidity and comorbidity in the probands 
(Bijl et al., 2002; de Graaf et al., 2002b; de Graaf et al., 2004).
Statistical analyses
Sociodemographic and clinical characteristics of the samples were compared. 
For continuous variables, independent Student’s T-tests were performed and for 
categorical variables, Pearson’s chi-squares were calculated. All tests were two-
tailed.
To study the effect of gender on the presence of lifetime comorbid disorders, binary 
logistic regression analyses were performed. Dependent variables were the comorbid 
disorders (0=absence and 1=presence). In the next step, the MDD characteristics - 
age of onset (early versus late), course (recurrent versus single) and severity (severe 
versus mild MDD) - were added to the logistic regression analysis to see whether 
apparent gender differences in comorbid disorders were due to differences in MDD 
characteristics in males and females.
Analyses were adjusted for age, marital status and educational attainment. These 
factors have been found to be associated with depression in community samples 
(Kessler et al., 2005a; Bijl et al., 1998a). Educational attainment was categorized 
into low, medium, high and university. Marital status was categorized into married, 
previously married, widow(er) and never married. In addition, the familial load for 
MDD (FLSD) and the number of first-degree relatives (parents and siblings) were 
used as covariates as these variables may influence depression in the proband. 
Covariates were entered simultaneously.
Associations between variables were expressed as odds ratios (ORs) and 95% 
confidence intervals (95% CIs). Analyses were performed using SPSS 12.0 (SPSS 
Inc., Chicago, IL, USA).
Results
Descriptive and clinical characteristics of the sample
Demographics of the NEMESIS sample are presented in Table 1. Overall, males with 
MDD were significantly older than females with MDD and attained higher educational 
level. No differences in marital status appeared. About 45% of all subjects had first-
degree relatives affected with MDD (f-MDD). This rate was similar in males and 
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females. In females, MDD was more frequently characterized by early age of onset, a 
recurrent course and greater severity than in males.
Gender differences in lifetime comorbid disorders
In two-thirds of the subjects, lifetime comorbidity was present, with comparable rates 
for males and females (Table 1). Results of the binary logistic regression analyses 
showed that lifetime dysthymia and anxiety disorders were more prevalent in 
females, whereas lifetime alcohol use disorders were more prevalent in males. Within 
the spectrum of anxiety disorders, females showed significantly more comorbid 
panic disorder, simple phobias, GAD and agoraphobia than males (Table 2: Female 
gender).
Familiality of MDD and gender differences in lifetime comorbid disorders
Figure 2 presents the lifetime prevalence of the various comorbid disorders in males 
and females from both the f-MDD and nf-MDD samples. More lifetime comorbidity 
was present in the f-MDD sample than in the nf-MDD sample.
Gender differences emerged with respect to comorbid disorders in the f-MDD and nf-
MDD samples. In the f-MDD sample, females reported significantly more comorbid 
dysthymia and GAD than males (Table 2: Female gender f-MDD), whereas in the 
nf-MDD sample females reported significantly more comorbid simple phobias and 
agoraphobia than males (Table 2: Female gender nf-MDD). In both the f-MDD and nf-
MDD samples, comorbid panic disorder was more often present in females, whereas 
comorbid alcohol abuse and alcohol dependence were more often observed in 
males. Adding the interaction term of Gender by Familial Load for depression did not 
improve the models in the logistic regression analyses.
Differences in the lifetime prevalence of comorbid disorders also existed between 
females from the f-MDD and nf-MDD samples and between males from both samples. 
Results of the binary logistic regression analyses showed that females with f-MDD 
reported significantly more overall lifetime comorbidity than females with nf-MDD, 
in particular dysthymia (Table 3: Females). Males from the f-MDD sample reported 
more agoraphobia than males from the nf-MDD, but only at trend level (Table 3: 
Males).
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Characteristics of MDD and gender differences in lifetime comorbid
disorders
Major depressive disorder characteristics were then added to the binary logistic 
regression analyses, as these characteristics differed between males and females 
(Table 1) as well as between the f-MDD and nf-MDD samples (Table 4). However, 
adding these MDD characteristics, such as age of onset, course of disease and 
severity of MDD, did not lead to significant changes in gender differences in lifetime 
comorbid disorders (data not shown).
Discussion
The current report is one of the first that describes gender differences in lifetime 
comorbid disorders in subjects with and without a family history of MDD. So far, little 
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Figure 2  Lifetime prevalence of dysthymia, anxiety disorders, and 
 alcohol use disorders in females and males, for both the familial 
major depressive disorder (f-MDD) and nonfamilial major 
depressive disorder (nf-MDD) samples
Note: Anxiety disorders include simple phobia, social phobia, generalized anxiety disorder 
(GAD), obsessive compulsive disorder (OCD), panic disorder with and without agoraphobia, 
and agoraphobia. Alcohol use disorders include alcohol abuse and alcohol dependence.
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is known about the influence of familiality of MDD on the expression of the disease. 
Our findings suggest that gender differences in the expression of comorbid disorders 
in depression differ by familiality of MDD. In the nf-MDD sample, females presented 
more comorbid simple phobias and agoraphobia than males, whereas in the familial 
MDD sample, females reported significantly more comorbid dysthymia and GAD 
than males. This may indicate that a familial vulnerability for MDD in females presents 
as a broader vulnerability for dysthymia and GAD as well, or that dysthymia and 
GAD load on the same genetic factors as MDD. Because these comorbid disorders 
3
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Table 2  Odds ratios and 95% CIs for the presence of lifetime comorbid 
disorders in females with MDD versus males with MDD in  
the total sample (n=1112), and in f-MDD (n=499) and nf-MDD 
(n=613) separately
Comorbid  Female gendera  Female gender  Female gender 
disorder  f-MDDb nf-MDDb
Dysthymia 1.6 (1.2-2.2)** 2.0 (1.3-3.0)** 1.4 (0.9-2.1)
Any anxiety disorder 1.6 (1.2-2.1)*** 1.6 (1.1-2.3)* 1.6 (1.2-2.3)**
   Panic disorder# 2.2 (1.4-3.4)** 2.8 (1.3-6.0)** 1.8 (1.0-3.3)*
   Simple phobias 1.5 (1.1-2.1)* 1.3 (0.8-2.2) 1.7 (1.1-2.6)*
   Social phobia 1.2 (0.9-1.6) 1.3 (0.8-2.1) 1.1 (0.7-1.7)
   GAD 1.7 (1.2-2.4)** 1.9 (1.1-3.2)* 1.5 (1.0-2.5)
   Agoraphobia 1.7 (1.0-2.7)* 1.2 (0.6-2.2) 2.4 (1.2-4.9)*
   OCD 0.5 (0.2-1.0) 0.4 (0.1-1.0) 0.6 (0.2-2.1)
Alcohol use disorders 0.2 (0.1-0.2)*** 0.2 (0.1-0.3)*** 0.2 (0.1-0.3)***
   Alcohol abuse 0.2 (0.2-0.3)*** 0.2 (0.1-0.4)*** 0.2 (0.1-0.4)***
   Alcohol dependence 0.2 (0.1-0.3)*** 0.2 (0.1-0.3)*** 0.2 (0.1-0.5)***
Any disorder 0.9 (0.6-1.1) 1.0 (0.6-1.5) 0.8 (0.5-1.1)
Data regarding familiality of MDD was missing in 29 subjects (n=1112).
* p<0.05, ** p<0.01, *** p<0.001.
a Adjusted for age, educational level, marital status, number of first-degree relatives and 
FLSD.
b Adjusted for age, educational level, marital status, and number of first-degree relatives.
# Panic disorder with and without agoraphobia.
64
chapter 3
Table 3  Odds ratios and 95% CIs for the presence of lifetime comorbid 
disorders in females with f-MDD (n=350) versus females with 
nf-MDD (n=403) and in males with f-MDD (n=149) versus 
males with nf-MDD (n=210)
Table 4  MDD characteristics in the total sample, and separately for 
both the f-MDD and nf-MDD samples
Comorbid disorder Femalesa  Malesa 
Dysthymia 1.9 (1.4-2.6)*** 1.4 (0.8.-2.3)
Any anxiety disorder 1.2 (0.9-1.6) 1.2 (0.8-1.9)
   Panic disorder 1.1 (0.8-1.7) 0.8 (0.3-1.9)
   Simple phobias 1.1 (0.8-1.5) 1.3 (0.8-2.3)
   Social phobia 1.4 (1.0-1.9) 1.1 (0.6-1.9)
   GAD 1.1 (0.8-1.6) 1.0 (0.5-1.8)
   Agoraphobia 1.1 (0.7-1.7) 2.4 (1.0-5.7)*
   OCD 1.6 (0.5-4.8) 2.7 (0.8-8.6)
Alcohol use disorders 1.2 (0.8-2.0) 1.2 (0.7-1.8)
   Alcohol abuse 1.3 (0.7-2.3) 0.9 (0.5-1.6)
   Alcohol dependence 1.1 (0.5-2.4) 1.5 (0.8-2.7)
Any disorder 1.4 (1.0-2.0)** 1.3 (0.8-2.0)
Adjusted for age, educational level, marital status and number of first-degree relatives.
* p<0.1, ** p<0.05, *** p<0.001.
a Reference category: nf-MDD.
MDD  Total f-MDD nf-MDD Statistics
characteristics (n=1139) (n=499, (n=613,  (f-MDD versus
(n, %)   44.9%) 55.1%) nf-MDD)
Early onseta 441 (38.7) 215 (43.1) 218 (35.6) χ2 =  6.55, df=1, p<0.01
Recurrent MDDb 439 (38.5) 221 (44.3) 205 (33.4) χ2 = 13.69, df=1, p<0.001
Severe MDDc 383 (33.6) 200 (40.1) 175 (28.5) χ2 = 17.71, df=2, p<0.001
Data regarding familiality of MDD was missing in 29 subjects.
a Early onset vs. late onset, b Recurrent MDD vs. single MDD, c Severe MDD vs. mild MDD.
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were significantly more often present in females, this might suggest that different 
genes are involved in the etiology of comorbidity in males and females with f-MDD. 
The strong association between MDD and GAD is supported by findings from a 
female-twin study investigating genetic factors for axis I disorders, in which MDD 
and GAD seemed to load on the same genetic factor (Kendler et al., 1995). A review 
by Gorwood (2004) also put forward pleiotropy as an explanation for MDD and 
GAD comorbidity, suggesting a common genetic predisposition for MDD and GAD. 
Furthermore, factor analytic studies showed that MDD, dysthymia, and GAD cluster 
on the same internalizing factor of ‘anxious-misery’ (Krueger, 1999; Vollebergh et 
al., 2001), which is also indicative of a shared genetic variance for these disorders 
(Kendler et al., 1993c; Kendler et al., 1995; Kendler, 1996). However, in the studies 
mentioned, except for the one by Krueger (1999), no distinction has been made 
between males and females. We are unaware of other studies covering gender 
differences in comorbidity in community samples with f-MDD versus nf-MDD.
Some gender differences in lifetime comorbid disorders in MDD occurred 
independently of the familial load; comorbid alcohol use disorders were significantly 
more prevalent in males; comorbid panic disorder was significantly more prevalent in 
females. The observed gender differences in comorbidity cannot be explained by the 
gender of the parents transmitting MDD (or other psychiatric disorders) in different 
ways to male and female offspring, as gender does not seem to impact on the familial 
transmission of psychiatric disorders (Kendler et al., 1997; McGuffin et al., 1987).
When examining the effects of familiality of MDD within one gender, a significant 
difference was observed in comorbid dysthymia between females with f-MDD and 
with nf-MDD. An explanation for this finding might be that familial MDD leads to 
more chronic subtypes of depression (Klein et al., 2004) such as dysthymia. Another 
possibility is that the underlying vulnerability for comorbid dysthymia is stronger in 
females with f-MDD than with nf-MDD.
In this study, lifetime comorbid diagnoses were based on DSM-III-R axis I criteria of 
the CIDI without applying DSM-III-R hierarchical rules. This implies that exclusion 
criteria were not used and that each comorbid disorder was coded, whether present 
simultaneously with other axis I disorders, or appearing as completely separate 
disease periods. This procedure was followed to have a better insight in lifetime 
comorbidity patterns.
Kendler et al. (2002; 2006a) described developmental models for the etiology of 
major depression in both males (2006a) and females (2002) and suggested that 
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MDD is largely the same disorder in both sexes as the etiologic models revealed 
more similarities than differences across the sexes in the development of MDD. Twin 
studies have demonstrated that genetic factors and individual-specific environmental 
factors play an important role in the etiology of MDD (Sullivan et al., 2000). Shared 
environmental factors, such as parenting style and socioeconomic status, are not 
etiologically important in MDD (Sullivan et al., 2000). In the absence of shared 
environmental effects, familial associations in depression largely reflect shared 
genetic variance (Glowinski et al., 2003; Kendler & Prescott, 1999). More severe 
subtypes of depression and depression with associated comorbid conditions may 
be more strongly affected by genetic factors, whereas less severe depression may 
be more responsive to environmental factors (Lyons et al., 1998). Comorbid disorders 
were not explicitly taken into account in these studies, though. Our data suggest that 
different models might explain comorbidity in subjects with f-MDD and nf-MDD, and 
that etiologic models of MDD plus a comorbid disorder might be different across 
genders.
Although MDD characteristics, such as age of onset, disease course, and severity 
(Kendler et al., 1994; Kendler et al., 1999; Kendler et al., 2005a; McGuffin et al., 1996; 
Weissman et al., 1986) have been shown to be associated with both gender and 
familiality, adding these MDD characteristics to the analyses did not affect our results. 
This indicates an effect of familiality of MDD on the presence of gender differences 
in comorbid disorders, independent of MDD characteristics. That this association is 
independent of severity is remarkable as it is often thought that more severe forms of 
illness are accompanied by more comorbidity (Dalrymple & Zimmerman, 2007; Rush 
et al., 2005). This finding has not been reported earlier.
Findings of this study should be interpreted in light of some strengths and limitations. 
A major strength of the present report is the use of community subjects with MDD. 
Community samples are generally representative and large. Moreover, referral bias is 
avoided. By stratifying subjects into f-MDD and nf-MDD samples, we tried to achieve 
more MDD homogeneity within samples.
A limitation is the use of retrospective reports of axis I disorders. This can be 
subject to recall bias (de Graaf et al., 2002a), although studies suggest that it is 
possible to collect reliable lifetime diagnoses (Andreasen et al., 1981; Mannuzza et 
al., 1989). Overall, the reliability and validity for CIDI axis I disorders have shown to 
be acceptable to high (de Graaf et al., 2004). Moreover, the reliability of the lifetime 
diagnosis of MDD has been classified as modest (Kendler et al., 1993d) to fair (Foley 
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et al., 1998). To reduce the possible recall bias, we also performed analyses for 
12-month comorbidity. This yielded essentially the same results (data available from 
first author on request).
Another limitation is the use of family history information, relying solely on proband 
knowledge. This method has limitations in sensitivity compared with direct family 
study methods (Andreasen et al., 1977; Duggan et al., 1998). However, direct 
interviews with first-degree relatives could not be performed, considering the large 
sample size of this study. Moreover, Roy et al. (1996) observed that familiarity of 
the informant with manifestations of psychopathology increases the accuracy of the 
reporting in relatives. In our sample, MDD probands reported about MDD in their 
relatives and we have demonstrated substantial agreement between the questions 
regarding family history for depression and direct CIDI interviews in the relatives in an 
independent sample, which thus supports the accuracy of the data.
In conclusion, familiality of MDD must be taken into account when analyzing gender 
differences in MDD comorbidity. This is important for a better understanding of both 
phenotypical expressions of disorders and of the etiology and clustering of comorbid 
disorders in males and females, respectively, with and without f-MDD. This could lead 
to better treatment and prevention strategies applied to MDD and comorbid disorders 
instead of focusing on MDD only. Studies of susceptibility genes involved in f-MDD 
and nf-MDD with comorbid disorders are important for a better understanding of 
genetic phenotypes. In molecular genetic studies, it might be useful to use comorbid 
diagnoses in defining more genetically homogeneous forms of MDD for mapping of 
the disease genes.
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Abstract
Objectives The serotonin transporter gene (5-HTT) has been proposed as a candidate 
gene for major depressive disorder (MDD). Association studies, however, have 
revealed inconsistent results. This could be because of the phenotypic heterogeneity 
of MDD, as it often presents with comorbid disorders such as generalized anxiety 
disorder (GAD), alcohol-related disorders and dysthymia.
Methods In this exploratory study we performed regression analyses with 
generalized estimating equations in patients with familial MDD (n=233) in order 
to explore whether a polymorphism in the serotonin transporter gene (5-HTTLPR) 
is differentially associated with MDD plus a comorbid disorder compared to MDD 
without that particular comorbidity. As in general GAD is more common in females 
and alcohol-related disorders are more common in males, the analyses were stratified 
for gender.
Results Comorbid dysthymia was less common in s-allele carriers with MDD (p<0.05) 
than in subjects homozygous for the long allele. In the gender-specific analyses, 
an association between the 5-HTTLPR and comorbid alcohol use disorders was 
observed in females, with s-carriers reporting significantly less alcohol use disorders. 
The relationship with comorbid GAD differed by gender with male s-carriers reporting 
more comorbid GAD than female s-carriers.
Conclusion The effect of the 5-HTTLPR polymorphism on MDD is codependent 
on the presence of comorbid disorders and gender. In this study the s-allele of the 
5-HTTLPR polymorphism was associated with significantly lower rates of particular 
lifetime comorbid disorders. Therefore, the presence of comorbid psychiatric 
disorders should be taken into account to clarify the association of the 5-HTTLPR 
polymorphism with MDD phenotypes.
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Introduction
Family and twin studies have shown that major depressive disorder (MDD) has a 
familial pattern. Its prevalence is higher in first-degree relatives of MDD subjects than 
in relatives of controls (Sullivan et al., 2000). The estimated heritability of MDD is 35%-
40% (Shih et al., 2004; Sullivan et al., 2000). Candidate gene studies trying to identify 
genetic MDD risk factors have revealed inconsistent results. The most frequently 
studied gene is the gene encoding the serotonin transporter (SLC6A4, 5-HTT, SERT: 
Heils et al., 1996; Lesch et al., 1996). The protein product of this gene is the target of 
selective serotonin reuptake inhibitors. The 5-HTT gene is located on chromosome 
17q11.2 and is comprised of 14 exons. An insertion/deletion polymorphism with a short 
(s) allele (14 copies of a 20-23 base pair repeat unit) and a long (l) allele (16 copies) 
has been described in the promoter of the gene (Heils et al., 1996; Lesch et al., 1996). 
This variant, denoted 5-HTTLPR, is a functional polymorphism in which the short 
allele (s-allele) is associated with lower 5-HTT transcription and function compared 
with the long allele (l-allele) (Lesch et al., 1996). This results in lower serotonin reuptake 
from the synaptic cleft in s-allele carriers compared with patients homozygous for 
the l-allele (Collier et al., 1996). The transcription efficiency influences mood tone, 
circadian and neuroendocrine functions such as sleep, appetite, sexual behavior, 
and motor function (Lesch & Mossner, 1998). These features are often disturbed in 
depression. Multiple association studies of the 5-HTTLPR polymorphism with MDD 
have been performed. Two meta-analyses (Furlong et al., 1998; Lotrich & Pollock, 
2004) described a small but significant association of s-allele carriership and the s/s 
genotype with depression. However, in a more recent meta-analysis (Lasky-Su et al., 
2005) no significant association was observed between this variant and MDD.
Besides studies testing the association of the 5-HTTLPR polymorphism with 
depression, gene-environment interaction (G x E) studies have been carried out. 
Caspi et al. (2003) were the first to show that s-carriers were more likely to develop 
depression following stressful life events than individuals homozygous for the l-allele. 
Since then, it has been suggested that the effects of the 5-HTTLPR may only be 
observed in the presence of stressful life events. A recent review of the G x E studies 
(Uher & McGuffin, 2008) showed that many G x E studies replicated the Caspi et al. 
(2003) findings, though a few did not support the interaction.
In addition to the effects of environmental factors, diagnostic diversity and phenotypic 
heterogeneity in MDD might also contribute to the inconsistency of association results 
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seen for the 5-HTTLPR polymorphism. Phenotypic heterogeneity is clearly reflected 
by the high frequencies of different comorbid disorders presenting in subjects with 
MDD. Especially generalized anxiety disorder (GAD), several other anxiety disorders, 
and alcohol use disorders are common in MDD (Kessler et al., 1996; Middeldorp et 
al., 2005b; Ravelli et al., 1998). Interestingly, for some of these disorders, associations 
with the 5-HTTLPR polymorphism have also been described (Denys et al., 2006; 
Dick et al., 2007; Feinn et al., 2005). As the association between 5-HTTLPR and 
MDD remains controversial, we postulated that taking into account specific comorbid 
disorders in the definition of the MDD phenotype for association studies would 
help to clarify the relationship between the 5-HTTLPR polymorphism and MDD, as 
clinically (and thus possibly also genetically) more homogeneous study samples 
are included. Such an approach is warranted, given several reports of familiality of 
MDD plus a specific comorbid disorder, as is for example the case for MDD plus 
GAD (Middeldorp et al., 2005b; Middeldorp et al., 2005a) and MDD plus alcohol use 
disorders (Merikangas et al., 1994; Nurnberger, Jr. et al., 2001; Nurnberger, Jr. et al., 
2004).
In this exploratory study, we stratified the analyses for gender, as prevalences of 
comorbid disorders (such as anxiety and alcohol use disorders) are known to vary 
between females and males (Carter et al., 1999; Verhagen et al., 2008). A sample with 
familial MDD was used because of the higher heritability of this type of MDD. To our 
knowledge, this is the first attempt to evaluate the association between the 5-HTTLPR 
variant and MDD, while taking comorbid psychiatric disorders into account.
Participants and Methods
Our sample was collected in the context of an ongoing clinical family study into the 
genetics of MDD that started in 2004 in the Netherlands (GenMood study). The study 
was approved by the Dutch Central Medical Ethics Review Board and Local Ethics 
Boards. Patients were invited to participate through psychiatric treatment settings 
and advertisements. Inclusion criteria were (1) European Caucasian ethnicity; (2) 
history of MDD with a first episode between 12 and 50 years of age, defined by 
the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV); (3) at least one 
first-degree relative with a history of MDD (formally diagnosed and treated); (4) MDD 
in remission at enrollment, and (5) no history of manic episodes. For the majority 
chapter 4
73
of families we were able to include affected first-degree relatives. The GenMood 
sample currently consists of 139 probands and 124 of their affected first-degree 
family members (n=263, age 16-81). Written informed consent was obtained from all 
participants after the procedures were fully explained.
The CIDI-AUTO lifetime version 2.1 (WHO-CIDI, 1998) was used for the assessment 
of psychiatric disorders. The Composite International Diagnostic Interview (CIDI) 
is a structured interview developed by the World Health Organization that can be 
administered by trained interviewers who are not clinicians. The CIDI has acceptable 
interrater reliability and test-retest reliability for most diagnoses including major 
depression (Janca et al., 1992; Wittchen, 1994). Although few studies have validated 
the CIDI, it is considered to have acceptable validity (Janca et al., 1992). For this 
report, the CIDI section of depressive disorders was used for the confirmation of 
a lifetime MDD diagnosis and the following lifetime comorbid disorders were 
assessed: dysthymia, GAD, and alcohol use disorders (alcohol abuse and alcohol 
dependence).
High molecular DNA was isolated by a routine procedure (Miller et al., 1988). 
Amplification of DNA was on 50 ng genomic DNA by using 10 pmol of forward 
primer (5’-GGCGTTGCCGCTCTGAATGC-3’) and 10 pmol reverse primer 
(5’-GAGGGACTGAGCTGGACAACCAC-3’), 0.25 mmol/l dNTPs, 0.5 U Taq DNA 
polymerase (Invitrogen, Breda, the Netherlands) in a polymerase chain reaction 
(PCR) buffer containing 0.3 mol/l Tris-HCl (pH 8.5), 75 mmol/l ammoniumsulfate, 
and 7.5 mmol/l MgCl2. The cycling conditions for the PCR started with 5 min at 92°C, 
followed by 35 cycles of 1 min at 92°C, 1 min at the optimized annealing temperature 
(57.5°C), and 1 min 72°C, then followed by an extra 5 min 72°C. PCR products were 
analyzed on a 2% agarose gel. The amplification yielded distinct bands at 484 bp 
(s-allele) and 528 bp (l-allele).
A control sample of anonymous blood donors (n=166) was included to check the 
allele frequencies and genotype distribution of the 5-HTTLPR polymorphism. Hardy-
Weinberg equilibrium assumptions for the 5-HTTLPR variant in the control sample 
were examined using Genepop [http://genepop.curtin.edu.au/genepop_op1.html] 
(Raymond & Rousset, 1995). Chi-square analysis was used to compare allele and 
genotype frequencies between the cases and controls.
To correct for the potential bias because of the dependency of family data (Rebollo 
et al., 2006), we performed generalized estimating equations (GEE) analyses for 
a logistic regression model using the Stata software StataCorp (Stata Statistical 
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Software: Release 9, College Station, Texas, USA) (Stata, 2005). We used two different 
models to explore whether the 5-HTTLPR polymorphism was associated with a 
particular comorbid disorder in our MDD-affected sample. The l/l genotype was used 
as the reference group and the presence or absence of either dysthymia, GAD, or 
alcohol use disorders as outcome measure. For each of these comorbid disorders, 
MDD cases with a particular comorbid disorder were compared with all MDD cases 
without that specific comorbidity. In the first model, the MDD characteristics age 
of onset, severity (mild, moderate, severe), and disease course (recurrent versus 
single) were included as covariates, as these MDD characteristics were found to 
be associated with comorbidity (Kendler et al., 1996; Rush et al., 2005; Sullivan et 
al., 1998). In the second model, MDD characteristics were excluded. As more than 
one comorbid disorder was often present in individual patients, we adjusted for the 
presence of other comorbidities in both models. Analyses were also adjusted for 
gender, age, and educational attainment (low, medium, high, and university). These 
factors have been found to be associated with depression in community samples 
(Bijl et al., 1998a; Kessler et al., 2005a).
Analyses were performed for the total sample as well as for males and females 
separately, given the gender differences in both MDD prevalence and comorbid 
disorder prevalence (Carter et al., 1999; Verhagen et al., 2008). The effect estimates 
were expressed as odds ratios and 95% confidence intervals. Differences between 
odds ratios were considered statistically significant when the confidence intervals 
of a risk factor mutually excluded the point estimates for one or both of the other 
categories (Gardner & Altman, 1986).
Results
The study sample with complete phenotypic and genotypic data consisted of 263 
MDD cases. The genotype distribution of the 5-HTTLPR polymorphism was in Hardy-
Weinberg equilibrium (p=0.54). Genotype and allele distributions were similar in 
MDD cases and controls (genotype χ2 = 3.3, d.f.=2, p=0.19; allele χ2 = 2.9, d.f.=1, 
p=0.09).
The mean age of the MDD sample was 47.7 (SD 13.5), 28.5% of subjects were male. 
Males were significantly older (52.1 years) than females (46.0 years, t=3.3, d.f. 261, 
p<0.01). Females had a significantly younger age of onset of MDD (25.0 years) 
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than males (30.4 years, t=3.7, d.f. 261, p<0.001) and had experienced more severe 
episodes of MDD (χ2 = 8.9, d.f.=2, p<0.05). No gender differences in disease course 
of MDD were observed. The 5-HTTLPR genotype was not significantly associated 
with the MDD characteristics age of onset, severity, and disease course. No gender 
differences were found in 5-HTTLPR genotype or allele frequencies (Table 1).
In 16.3% of cases with MDD, no lifetime comorbid disorders were present. Comorbid 
GAD was most prevalent (43.3%) in the MDD sample, followed by dysthymia 
(36.9%), and alcohol use disorders (16.7%). The prevalence of comorbid alcohol use 
disorders differed significantly between males and females (24.0% versus 13.8%: χ2 
= 4.0, p<0.05). Figure 1 shows prevalences of (combinations of) lifetime comorbid 
disorders, as they were present in individual patients. Most subjects have MDD with 
comorbid GAD and dysthymia. MDD with both comorbid dysthymia and alcohol 
use disorders is least frequent. Table 2 presents the genotype frequencies for the 
comorbid disorders.
For 233 patients we had complete information for the GEE analyses. For the first model, 
GEE regression analyses showed an association of the 5-HTTLPR polymorphism 
with lifetime comorbid dysthymia in the overall sample (Table 3). S-carriers had 
significantly less comorbid dysthymia compared to carriers of the l/l genotype. In 
the gender-specific analyses, an association of the 5-HTTLPR polymorphism with 
lifetime alcohol use disorders was observed in females, with s-carriers reporting 
significantly less alcohol use disorders (Table 3). In addition, the relationship of the 
5-HTTLPR polymorphism with comorbid GAD differed by gender; male s-carriers 
reported more GAD than female s-carriers (Table 3).
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Table 1  Genotype and allele distribution of the 5-HTTLPR  
polymorphism in subjects with lifetime MDD
 Genotype distribution (n, %) Allele frequency (n, %)
 n s/s (%) s/l (%)  l/l (%) n s (%) l (%)
Overall  
sample 263 54 (20.5) 117 (44.5) 92 (35.0) 526 225 (42.8) 301 (57.2)
Males 75 14 (18.7) 31 (41.3) 30 (40.0) 150 59 (39.3) 91 (60.7)
Females 188 40 (21.3) 86 (45.7) 62 (33.0) 376 166 (44.1) 210 (55.9)
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Excluding the MDD characteristics age of onset, severity, and disease course from 
the analyses (model two) did not lead to major changes (data not shown).
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Table 2  Genotype and allele distribution of the 5-HTTLPR  
polymorphism in subjects with lifetime MDD
Comorbid disorder n (%) s/s (%) s/l (%)  l/l (%) s-carrier (%)
Dysthymia 97 (36.9) 18 (18.6) 35 (36.1) 44 (45.4) 53 (54.6)
GAD 114 (43.3) 25 (21.9) 47 (41.2) 42 (36.8) 72 (63.2)
Alcohol use disorders 44 (16.7) 9 (20.5) 16 (36.4) 19 (43.2) 25 (56.8)
No comorbidity 43 (16.3) 9 (20.9) 20 (46.5) 14 (32.6) 29 (67.4)
GAD: generalized anxiety disorder. Alcohol use disorders include alcohol abuse and 
alcohol dependence. No comorbidity: no comorbid dysthymia, GAD, alcohol use 
disorders, or other anxiety disorders.
Figure 1  Prevalences of (combinations of) comorbid disorders in  
subjects with lifetime MDD
1. Major depressive disorder without comorbidity, 2. Dys-GAD, 3. Comorbid GAD, 4. Comorbid 
Dys, 5. Comorbid Alc, 6. GAD-Dys-Alc, 7. GAD-Alc, 8. Dys-Alc. Alc, alcohol use disorders;  
Dys, dysthymia; GAD, generalized anxiety disorder
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Discussion
This exploratory study examines the potential of MDD comorbidity to serve as a 
tool to define a more homogeneous MDD sample for genetic studies, using the 
5-HTTLPR polymorphism as an example. We found the s-allele of the polymorphism 
to be associated with the presence of significantly lower rates of lifetime comorbid 
dysthymia in the overall MDD sample. In females, the s-allele was associated with 
significantly lower rates of lifetime comorbid alcohol use disorders. The size of the 
effects was limited, which is not surprising given that MDD and the associated 
comorbid conditions are thought to be polygenic in etiology (Johnson et al., 2006; 
Lesch, 2001; Lotrich & Pollock, 2004; Ogilvie et al., 1996). The relationship was not 
influenced by the MDD characteristics age of onset, disease severity, and MDD 
course. Although more severe forms of illness with an earlier age of onset are often 
accompanied by more comorbidity (Dalrymple & Zimmerman, 2007; Rush et al., 
2005), this finding was not surprising as the 5-HTTLPR polymorphism has not been 
found significantly associated with these MDD characteristics.
The 5-HTTLPR polymorphism has also been investigated for association with 
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Table 3  Odds ratios (and 95% CIs) for 5-HTTLPR s-carriership  
and the presence of MDD-comorbid disorders for the overall 
sample and males and females, separately
Comorbid disorder Overall sample Males Females 
 n=233a n=67 n=166
Dysthymia 0.5 (0.3-1.0)* 1.2 (0.3-5.2) 0.5 (0.2-1.0)
GAD 1.0 (0.6-1.9) 2.2 (0.7-7.0) 0.7 (0.3-1.5)
Alcohol use disorders 0.5 (0.2-1.2) 0.8 (0.2-3.3) 0.3 (0.1-0.8)*
5-HTTLPR l/l genotype used as reference category.
a Analyses included only subjects with complete information. Information regarding 
 educational attainment was missing in 30 subjects.
Analyses were adjusted for age, educational attainment, other comorbid disorders,  
and MDD characteristics age of onset, severity of MDD, course of MDD.
GAD: generalized anxiety disorder. Alcohol use disorders include alcohol abuse  
and alcohol dependence.
* P<0.05.
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alcohol use disorders. A meta-analysis investigating the association with alcohol 
dependence (Feinn et al., 2005) described a weak but significant association of the 
s-allele with alcohol dependence. Interestingly, the association with the s-allele was 
greatest for alcohol use disorder with comorbid psychopathology. Two studies of 
the 5-HTTLPR association with alcoholism and comorbid depression also showed 
that the frequency of the s-allele was higher in patients with alcohol dependence 
and comorbid depression than in healthy controls (Marques et al., 2006; Nellissery 
et al., 2003) and alcoholics without comorbid depression (Marques et al., 2006). 
These findings support the hypothesis that taking comorbid disorders into account 
might help to clarify relationships in association studies. As a difference in sample 
selection exists, with patients with primary alcohol use disorders being included in 
the former studies, whereas for the GenMood study subjects with lifetime depression 
were selected, this does not allow comparisons. Moreover, because of the gender 
difference in the prevalence of alcohol use disorders and depression, the observations 
in the alcoholics sample were predominantly driven by males, whereas the GenMood 
results were mainly based on females.
Regarding dysthymia, we found only one association study of the 5-HTTLPR 
polymorphism. No association of either the s-allele or l-allele with dysthymia was 
observed in a small Brazilian sample (Oliveira et al., 2000).
We found no association of the 5-HTTLPR polymorphism with MDD in the presence 
of GAD. Though, a gender difference in comorbid GAD was observed with male 
s-carriers reporting significantly more GAD than female s-carriers. In a Spanish 
primary-care attendee sample, an association with the 5-HTTLPR polymorphism and 
depression was observed for the s/s genotype (Cervilla et al., 2006). Adjustment for 
the presence of comorbid GAD did not change this association. This is in agreement 
with our findings. Unfortunately, gender differences were not taken into account in 
this Spanish study.
In biological sense, results showing association of the assumed low-risk allele for 
MDD (the l-allele) and a particular comorbid disorder seems puzzling. Probably, the 
l-allele predisposes to a more complicated MDD-phenotype, especially in females. 
An explanation could be that MDD and comorbidity is etiologically different from 
single MDD, as has been suggested by heritability studies (Merikangas et al., 1994; 
Middeldorp et al., 2005b; Nurnberger, Jr. et al., 2004). To investigate this issue, a large 
control sample with single MDD cases could be used in future studies. In other studies 
describing the 5-HTTLPR association with MDD, information regarding comorbidity 
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is mostly missing. Therefore, it is hard to judge whether the probable presence of 
comorbid disorders influences the associations described in other studies. One 
could argue that the gender difference in the 5-HTTLPR association with comorbid 
disorders in the present study is caused by functional differences of the two alleles 
between the genders. From animal studies it appeared that the serotonergic system 
is differentially regulated by gender, because of the influence of estrogen (McQueen 
et al., 1997; McQueen et al., 1999). Thus, the serotonin transporter polymorphism 
may affect comorbidity in males and females differently. Another interesting point 
to raise here is that recent studies described another functional variant within the 
l-allele of the 5-HTTLPR (Chorbov et al., 2007; Hu et al., 2006; Wendland et al., 2006), 
with the lg-allele effectively behaving like the s-allele, in contrast to the la-allele. This 
additional variant has an allele frequency of 6.5% in Caucasians (Wendland et al., 
2006). As we did not take into account this additional variant in our study, a part of 
the l/l-group might phenotypically be s-carrier.
Altogether, this exploratory study was set up to describe a method of performing 
genetic studies with specific attention to the presence of comorbid disorders. Our 
study supports the hypothesis that narrowing down the phenotype or considering 
psychiatric phenotypes with comorbid disorders to create more homogeneous 
subgroups may help to clarify the relationship of disease with genetic factors, though 
the specific alleles involved need clarification. Furthermore, the finding that the 
effect of the 5-HTTLPR polymorphism on MDD is codependent on the presence of 
comorbid disorders and gender requires replication in larger samples, as the power 
of our study was limited (Munafo et al., 2005). As statistical power was limited, we 
cannot rule out that our results might represent type I error findings, as we chose to 
refrain from adjusting for multiple testing in this exploratory study. In addition, we did 
not formally establish familiality of MDD and specific comorbidities. Our results may 
have implications for association and G x E studies in MDD, in which the presence 
of comorbid psychiatric disorders should not be ignored. Taking comorbidity into 
account might help to clarify the relationship of the 5-HTTLPR polymorphism with 
MDD phenotypes.
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Abstract
Brain-derived neurotrophic factor (BDNF) is a nerve growth factor that has 
antidepressant-like effects in animals and may be implicated in the etiology of mood-
related phenotypes. However, genetic association studies of the BDNF Val66Met 
polymorphism (single nucleotide polymorphism rs6265) in major depressive disorder 
(MDD) have produced inconsistent results.
We conducted a meta-analysis of studies comparing the frequency of the BDNF 
Val66Met-coding variant in depressed cases (MDD) and nondepressed controls. A 
total of 14 studies involving 2,812 cases with DSM-III or -IV defined MDD and 10,843 
nondepressed controls met the inclusion criteria. Analyses were stratified either 
by gender or ethnicity (Asian and Caucasian) because MDD is more prevalent in 
females and in Caucasians and because BDNF allele frequencies differ by ethnicity. 
Pooled odds ratios (ORs) and 95% confidence intervals (CIs) were provided for allelic 
analyses (Met versus Val), as well as for genotypic analyses (Met/Met and Val/Met 
versus Val/Val).
In the total sample, the BDNF Val66Met polymorphism was not significantly associated 
with depression. However, the gender stratified analyses revealed significant effects 
in both the allelic and genotypic analyses in males (ORMET, 95% CI; 1.27 (1.10-1.47); 
ORMET/MET, 95% CI 1.67 (1.19-2.36)). Stratification according to ethnicity did not show 
significant effects of the Val66Met polymorphism on MDD.
Our results suggest that the BDNF Val66Met polymorphism is of greater importance 
in the development of MDD in males than in females. Future research into gender 
issues will be of interest.
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Introduction
Major depressive disorder (MDD) is one of the most common psychiatric disorders 
and causes impairment in several aspects of life. MDD is a multifactorial disorder with 
multiple genetic and nongenetic factors contributing to the disorder with relatively 
small effect (Ebmeier et al., 2006). Twin studies estimate the heritability of MDD 
to be moderate, in the range of 35%-40% (Shih et al., 2004; Sullivan et al., 2000). 
Several candidate genes have been described for MDD (Levinson, 2006; Lopez-
Leon et al., 2008), one of which is the gene encoding the brain-derived neurotrophic 
factor (BDNF), located on chromosome 11p13 (Maisonpierre et al., 1990). The BDNF 
gene codes for a neurotrophin that is highly expressed in the central nervous system, 
especially in the hippocampus (Martinowich et al., 2007; Willis-Owen et al., 2005). 
BDNF plays a role in the proliferation, differentiation and survival of neuronal cells 
(Bath & Lee, 2006; Duman, 2004; Schumacher et al., 2005), and regulates synaptic 
plasticity and connectivity in the adult brain (Angelucci et al., 2005; Bath & Lee, 
2006). According to the ‘neurotrophic hypothesis’ of depression (Duman, 2004), a 
reduction in BDNF expression is involved in the pathophysiology of MDD (Angelucci 
et al., 2005; Duman, 2004; Karege et al., 2002; Lang et al., 2005; Schumacher et 
al., 2005), whereas the use of antidepressants leads to an upregulation of BDNF 
in the hippocampus of subjects with MDD (Angelucci et al., 2005; Duman, 2004; 
Duman & Monteggia, 2006; Shimizu et al., 2003). A single nucleotide polymorphism 
(rs6265) in exon 11 of the BDNF gene results in an amino-acid substitution from 
valine to methionine at codon 66 (Val66Met) in the prodomain of BDNF (Schumacher 
et al., 2005). Val66Met is a common polymorphism with allele frequencies that are 
dependent on ethnic background. In Caucasian populations, the frequency of the 
Met allele is 25-32% (Cargill et al., 1999; Shimizu et al., 2004), whereas in Asian 
populations the Met allele is more frequent, around 40-50% (Choi et al., 2006; Itoh et 
al., 2004; Tsai et al., 2003).
Currently, it is still unclear what the consequences of the Val66Met polymorphism 
are on brain function, as both alleles have been associated with different disease 
processes including substance-related disorders, schizophrenia, and eating 
disorders (Gratacos et al., 2007). The risk allele for depression and depression-
related traits has also not been clearly defined. A number of studies have suggested 
that the Met allele is associated with poorer episodic memory performance (Egan et 
al., 2003; Hariri et al., 2003), a symptom often observed in subjects with MDD (Veiel, 
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1997). Furthermore, it has been shown that the Met allele is associated with reduced 
hippocampal activity (Chen et al., 2004; Egan et al., 2003). Studies in in vitro and in 
animal models have shown that the presence of the Met allele alters the sorting and 
secretion of proBDNF, such that less regulated (activity dependent) secretion is likely 
to occur in carriers of at least one Met allele. This is reflected in reduced hippocampal 
synaptic activity. Those individuals may, however, have more constitutively secreted 
BDNF (Chen et al., 2005; Egan et al., 2003; Hariri et al., 2003). In contrast, the 
Val allele has been found associated with higher trait anxiety and higher mean 
neuroticism scores (Lang et al., 2005; Sen et al., 2003), which are potent risk factors 
for the development of depression (Hettema et al., 2006; Kendler et al., 2004). Also, 
a family-based study showed the Val allele to be associated with childhood-onset 
mood disorders (Strauss et al., 2005). Other studies did not observe any association 
of the Val66Met polymorphism with MDD (Cohen et al., 2004; Oswald et al., 2005; 
Schumacher et al., 2005; Surtees et al., 2007) (see also Table 1).
The inconsistencies in association studies of the BDNF Val66Met polymorphism 
with mood disorders might also result from the lack of statistical power in studies 
of small sample size and from variation across studies in inclusion criteria, such as 
the definition of psychiatric phenotype, or ethnicity. For example, some studies used 
broad criteria in which individuals with MDD, bipolar disorders, and dysthymia were 
included (Hong et al., 2003; Kunugi et al., 2004; Lohoff et al., 2005; Neves-Pereira et 
al., 2005; Oswald et al., 2004), whereas others included individuals with MDD only 
(Hwang et al., 2006; Oswald et al., 2005; Schumacher et al., 2005; Strauss et al., 
2004a).
There are two other issues in MDD which might contribute to the inconsistency 
of association findings. The first is the gender difference in MDD prevalence and 
gender-related differences in the etiology of MDD (Nolen-Hoeksema, 2002). Two large 
population-based studies, the National Comorbidity Survey-Replication (NCS-R; 
9,892 inhabitants of the United States; Kessler et al., 2003) and the Netherlands 
Mental Health Survey and Incidence Study (NEMESIS; 7,076 Dutch adults; Bijl et 
al., 1998a), have shown a gender difference in the lifetime prevalence of MDD of 
20.1-21.3% in females and 10.9-12.7% in males (Bijl et al., 1997; Bijl et al., 1998a; 
Kessler et al., 1993). In Asian populations, the female/male ratio is also around 2:1 
(Weissman et al., 1996). Some studies have reported a significantly higher heritability 
of MDD in females (40-42%) than in males (29-31%) (Bierut et al., 1999; Kendler et 
al., 2001; Kendler et al., 2006b), whereas others did not observe gender differences 
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in heritability (Kendler & Prescott, 1999; McGuffin et al., 1996; Sullivan et al., 2000). 
Furthermore, genetic linkage studies in families with recurrent, early-onset MDD 
showed significant log of the odds scores for multiple loci of which some regions were 
only observed among female affected relative pairs and not among males (Fullerton 
et al., 2003; Zubenko et al., 2002b; Zubenko et al., 2003b). This might indicate that 
gender-specific susceptibility genes contribute to the development of MDD.
The second issue is the difference in lifetime prevalence rates of MDD between 
Western and Asian countries. Lower lifetime prevalence of MDD has been observed 
in Chinese, Japanese and Korean populations (Hwu et al., 1996; Parker et al., 2007). 
Cross-national epidemiologic surveys indicated that the lifetime prevalence of MDD 
is 1.5% in Taiwanese and 2.9% in Koreans (Weissman et al., 1996), compared to a 
mean of 15-17% in Western populations (Bijl et al., 1998a; Kessler et al., 1993; Kessler 
et al., 1994). Although a number of the studies mentioned above have suggested the 
Met allele to be the risk allele for depression, the higher frequency of the Met allele 
in Asians in the presence of lower MDD prevalence rates might suggest that the Met 
allele protects against MDD.
The aim of the current study was to perform a meta-analysis (see Munafo & Flint, 
2004; Trikalinos et al., 2008) of all available case-control association studies of the 
BDNF Val66Met polymorphism in adults and elderly with current MDD or MDD within 
1 year before study inclusion. We examined the roles of gender and ethnicity as 
potential modifiers of the relationship between the Val66Met polymorphism of BDNF 
and MDD, because 1) MDD is more prevalent in females than males, 2) the lifetime 
prevalence of MDD differs between Caucasians and Asians and 3) the frequency of 
the BDNF Val66Met polymorphism is dependent on ethnic origin.
Materials and Methods
Search strategy
Studies were identified through Medline, PubMed, EmBase, and PsychINFO using 
the search terms 1) Val66Met and (depress* or mood disorde* or major depress*), 
and 2) rs6265 and (depress* or mood disorde* or major depress*). Studies published 
in the English language before January the 1st, 2008, were considered. We searched 
the reference lists of studies included to identify other potentially eligible studies.
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Inclusion criteria
Case-control studies reporting genotype or allele frequencies of the BDNF Val66Met 
polymorphism in depressed cases (MDD) and in (nondepressed) controls were 
eligible for inclusion in this meta-analysis. Case status was defined as having a current 
or one-year DSM-III-, DSM-III-R-, or DSM-IV- (Diagnostic and Statistical Manual of 
Mental Disorders) based diagnosis of MDD assessed by established psychiatric 
interviews. Studies of any ethnic group were included as were several age categories 
(adults, elderly and geriatric subjects). For inclusion of a study, we required genotype 
frequencies to be in Hardy-Weinberg equilibrium (HWE) in the healthy controls (p > 
0.01).
Case-only studies, family-based designs, and population studies with healthy 
subjects were excluded, as were studies describing effects of BDNF on depression-
related phenotypes such as anxiety or personality traits.
In most studies, control subjects had been screened for the presence of 
psychopathology. In a minority of the studies this was not reported (Hwang et al., 
2006; Ribeiro et al., 2007; Zhang et al., 2006). This was not an exclusion criterion.
The methods used for genotyping in the different reports included restriction 
fragment length polymorphism analysis (Choi et al., 2006; Hwang et al., 2006; 
Ribeiro et al., 2007; Surtees et al., 2007; Tsai et al., 2003; Zhang et al., 2006), TaqMan 
analysis (Anttila et al., 2007; Iga et al., 2007; Oswald et al., 2005), MassArray analysis 
(Schumacher et al., 2005; Surtees et al., 2007), pyrosequencing (Oswald et al., 2005), 
fluorescence resonance energy transfer method (Frodl et al., 2007) and an Illumina 
Beadarray-based analysis (Ribeiro et al., 2007).
Data extraction
Two investigators (MV, AvdM) performed the literature search and reviewed the results, 
independently. Full articles were retrieved for further assessment if the information 
in the title or abstract suggested that the study: 1) compared depressed subjects 
(MDD) with healthy controls; and 2) assessed the BDNF-coding variant Val66Met 
(rs6265). Studies that were not available on the Internet or via libraries were obtained 
by contacting the authors (Demiryurek et al., 2006; Hong et al., 2003; Tsai et al., 
2004). We obtained all requested data.
Data from each study were extracted independently by three investigators (MV, AvdM, 
PvD), using a standardized data extraction form. In case of disagreement of study 
inclusion, a fourth investigator was involved (JJ). In case more psychiatric diagnoses 
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were described in one study, only data from the MDD samples were extracted. If 
essential data were missing from the study reports, the authors of the respective 
papers were contacted and asked to provide additional data. This was successful 
in all cases.
The following data were coded: author(s) and year of publication, methods (study 
design, sample sizes for both cases and controls, diagnostic tools for determination 
of case status, definition of case status) and sample characteristics (gender ratio, 
mean age, ethnic background, HWE in controls, genotype and allele frequencies). 
Ethnic origin was either Caucasian or Asian.
In addition, we contacted all authors by email to obtain gender-specific data such 
as mean age, and genotype and allele frequencies per gender, which most of them 
made readily available to us (Anttila et al., 2007; Choi et al., 2006; Hwang et al., 2006; 
Iga et al., 2007; Oswald et al., 2005; Schumacher et al., 2005; Surtees et al., 2007; 
Taylor et al., 2007; Tsai et al., 2003; Zhang et al., 2006).
Statistical analysis
The meta-analysis examined the allelic association of the Met allele with the risk 
of MDD relative to the Val allele (OR Met versus Val). Besides this, genotypic ORs 
were calculated for the heterozygous Val/Met and homozygous Met/Met genotypes 
separately, with the Val/Val genotype as the reference. Allele frequencies and 
genotype distribution were extracted for cases and controls. For some studies, allele 
frequencies were calculated from the available data. Zero cell correction (Deeks 
et al., 2006; Sterne et al., 2001) was applied in the studies where cells from the 
crosstabulations contained zeros (Frodl et al., 2007; Strauss et al., 2004a; Taylor et 
al., 2007; Zhang et al., 2006). This correction is necessary to obtain ORs from every 
crosstabulation. The distribution of genotypes in the control group was tested for 
HWE in each paper using an exact test (Weir, 1996).
To combine the individual study results, we conducted meta-analyses using RevMan 
(Review Manager (RevMan), 2003; RevMan Analyses, 2003). The heterogeneity 
between studies was tested using the Q-statistic, which is a weighted sum of the 
squares of the deviations of individual study OR estimates from the overall estimate. 
When the ORs are homogeneous, Q follows a χ2 distribution with r-1 (r is the number 
of studies) degrees of freedom (d.f.). If PQ < 0.10, the heterogeneity was considered 
to be statistically significant (Lau et al., 1997; Fleiss, 1981). Inconsistency across 
studies was quantified with the I2 metric (I2 = Q-d.f./Q), which can be interpreted 
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as the percentage of total variation across several studies due to heterogeneity. I2 
takes values between 0 and 100%, with higher values denoting a greater degree of 
heterogeneity (0-25%: no heterogeneity; 25-50% moderate heterogeneity; 50-75%: 
large heterogeneity; 75-100% extreme heterogeneity) (Zintzaras & Hadjigeorgiou, 
2004). When no heterogeneity was present, the pooled OR was estimated using 
fixed effects models (Mantel & Haenszel, 1959; Laird & Mosteller, 1990). Otherwise, 
random effects models (DerSimonian & Laird, 1986) were applied to obtain the 
pooled OR. Random effects modeling assumes a genuine diversity in the results of 
various studies and it incorporates a between-study variance into the calculations 
(Whitehead, 2002). The results of the association tests are indicated as pooled ORs 
with the corresponding 95% confidence intervals of the Val66Met-induced risk of 
MDD. P < 0.05 was considered statistically significant.
A random effects meta-regression of effect size with mean age and the proportion 
of females as covariates was performed with use of R 2.7.0 (R Development Core 
Team, 2008) to determine whether these covariates influenced effect size. Studies 
were weighted, so that the more precise studies had more influence in the regression 
analyses.
The STATA statistical software package (Stata, 2003) was used to detect the presence 
of potential publication bias. A differential magnitude of effect in large versus small 
studies for the genetic contrasts under investigation was checked using the Egger 
regression test for funnel plot asymmetry (Egger et al., 1997) and the Begg-Mazumdar 
test, which is based on Kendall’s-τ (Begg & Mazumdar, 1994). They were considered 
statistically significant at p < 0.10.
The meta-analysis consisted of two steps: 1) the overall analysis, which included all 
available data, and 2) subgroup analyses by ethnicity and gender. In addition, we 
performed sensitivity analyses and meta-regression analyses. In total, five different 
samples (total sample, males only, females only, Asians only, Caucasians only) were 
analyzed for both allelic and genotypic contrasts.
Results
The literature search yielded 42 studies. We excluded 28 studies for reasons specified 
in Figure 1 and included 14 studies with 16 samples in the meta-analysis (Table 1 
and Figure 1). In total, 12 authors provided additional data for the gender-specific 
analyses in 12 samples (Figure 1).
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Figure 1  Study selection for the meta-analysis
Excluded: No MDD phenotype (Demiryurek et al., 2006; Hunnerkopf et al., 2007; Jiang et al., 2005; 
Kim et al., 2008; Krabbe et al., 2007; Kremeyer et al., 2006; Lang et al., 2005; Neves-Pereira et al., 
2002; Oroszi et al., 2006; Rybakowski et al., 2005; Rybakowski, Borkowska, Skibinska, & Hauser, 
2006; Rybakowski et al., 2006; Shimizu et al., 2005; Tramontina et al., 2007; Tsai et al., 2004; Tsai et 
al., 2005; Willis-Owen et al., 2005), No case-control design (Gratacos et al., 2007; Groves, 2007; 
Post, 2007; Schule et al., 2006; Sen, 2005; Strauss et al., 2004b; Strauss et al., 2005; Tsai, 2007), 
No adults (Chen et al., 2006; Kaufman et al., 2006), No Hardy-Weinberg equilibrium (HWE) (Kim et 
al., 2007).
Included: Caucasian studies (Anttila et al., 2007; Frodl et al., 2007; Oswald et al., 2005; Ribeiro et 
al., 2007; Schumacher et al., 2005; Strauss et al., 2004a; Surtees et al., 2007; Taylor et al., 2007; 
Zhang et al., 2006), Asian studies (Choi et al., 2006; Hong et al., 2003; Hwang et al., 2006; Iga et al., 
2007; Tsai et al., 2003), Gender studies (Anttila et al., 2007; Choi et al., 2006; Frodl et al., 2007; Hong 
et al., 2003; Hwang et al., 2006; Iga et al., 2007; Schumacher et al., 2005; Strauss et al., 2004a; 
Surtees et al., 2007; Taylor et al., 2007; Tsai et al., 2003; Zhang et al., 2006).
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Overall, the studies provided 2,812 cases (57.4% female, mean age 50.6 years) and 
10,843 controls (51.2% female, mean age 47.6 years; Table 1). Genotype distributions 
and allele frequencies are shown in Table 2. The Val allele was most common in both 
cases and controls and was significantly higher in the Caucasian pooled sample 
(t = 11.37, d.f. = 14, p < 0.001).
In the majority of our meta-analytic tests, no significant heterogeneity was observed 
(Table 3). No evidence of potential publication bias was found (results not shown).
Association of BDNF Val66Met and MDD
Figures 2a-c and Table 3 show the results of the different association tests for the 
genetic polymorphism and MDD risk for several subgroups.
The analysis of the allelic association of the Met allele with the risk of MDD revealed 
significant heterogeneity between the 16 samples. The random effects pooled OR 
was not significant (Table 3). For the genotypic analyses (the Met/Met and Val/Met 
genotype relative to the Val/Val genotype), no evidence of heterogeneity was found. 
Therefore, fixed effects models were applied; the genotypic pooled ORs were not 
significant, either.
chapter 5
Table 2  Genotype distribution and allele frequencies for Caucasians, 
Asians and the total sample
 Val/Val Val/Met Met/Met  Val Met
 (n, %) (n, %) (n, %) (n, %) (n, %)
Caucasians
MDD cases 1449 (65.0) 714 (32.0) 66 (3.0) 3612 (81.0) 846 (19.0)
Controls 6299 (64.7) 3113 (32.0) 331 (3.4) 15711 (80.6) 3775 (19.4)
Asians      
MDD cases 156 (26.8) 275 (47.2) 152 (26.0) 587 (50.3) 579 (49.7)
Controls 290 (26.4) 583 (53.0) 227 (20.6) 1163 (52.9) 1037 (47.1)
Total sample      
MDD cases 1605 (57.1) 989 (35.2) 218 (7.8) 4199 (74.7) 1425 (25.3)
Controls 6589 (60.8) 3696 (34.1) 558 (5.1)  16874 (77.8) 4812 (22.2)
Abbreviations: MDD, major depressive disorder; Met, methionine; Val, valine.
93
BDNF Val66Met, MDD and gender
The subgroup analyses based on stratification by gender showed significant effects 
of BDNF on MDD in males (Table 3 and Figure 2a; Males). When comparing male 
MDD cases with male controls for the increase in risk of MDD due to BDNF alleles, 
male MDD cases carried the Met allele significantly more often (p = 0.001; 32.5% in 
MDD cases versus 22.2% in controls). For the Met/Met genotype, the same pattern 
emerged (p = 0.003; 21.9% in MDD cases versus 7.9% in controls; Figure 2b; Males). 
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Table 3  Numbers of cases and controls, ORs (95% CIs) for the effect 
of BDNF on MDD and an estimate of heterogeneity
 Cases Controls OR (95% CI) Heterogeneity (d.f.)
Total sample
Met vs Val 5624 21686 1.06 (0.94-1.19) I2 = 48.6% (15)*
Met/Met vs Val/Val 1822 7150 1.15 (0.93-1.41) I2 = 14.3% (15)
Val/Met vs Val/Val 2594 10289 1.00 (0.91-1.11) I2 = 23.8% (15)
Female gender    
Met vs Val 2092 10156 1.08 (0.96-1.22) I2 = 5.9% (11)
Met/Met vs Val/Val 642 3334 1.08 (0.80-1.47) I2 = 0% (11)
Val/Met vs Val/Val 943 4797 1.08 (0.92-1.27) I2 = 7.5% (11)
Male gender    
Met vs Val 1362 9424 1.27 (1.10-1.47)** I2 = 0% (11)
Met/Met vs Val/Val 424 3117 1.67 (1.19-2.36)** I2 = 0% (11)
Val/Met vs Val/Val 589 4466 1.14 (0.93-1.41) I2 = 0% (11)
Asian ethnicity    
Met vs Val 1166 2200 1.14 (0.91-1.43) I2 = 56.9% (4)*
Met/Met vs Val/Val 308 517 1.31 (0.85-2.03) I2 = 53.5% (4)*
Val/Met vs Val/Val 431 873 0.92 (0.72-1.18) I2 = 0% (4)
Caucasian ethnicity    
Met vs Val 4458 19486 1.02 (0.88-1.17) I2 = 45.1% (10)*
Met/Met vs Val/Val 1514 6633 1.00 (0.73-1.35) I2 = 0% (10)
Val/Met vs Val/Val 2163 9416 1.02 (0.91-1.14) I2 = 34.4% (10)
Abbreviations: OR, odds ratio; CI, confidence interval; Met, methionine; Val, valine.
* P<0.05, ** P<0.01.
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Figure 2  Forest plots for the 15 meta-analyses. Pooled odds ratios for  
(1) the total sample, (2) females only, (3) males only, (4) Asians and (5) Caucasians  
(2a) Met versus Val
The model used for most analyses is indicated above the figure. If the other model is used,  
this is indicated above the individual analysis. ‘Total events’ describe the numbers of MDD cases and controls, 
respectively, with the allele/genotype under study.
Oswald et al. (2005) a first sample, b replication sample;  
Schumacher et al. (2005) a Munich sample, b Bonn sample.
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Figure 2  (2b) Met/Met versus Val/Val: 
 (1) total sample, (2) females only, (3) males only, (4) Asians, (5) Caucasians
The model used for most analyses is indicated above the figure. If the other model is used, this is indicated 
above the individual analysis. ‘Total events’ describe the numbers of MDD cases and controls, respectively, 
with the allele/genotype under study.
Oswald et al. (2005) a first sample, b replication sample;  
Schumacher et al. (2005) a Munich sample, b Bonn sample.
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Figure 2  (2c) Val/Met versus Val/Val: 
 (1) total sample, (2) females only, (3) males only, (4) Asians, (5) Caucasians
The model used for most analyses is indicated above the figure. ‘Total events’ describe the numbers  
of MDD cases and controls, respectively, with the allele/genotype under study.
Oswald et al. (2005) a first sample, b replication sample; 
Schumacher et al. (2005) a Munich sample, b Bonn sample.
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After correcting for multiple testing with use of the Bonferroni method (p = 0.0033), 
these results remained significant. The Val/Met genotype did not show an association 
with MDD in males. For females no differences between cases and controls were 
observed for the BDNF polymorphism (Table 3).
BDNF Val66Met, MDD and ethnicity
In the subgroups stratified by ethnicity (Caucasian or Asian), neither the allele-based 
analysis nor the genotype-based analyses showed significant effects of the Val66Met 
polymorphism on MDD risk.
Sensitivity analyses
Sensitivity analyses were performed excluding studies that did not report on the 
screening for the presence of psychopathology in control subjects (Hwang et al., 2006; 
Ribeiro et al., 2007; Zhang et al., 2006). Excluding these studies did not substantially 
alter the ORs as reported above. A sensitivity analysis was also performed with the 
inclusion of a study (Kim et al., 2007) with genotype frequencies deviating from HWE. 
The reported ORs hardly changed (data not shown).
Meta-regression analyses
Results of the meta-regression analyses showed that mean age significantly 
influenced the variation in effect size in the Met/Met analyses (p = 0.009) and in the 
allelic analyses (p = 0.01), with elderly subjects showing higher ORs. The effect of 
gender was also in the expected direction, though this result did not reach statistical 
significance (data not shown).
Discussion
This meta-analysis of the association of the BDNF Val66Met polymorphism with MDD 
investigated 2,812 patients and 10,843 controls from 14 case-control studies. Our 
overall meta-analysis did not detect any significant genetic association between the 
BDNF Val66Met polymorphism and MDD. This result is in line with that of three other 
previously published meta-analyses that had included fewer studies of the BDNF 
Val66Met polymorphism and MDD (Chen et al., 2008; Gratacos et al., 2007; Lopez-
Leon et al., 2008).
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As far as we know, this is the largest meta-analysis carried out so far aimed at 
investigating the relationship between BDNF and MDD. Also, our meta-analysis is 
the first one to take gender and ethnicity into account. This was done given earlier 
evidence of females being affected with MDD two times as often as males (Weissman 
et al., 1996) and the Met allele frequency being higher in Asians in the presence of 
lower MDD prevalence rates compared to Caucasians. The exploration of gender-
specificity indeed revealed significant allelic (Met versus Val) and genotypic (Met/Met 
versus Val/Val) associations of BDNF with MDD in the male gender. We will discuss 
these findings in more depth below, but like to note here that the results of genetic 
association studies of the BDNF Val66Met polymorphism with different psychiatric 
phenotypes have shown to be complex (Gratacos et al., 2007). As illustrated in a 
recent meta-analysis of Gratacos et al. (2007), the Val/Met and Met/Met genotypes 
were found to increase the risk of eating disorders and schizophrenia, although 
reducing the risk of substance-related disorders.
There is no straightforward explanation for the Met allele increasing MDD risk for males, 
but not females, in both allelic and genotypic analyses as the allele and genotype 
frequencies of Val66Met are equally distributed among both genders. Further, as 
no gender differences have been reported in the levels of serum or plasma BDNF 
(Karege et al., 2002; Lommatzsch et al., 2005; Tan et al., 2005), simple biochemical 
explanations are unlikely.
How could the BDNF gene influence MDD development in a gender-specific way? 
Probable explanations can be sought when we consider that the total constellation of 
causal factors, that is the interplay between genetic and environmental factors, may 
in essence differ for males and females. As outlined above, genetic linkage studies 
have identified gender-specific MDD-linked regions of the genome; a 451 kb region 
of 2q33–35 for example, exhibited significant evidence of linkage to MDD among 
females, but not males (Zubenko et al., 2002b), and a follow-up study identified 
CREB1 as a gender-limited susceptibility gene for MDD (Zubenko et al., 2003a). In 
this context, it might merit further research whether gender-related epistatic effects 
exist, in which gene-gene interactions involving the Val66Met polymorphism and 
leading to MDD are different in males compared to females.
Four other possible explanations may be sought at the level of gender differences 
in gene-environment interaction, of sexual dimorphism of the hippocampus, of 
gender-related differences in symptoms of depression and of a type I error finding. 
First, interactions between the BDNF Val66Met polymorphism and environmental 
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influences may differ between males and females. Life events are part of the 
etiologic constellation of MDD and are found to be associated with the development 
of depression (Brown & Harris, 1978a; Kessler, 1997; Paykel, 2003). Although the 
amount of life events males and females experience is rather similar, several studies 
conclude that females subjectively experience more stress, have an increased stress 
response (Becker et al., 2007) and show higher stress vulnerability in relation to life 
events and chronic difficulties (Kessler & McLeod, 1984; Troisi, 2001). Interactions 
between a candidate gene for depression, the serotonin transporter polymorphism 
(5-HTTLPR), and life events have been described as etiologic factors for MDD (Caspi 
et al., 2003; Kendler et al., 2005b; Kim et al., 2007; Uher & McGuffin, 2008). Some 
reports have indicated that the interaction between this polymorphism and life events 
differs with gender (Sjoberg et al., 2006; Eley et al., 2004). Adolescent girls with the 
short allele of the 5-HTTLPR displayed more depression when they had experienced 
adverse events, whereas in boys, adverse events in interaction with the long allele 
led to higher depression scores (Sjoberg et al., 2006). This opposite finding in girls 
and boys may be due to the gender-specific influence of gonadal or adrenocortical 
hormones interacting with the 5-HTTLPR polymorphism (Sjoberg et al., 2006). In a 
similar way, gender-specific mechanisms could also operate for the BDNF Val66Met 
polymorphism and life events.
Second, the gender-related influence of the BDNF Val66Met polymorphism in 
depression may be due to sexual dimorphism in brain structures involved in the 
neurobiology of depression, particularly, the hippocampus (Cahill, 2006). Male and 
female hippocampi have been documented to differ significantly in their anatomical 
structure, their neurochemical make-up and their reactivity to stressful situations 
(Cahill, 2006; Madeira & Lieberman, 1995). Imaging studies consistently show that 
the hippocampus is larger in females than in males when adjusted for total brain 
size (Goldstein et al., 2001). Biochemical studies have revealed gender differences 
in many neurotransmitter systems within the hippocampus, including the adrenergic, 
serotonergic, cholinergic and corticosterone systems (Madeira & Lieberman, 1995). 
An intriguing but relatively unknown hippocampal gender difference is the reaction 
to chronic stress. In both rats and monkeys, chronic stress causes damage to the 
hippocampus in males, but does so far less, if at all, in females (McEwen, 2000). 
Stress leads to decreased levels of BDNF expression in the hippocampus (Smith 
et al., 1995), and upregulation of BDNF is associated with the therapeutic effects 
of antidepressant medication and electroconvulsive shock treatment in depression 
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(Duman & Monteggia, 2006). As the BDNF gene plays a role in survival of neuronal 
cells, in connectivity, and in plasticity, a more efficiently expressing BDNF allele might 
protect the brain against hippocampal damage after stress, or at least might render an 
individual less vulnerable to the effects of sustained stress and thus, less vulnerable 
to MDD. Given these findings, the BDNF Val66Met polymorphism may play a larger 
role in the neurobiological underpinnings of depression in males than in females.
Third, depression at the symptomatic level is characterized by both symptoms of 
behavioral despair, such as negative mood, hopelessness, agitation and suicidal 
ideation, and by an inability to experience pleasure (anhedonia). These different sets of 
symptoms appear to be related to two distinct brain systems, the hippocampus-HPA 
stress system, and the dopaminergic brain reward systems in the ventral tegmentum 
area and the nucleus accumbens (Martinowich et al., 2007). In this context, it is 
relevant that BDNF seems to exert opposing effects on these two systems, with the 
result that infusion of BDNF in the hippocampus produces antidepressant effects 
(Shirayama et al., 2002; Siuciak et al., 1997), and application of BDNF in the ventral 
tegmentum area and the nucleus accumbens leads to prodepressive effects (Eisch et 
al., 2003). Gender differences in symptomatic expression of depression and gender 
differences in the involvement of brain stress and reward systems could explain 
gender-dependent effects of the BDNF Val66Met polymorphism in depression.
Fourth, as a substantial number of tests was performed, one could argue that the 
gender-specific finding actually is a type I error finding. However, after applying the 
Bonferroni method to correct for multiple testing, the gender-specific finding remained 
significant, both in the genotypic and allelic analyses.
The results of our meta-analysis do not support a clear role for ethnicity in relation to 
the BDNF Val66Met polymorphism and MDD risk. The lower prevalence of MDD in 
Asians compared to Caucasians in the presence of higher Met allele frequencies in 
Asians may suggest the Met allele to be protective against MDD in Asian subjects. 
However, in the ethnicity-specific analyses this was not observed. The lower 
prevalence of MDD in Asians might partly be accounted for by underreporting due to 
cultural reluctance to endorse symptoms, by depressive symptoms being expressed 
as somatic symptoms, by greater resilience, by availability of more social support in 
Asian societies or by higher tolerance of symptoms and disease (Compton, III et al., 
1991; Hwu et al., 1996; Parker et al., 2007; Weissman et al., 1996).
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It is remarkable that the studies carried out in the eldest age groups appeared to have 
the highest ORs for the association of the BDNF Val66Met polymorphism with MDD 
(Figures 2a and b: Hwang et al., 2006; Taylor et al., 2007). Both samples had late 
onset depression (mean age of 68.4 and 45.0 years, respectively). This age effect has 
also been noted in the meta-analysis by Chen et al. (2008). Samples with late-onset 
or geriatric depression are etiologically different from adult-onset depression with 
a larger role of cardiovascular risk factors (Alexopoulos et al., 1997) and a stronger 
involvement of the hippocampus, which is the major site of BDNF expression (Hwang 
et al., 2006; Steffens et al., 2000). From the meta-regression analysis with mean age 
as covariate it appeared that age might modify the relationship between the Met 
allele and depression. However, firm conclusions cannot be drawn and cautiousness 
about an age effect is required, the more since a haplotype containing the BDNF Val 
allele was found to be associated with childhood-onset MDD in two independent 
samples using a family-controlled design (Strauss et al., 2005). This subject needs to 
be explored in future studies.
This meta-analysis should be viewed in the context of its strengths and limitations. An 
obvious strength is that this is the largest sample studied in a meta-analysis to date and 
that stratified analyses were performed for gender and ethnicity. The inferences from 
this meta-analysis are necessarily limited by the quality and quantity of the available 
case-control studies on the association of the BDNF Val66Met polymorphism and 
MDD. In particular, the reports available covered a wide age range, which could 
imply that different age of onset groups were included. Furthermore, a breakdown 
of the results according to gender proved to be impossible in a subsample of 
studies. Lastly, MDD seldom presents as a single disorder (Kessler et al., 2003) but 
information about the presence of comorbid psychiatric conditions in the subjects 
was not available to us. Thus, this meta-analysis reports on the association of the 
BDNF Val66Met polymorphism and MDD without taking into account the possible 
effect of comorbid disorders.
In conclusion, our results suggest that the BDNF Val66Met polymorphism is of 
greater importance in the development of MDD in males than in females. However, 
a larger primary study will be necessary to confirm or refute this. Power analysis 
for such a study revealed that to detect a significant allelic association (Met versus 
Val) with 80% power at the 5% significance level (OR ≥ 1.27), at least 870 and 1,300 
male case-control pairs are required, in Asians and Caucasians, respectively. Our 
study provides clues for further research, such as the exploration of differences in 
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genetic risk factors and gene-environment interaction constellations between males 
and females and the study of gender-issues in MDD.
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Abstract
Objective Neuroticism, a personality trait with an estimated heritability between 30% 
and 60%, is a vulnerability factor for psychopathology and in particular associated 
with depressive and anxiety disorders. Previous genetic linkage and association 
studies performed to identify loci or common genetic variants involved in the trait 
of neuroticism have shown little overlap and inconsistent results. In this study we 
extended former genetic approaches by performing a genome-wide association 
study (GWAS) of neuroticism. We postulated a priori that gender differences in the 
SNPs associated with neuroticism would be apparent, given the known gender 
difference in neuroticism scores.
Methods A population-based sample of 1,313 individuals (651 males, 662 females) 
taking part in the Nijmegen Biomedical Study (NBS) was evaluated with the short 
version of the Eysenck Personality Questionnaire (EPQ-RSS) and genotyped for more 
than 300,000 single nucleotide polymorphisms (SNPs). Genome-wide association 
was tested using the software program Plink and correction for multiple testing was 
applied by Bonferroni methods.
Results Four SNPs were associated with neuroticism with p-values smaller than 10-5. 
These SNPs were located within the STK39, CXCR5, MTUS1 and MACF1 genes and 
have been associated with harm avoidance, MDD and other psychiatric disorders 
in previous studies. However, results did not remain significant after correction for 
multiple testing. In addition, we identified 41 SNPs (p-values < 10-4) with gender-
specific effects, with 18 of them being located within known genes, including 
interesting candidate genes like SUPT3H, CDH13 and RUNX2.
Discussion In addition to gender-specific SNPs, our study has identified interesting 
new candidate genes for neuroticism. However, replication studies are necessary to 
confirm or refute these (gender-specific) findings. Future studies should investigate 
whether the identified SNPs/genes are risk factors for MDD psychopathology, as well.
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Introduction
Neuroticism is a personality trait that reflects a broad domain of negative affect 
or emotional instability, including predispositions to experience anxiety, anger, 
depression and shame. Neuroticism is also a vulnerability factor for experiencing 
stress (Costa, Jr. et al., 2001; Kendler et al., 1993b). High levels of neuroticism 
predispose individuals to a range of psychiatric disorders, in particular to major 
depressive disorders (MDD) and anxiety disorders (Jacobs et al., 2006; Levinson, 
2006; Sen et al., 2003). It has been suggested that the liability to both MDD and 
anxiety disorders is caused by neuroticism as an underlying shared vulnerability 
marker (Gorwood, 2004; Levinson, 2006).
Twin studies have shown that neuroticism is a complex trait, with heritability estimates 
ranging from 0.30 to 0.60 (Jang et al., 1996; Lake et al., 2000; Tambs et al., 1991). 
Genetic risk factors for neuroticism and MDD seem to be closely related (Fanous 
et al., 2002; Hettema et al., 2006; Kendler et al., 2002; Kendler et al., 2004; Kendler 
et al., 2006a; Kendler et al., 2006c) and there is co-segregation of high neuroticism 
scores and MDD within families (Duggan et al., 1995; Hettema et al., 2006). Twin 
studies suggested that the covariation of MDD and neuroticism is largely due to gene 
effects common to both (Kendler et al., 1993b; Jardine et al., 1984). Around 55% of 
the genetic liability to MDD appeared to be shared with that of neuroticism, while 45% 
was unique to MDD. For environmental factors, the sharing was very limited, with only 
5% being shared.
A relationship between gender and neuroticism has been consistently reported, both 
in healthy populations as well as in MDD cases. Females generally score higher on 
this trait than males (Costa, Jr. et al., 2001; Francis, 1993; Goodwin & Gotlib, 2004; 
Greenberg et al., 2000; Lang et al., 2005; Maier et al., 1992). These gender differences 
in the levels of neuroticism could suggest gender differences in heritability. However, 
studies on this issue have reported conflicting results. Some studies did observe 
gender-specific genetic factors (Eaves et al., 1998; Kendler & Prescott, 1999; Kendler 
et al., 2001), whereas others did not (Fanous et al., 2002; Katz & McGuffin, 1987; Lake 
et al., 2000).
So far, a number of genome-wide linkage studies of neuroticism have been 
performed. These have the potential of identifying genes for the trait in a hypothesis-
free manner. A number of potential susceptibility regions have been identified of 
which some have been replicated and some have shown evidence for gender-
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specificity (Table 1). In a QTL linkage study with a sample of siblings concordant and 
discordant for neuroticism (Fullerton et al., 2003), five significant loci were observed 
on chromosomes 1q, 4q, 7p, 12q, 13q. Several of these loci showed evidence of 
gender-specificity, with QTLs on chromosomes 1q, 12q and 13q appearing to be 
female-specific, whereas chromosomes 7p and 8p showed male-specific effects 
(Fullerton et al., 2003). In another QTL linkage analysis in selected sibships with 
extreme scores for neuroticism, potential linkage signals were observed on 
chromosomes 1p and 6p (Nash et al., 2004). Gender-specific analyses revealed 
suggestive linkage signals on chromosomes 1p and 7p in females, whereas brother-
pair analyses showed a peak for neuroticism measures on chromosome 6p (Nash 
et al., 2004). Comparison of these reports showed an inconsistency of findings for 
the linkage signal on chromosome 7p, which was female-specific in the study of 
Nash et al. (2004) whereas it was male-specific in the study by Fullerton et al. (2003). 
The male-specific locus on chromosome 6p has not been found in previous 
studies.
A genome scan of neuroticism in nicotine-dependent smokers (Neale et al., 2005) 
replicated the linkage results for chromosomes 1q and 11q as found by Fullerton 
et al. (2003) and also gave suggestive evidence for a locus on chromosome 12p 
(Table 1). Another linkage study in alcohol-dependent subjects found linkage 
of neuroticism on chromosomes 11p, 12q and 15q (Kuo et al., 2007). This study 
replicated the loci on chromosomes 11p and 12q and the female-specific findings on 
chromosomes 12q and 13q as identified by Fullerton et al. (2003). Two other of the 
gender-specific regions (region 15q in males and 18q in females) reported by Kuo 
et al. (2007) have been previously reported in linkage studies of major depression 
(Camp et al., 2005; Holmans et al., 2004). The most recent genome-wide linkage 
analysis of neuroticism in large Dutch and Australian twin samples and their family 
members identified statistical linkage to 14q and suggestive linkage to 10p and 18q 
(Wray et al., 2008). Gender-specific analyses resulted in three regions of interest; 2p 
and 5q in males and 15cen in females (Table 1). The regions all showed overlap with 
regions identified in earlier studies of neuroticism and/or MDD (Camp et al., 2005; 
Fullerton et al., 2003; Kuo et al., 2007; Middeldorp et al., 2008a).
Linkage studies in complex disorders or traits are generally limited by the fact that 
they assume the existence of genetic factors influencing the phenotype with rather 
large effect sizes. However, these have not been found to exist in most multifactorial 
disorders and traits, thus far (Fullerton et al., 2003; Sen et al., 2004; van den Oord 
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et al., 2008; Wray et al., 2008). More knowledge about genetic factors involved in 
neuroticism may contribute not only to a better understanding of the etiology of this 
personality trait, but also of the common psychiatric disorders MDD and anxiety.
Genome-wide association studies (GWAS) are thought to be a more powerful 
alternative for the identification of genetic factors of limited effect size (McCarthy et 
al., 2008; Shifman et al., 2008; van den Oord et al., 2008). A multistage GWAS using 
eight DNA pools from 2,054 individuals selected for extremeness of neuroticism and 
investigating 452,574 SNPs (Shifman et al., 2008) identified several SNPs nominally 
associated with the trait, but none remained statistically significant after correcting for 
multiple testing. For replication, the most significant SNPs were individually genotyped 
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Table 1  Overview genome-wide linkage studies of neuroticism
Study Sample  Statistical Female- Male-
 selection significant  specific specific
  (or suggestive)  loci loci
  loci 
Fullerton Concordant /  1q, 4q, 7p,  1q, 12q, 13q 7p (sugg),
et al. 2003 discordant sibpairs 11q (sugg),    8p
 for neuroticism 12q, 13q
 (population)  
Nash  Concordant / 1p, 6p 1p, 7p 6p
et al. 2004 discordant sibpairs 
 for neuroticism 
 (population)   
Neale  Nicotine-dependent  1q, 11q,  NA NA
et al. 2005 smokers  12p (sugg)  
  
Kuo  Alcohol- 11p, 12q, 15q 2q, 4q, 9q, 1p, 4p,
et al. 2007 dependence  12q, 13q, 11p, 12q,
   18q 15q, 16p,
    16q, 22q
Wray  Dutch and   10p (sugg),  15cen 2p, 5q
et al. 2008 Australian population 14q, 18q (sugg)
 twins   
Regions indicated in bold have been replicated in linkage studies.
NA = not analyzed, sugg = suggestive linkage.
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in independent samples. From the nineteen highest scoring SNPs, one SNP within 
the cAMP-specific phosphodiesterase 4D (PDE4D) gene (rs702543, chromosome 5) 
was replicated in another sample from the same cohort. However, the finding was not 
replicated in two other populations that used related but slightly different phenotypes 
(Shifman et al., 2008). A second recent GWAS of neuroticism in 1,227 participants 
from the US, with a replication study in a German sample of 1,880 subjects (van 
den Oord et al., 2008) identified several promising SNPs. In particular, four SNPs 
(rs1959813, rs3007105, rs12883384 and rs7151262) in the MAMDC1 gene tagging two 
haplotypes were associated with neuroticism. The four SNPs in the MAMDC1 gene 
were replicated despite differences in sample recruitment, genotyping platforms, and 
ethnicity between the original and replication study. Further, the finding was robust to 
the use of different questionnaires for the assessment of neuroticism: the EPQ-N (12 
items) was used in the original GWAS and the NEO-PI-R in the replication sample.
In the current study, we aimed at identifying additional genes for neuroticism from 
genome-wide association data available from the analysis of an elderly population 
sample of 1,313 individuals taking part in the Nijmegen Biomedical Study (NBS). We 
postulated a priori that gender differences in the SNPs associated with neuroticism 
would be apparent, given the gender differences in this trait.
Materials and Methods
Sample collection
Participants from the Nijmegen Biomedical Study (NBS), a survey of the general 
population performed in 2002–2003 by the Radboud University Nijmegen Medical 
Centre, the Netherlands, were included in the current study. The NBS has been 
described in detail previously (Wetzels et al., 2007). NBS was based on an age- 
and sex-stratified random sample of 22,451 adults of the population of Nijmegen. 
Questionnaire information on lifestyle, personality, history of depression and other 
psychiatric disorders, family history of depression, medical history as well as blood 
samples were available from a group of 6,700 individuals.
From this group, 2,080 individuals in the age range of 27.1 to 78.9 years (mean age 
61.4, SD 10.3), equally distributed over the two genders were selected for genome-
wide genotyping.
All individuals were fully informed about the goals and the procedures of the study 
and gave informed consent. Informed consent was obtained for the collection of 
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questionnaire data, the collection of two 10 ml blood samples, linkage to population 
and disease registries, collection of additional clinical data from medical records and 
the keeping of identifying information for the duration of 25 years. The study protocols 
were approved by the Institutional Review Board of the Radboud University Nijmegen 
Medical Centre.
Personality assessment
Participants received an invitation to fill out postal questionnaires on personality 
measures. Neuroticism, extraversion, psychoticism, and social desirability were 
measured with the short version of the Dutch Eysenck Personality Questionnaire 
(EPQ-RSS: Eysenck & Eysenck, 1991). Each domain is interrogated by 12 items 
scored on a two-point scale with either yes (1) or no (0). These domain-specific items 
were summed for each individual. In this study, we were particularly interested in the 
trait of neuroticism.
The internal reliability of the short version of the EPQ for neuroticism (EPQ-N) is 
good (Cronbachs α of 0.81-0.84), as are the test-retest reliability and the construct 
validity (Sanderman et al., 1995). The results for the Dutch version of the EPQ strongly 
resemble those obtained with the English EPQ (Sanderman et al., 1991).
The data distribution of the sum scores of neuroticism showed deviations from the 
normal distribution. Therefore, we transformed the data according to a strategy 
used previously (Fullerton et al., 2003; Wray et al., 2008). Briefly, the raw scores of 
neuroticism (0 to 12) were converted to a proportional score and normalized with 
angular transformations to arcsin values (Freeman & Tukey, 1950) and then regressed 
on age and gender. The residuals obtained through this regression were used in the 
overall analyses. The residuals of the raw scores regressed on age only were used in 
the gender-specific analyses.
Genotyping
The study participants were assayed with the Illumina HumanCNV370 SNP chip by 
deCODE Genetics. Genotyping procedures have been described earlier (Gudbjartsson 
et al., 2008). A total of 302,666 single nucleotide polymorphisms (SNPs) on the 
autosomal chromosomes were analyzed. A strict quality control (QC) procedure was 
applied to the raw genotyping data using the following criteria: 1) missing genotype 
rates in individuals (MIND) < 10%, 2) missing rates per SNP (GENO) < 10%; 3) Hardy-
Weinberg equilibrium p-value (HWE) ≥ 10-6; 4) minor allele frequency (MAF) ≥ 10%.
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Statistical analyses
Mean age and neuroticism scores for males and females were compared using 
independent t-tests. We tested allelic association between individual SNPs and 
the residuals of neuroticism scores using linear regression analyses. Results were 
corrected for population stratification using the genomic control method (Devlin 
et al., 2004). All findings with p-values of < 10-5 are reported here. Correction for 
multiple testing was performed using Bonferroni correction as implemented in Plink. 
A gender-specific analysis with a genotype-by-gender interaction test was performed 
as a secondary analysis. Results with p < 10-4 (uncorrected) are reported for this 
explorative analysis. These analyses were performed using SPSS 16.0 and Plink 
software (version 1.03; Purcell et al., 2007; Purcell, 2008).
The NCBI database (http://www.ncbi.nlm.nih.gov/sites/entrez/), the UCSC Genome 
Browser (http://genome.ucsc.edu/), the HapMap project (Data Rel Mar08, on NCBI 
B36 assembly, dbSNPb126; http://www.hapmap.org/cgi-perl/gbrowse/hapmap_B36/) 
and the website of the Sullivan Lab Evidence Project (SLEP: http://slep.unc.edu; 
Konneker et al., 2008) were used to investigate SNP characteristics and linkage 
disequilibrium between SNPs, as well as to check whether the observed SNPs/genes 
have been associated with psychiatric disorders before.
Results
A sample of 1,313 individuals had complete data for the neuroticism questionnaire 
(EPQ-N) and had valid genotyping data. The mean age of the sample was 61.3 years 
(SD 10.0; age range 30.1 to 78.9 years) and 49.6% was male. Males were significantly 
older than females (Table 2). The mean neuroticism score was 3.3 (SD 2.7). Females 
scored significantly higher on this trait than males (t = -7.8, p < 0.001; Table 2).
A total of 301,596 autosomal SNPs with a total genotyping rate of 99.6% survived QC. 
There was no evidence of population stratification (genomic inflation factor 1.008).
As shown in Table 3, four SNPs showed p-values <10-5 for association with 
neuroticism, all of them located within known genes. The most significant result was 
observed for SNP rs10930299 (p = 3.19 x 10-7), located within the STK39 gene. The 
three other SNPs were rs523604 (p = 4.57 x 10-6), located within the CXCR5 gene; 
rs7000487 (p = 6.42 x 10-6), located within the MTUS1 gene; and rs687848 (p = 9.50 
x 10-6), located within MACF1. Bonferroni correction resulted in a loss of statistical 
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significance for all SNPs. Further information regarding gene function and earlier 
reports of linkage/association of genes with psychiatric disorders is presented in 
Supplementary Table S1. For this matter, we report genome-wide linkage findings 
with a LOD-score ≥ 2.0.
Of the four SNPs identified in the analysis of the entire sample, only SNP rs687848 in 
the MACF1 gene revealed a nominally significant gender-specific effect (p = 0.03). 
This SNP increased the age adjusted neuroticism score with 0.24 points in females 
and only 0.08 points in males.
In the overall gender-specific analyses, forty-one SNPs achieved p-values smaller 
than 10-4, with 18 of them being located within known genes, including FMN2, PTPRU, 
CTTNA3, COL8A1, CDH13, UGT3A1, SUPT3H, RUNX2, ZBTB20, MYH9, MACROD2, 
COX10, DCC, and SPEF2 (Table 3 and Supplementary Table S2). Mostly, these SNPs 
were associated with an increase in neuroticism scores in males and a decrease in 
scores in females.
Two other GWA studies of neuroticism have been published, so far (Shifman et al., 
2008; van den Oord et al., 2008). When comparing our results to the top findings 
from the pooled GWAS of neuroticism (Shifman et al., 2008), there are two SNPs 
worth mentioning. One of the top SNPs (rs4841017; p = 6.5 x 10-6) found by Shifman 
et al. (2008) on 8p23.1 is cytogenetically close to one of our top SNPs (rs7000487) 
on 8p22. Another high scoring SNP in the Shifman et al. (2008) study (rs17385253; 
p = 3.3 x 10-5), located on 1p34.3, is cytogenetically close to our SNP on 1p34.2 
(rs687848). However, on both chromosomes 1 and 8, the physical distance between 
the SNPs is more than 5 Mb, which makes it unlikely that the findings are related. 
Comparing our best findings to the recent GWAS of Van den Oord et al. (2008) did 
not reveal overlap.
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Table 2  Mean age and neuroticism scores for the total sample and 
males and females separately
 Sample  Males Females Statistics
Sample (N, %) 1,313 651 (49.6) 662 (50.4) ns
Mean age (SD) 61.3 (10.0) 66.0 (7.0) 56.4 (10.5) t=19.7*, df=1157 
EPQ-RSS (mean, SD) 3.3 (2.7) 2.7 (2.5) 3.8 (2.8) t=-7.8*, df=1300
*p<0.001.
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Table 3  Results of GWAS of neuroticism and the gender-specific  
analyses. (See Supplementary Tables S1 and S2 for a  
complete overview)
SNP Chromosome  Position (bp) Gene name Uncorrected
 and locus   p-value
Overall analysis of neuroticism
rs10930299 2 (q24.3) 168.525.248 STK39 (intronic) 3.19E-07
rs523604 11 (q23.3) 118.260.948 CXCR5 (intronic) 4.57E-06
rs7000487 8 (p22) 17.586.826 MTUS1 /  6.42E-06
   KIAA1288
   (intronic)
rs687848 1 (p34.2) 39.691.821 MACF1 (intronic) 9.50E-06
Gender-specific analyses
rs4897939 19 (p13.3) 252.619 Intergenic 9.41E-05
rs507757 18 (p11.32) 572.838 Intergenic 8.48E-05
rs2030006 5 (p15.33) 2.777.582 Intergenic 6.99E-05
rs11089788 22 (q12.3) 3.501.047 MYH9 5.99E-05
rs331535 11 (p15.4) 4.433.275 Intergenic 2.53E-05
rs1976524 18 (p11.31) 4.512.661 Intergenic 3.38E-06
rs751355 18 (p11.22) 9.418.420 Intergenic 4.91E-05
rs2159132 17 (p12) 13.946.164 COX10 8.16E-05
rs6080106 20 (p12.1) 15.977.837 MACROD2 7.13E-05
rs165626 22 (q11.21) 19.284.760 Intergenic,  8.47E-06
   12.8 kb from 
   MED15 
rs2179795 1 (p35.3) 29.514.905 PTPRU 2.31E-05
rs3822735 5 (p13.2) 35.835.751 SPEF2 9.82E-05
rs2044416 5 (p13.2) 36.016.941 UGT3A1 4.08E-05
rs229747 14 (q21.3) 44.266.229 Intergenic 9.38E-05
rs2057553 6 (p12.3) 45.308.653 SUPT3H 4.38E-05
rs6458435 6 (p12.3) 45.330.652 SUPT3H 7.82E-05
rs7760112 6 (p12.3) 45.417.610 SUPT3H / RUNX2 5.08E-05
rs3763190 6 (p12.3) 45.455.622 RUNX2 8.58E-05
rs1460198 18 (q21.2) 48.466.647 DCC 9.37E-05
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The top SNPs from the two previous GWA studies (Shifman et al., 2008; van den Oord 
et al., 2008) did not reach significance in our sample (Table 4). However, inspection of 
our SNPs within two candidate genes for neuroticism from two earlier studies (PDE4D 
and MAMDC1) revealed five SNPs with nominal significant association to neuroticism 
for the PDE4D gene (p-values of .01 to .05) and for two SNPs in the MAMDC1 gene 
(p-values around .04).
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rs521664 6 (p12.1) 52.930.496 Intergenic 8.48E-05
rs2441755 10 (q21.3) 67.835.273 CTNNA3 2.78E-05
rs11149567 16 (q23.3) 82.004.528 CDH13 3.30E-05
rs10514573 16 (q23.3) 82.011.352 CDH13 6.64E-05
rs12922399 16 (q23.3) 82.023.539 CDH13 3.32E-05
rs3814018 1 (p21.3) 94.859.366 Intergenic 8.24E-05
rs7613565 3 (q12.1) 100.850.559 COL8A1 2.79E-05
rs1518611 2 (q12.2) 105.563.830 Intergenic 7.31E-05
rs1518618 2 (q12.2) 105.567.220 Intergenic 3.16E-05
rs2056533 3 (q13.31) 115.967.835 ZBTB20 5.79E-05
rs13262609 8 (q24.22) 134.775.844 Intergenic 3.20E-05
rs10484678 6 (q24.3) 148.333.855 Intergenic 1.50E-05
rs296171 5 (q33.2) 152.584.259 Intergenic 8.37E-05
rs962514 5 (q32.2) 152.675.042 Intergenic 1.64E-05
rs159977 5 (q33.2) 152.708.309 Intergenic 2.82E-05
rs3935541 1 (q23.1) 154.928.996 Intergenic 6.45E-05
rs346119 4 (q34.3) 179.920.397 Intergenic 6.85E-05
rs1947202 4 (q34.3) 179.942.302 Intergenic 2.00E-05
rs10520439 4 (q34.3) 181.002.632 Intergenic 1.37E-05
rs10520440 4 (q34.3) 181.035.999 Intergenic 2.11E-05
rs4951440 1 (q32.3) 210.406.423 Intergenic 6.51E-05
rs7545070 1 (q34.3) 238.566.113 FMN2 1.01E-05
Genes indicated in bold have been described to be associated with MDD or harm 
avoidance.
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Discussion
In this GWAS of neuroticism in a sample of 1,313 subjects, we identified four 
associated SNPs, with one of these SNPs showing evidence of gender-specificity. 
Further gender-specific analyses identified forty-one additional gender-specific 
SNPs within different candidate genes.
Due to the large number of statistical tests (being inherent to genome-wide association 
analyses), the analyses were corrected for multiple testing. This rendered all findings 
non-significant. However, as there is additional evidence for the involvement of 
the observed genes in harm avoidance, MDD and other psychiatric disorders 
(Supplementary Tables S1 and S2), we consider the results promising.
The finding in the MTUS1 gene on chromosome 8 (p22), in which our third-most 
significant SNP (rs7000487) was located, is of particular interest. Among findings 
of linkage for bipolar disorder and schizophrenia in the region including this gene 
(as listed in Supplementary Table S1), it also lies in a locus linked to the personality 
trait of harm avoidance in a genome-wide linkage scan in 758 sib pairs from 177 
nuclear families with a LOD-score of 3.2 (p < .0001) (Cloninger et al., 1998). Harm 
avoidance as measured by the Tridimensional Personality Questionnaire (TPQ) used 
in the study by Cloninger et al. (1998) resembles the neuroticism trait as measured by 
the EPQ (Heath et al., 1994; Stallings et al., 1996). Also interesting is the fact that the 
MACF1 gene on chromosome 1 (p34.2) has been described in psychiatric disorders 
before, especially in a genome-wide linkage study in families identified by recurrent, 
early-onset MDD (Camp & Cannon-Albright, 2005).
Comparison of our findings with the two published GWA studies of neuroticism 
(Shifman et al., 2008; van den Oord et al., 2008) did not reveal obvious direct replication 
of findings. Though, we did find some evidence of association for SNPs within the 
same genes. The two earlier publications (Shifman et al., 2008; van den Oord et al., 
2008) did not show similarities either. As already discussed by van den Oord et al. 
(2008), this should not be viewed as nonreplication since effect sizes are likely to 
be small and therefore power is still limited even with sample sizes of 1,000 to 2,000 
individuals. A number of differences between the studies should be mentioned here. 
One is the difference in study design; in the Shifman et al. (2008) study, pooled DNA 
was used and samples were selected on the extremeness of scores on the EPQ-N, 
whereas in van den Oord et al. (2008) and our study, individually genotyped DNA 
was used and the whole distribution of neuroticism was included. Further, slightly 
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different questionnaires were used; the long version of the EPQ (23 items) in Shifman 
et al. (2008) and the short EPQ with 12 items in van den Oord et al. (2008) and ours. 
However, we do not think that this small difference in the method of phenotyping 
considerably affected these results, the more since the EPQ-N findings of van den 
Oord et al. (2008) were replicated in a sample being phenotyped by the NEO-PI-R.
As gender differences exist in levels of neuroticism and several gender-specific 
regions have been identified in linkage studies, one could expect to identify gender-
specificity of SNPs in GWA studies. This was the case as the uncorrected analyses 
showed several SNPs having opposite effects on the neuroticism score in males 
(increase in score) and females (decrease). From the four top SNPs in this GWAS, 
the SNP in the MACF1 gene revealed some evidence of gender-specificity. Of the 
additional forty-one gender-specific SNPs, five were interesting, also with regard to 
MDD (Supplementary Table S2). One SNP (rs2159132) was located within the COX10 
gene (chromosome 17) which had been described to be associated with MDD 
(Middeldorp et al., 2008b). Four other SNPs were located within the SUPT3H and 
RUNX2 genes on chromosome 6 (from 45.308.653bp to 45.455.622bp), in a region 
for which association with MDD has also been described (Nash et al., 2004; Wray 
et al., 2008). It is of interest that gender-specific linkage analyses in brother-pairs on 
the EPQ-N also provided evidence for linkage peaks on both chromosomes 6p and 
17p (Nash et al., 2004). Though, gender-specific analyses by Wray et al. (2008) did 
not provide gender-specificity for these regions. Our gender findings did not show 
overlap with the other two GWA studies as no exploration of gender-specific SNPs 
had been performed (van den Oord et al., 2008) or no gender-specific SNPs had 
been observed (Shifman et al., 2008).
Our findings should be viewed in the light of some strengths and limitations. A 
strength of this study is that we performed a GWAS of neuroticism in a large sample of 
healthy volunteers and that we performed gender-specific analyses to investigate the 
possibility of genetic differences in association to neuroticism in males and females.
A potential limitation is the inclusion of an elderly sample. This implies that the results 
might not generalize to the entire population, especially not as levels of neuroticism 
decline with age (Loehlin & Martin, 2001; McCrae et al., 1999). Further, the use of 
self-report questionnaires for neuroticism might influence outcome. However, earlier 
genetic studies of neuroticism have successfully used the longer version of the EPQ 
self-report questionnaire (23 items instead of 12) (Shifman et al., 2008) and the NEO-
PI-R self-report (van den Oord et al., 2008). Therefore, we do not think that the self-
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reporting of neuroticism should be viewed as a limiting factor for this study.
In conclusion, we identified interesting (gender-specific) candidate SNPs/genes 
for association with neuroticism, but replication of the findings is clearly needed 
before any conclusions could be drawn from them. In comparison, the nominal 
p-values of the top SNPs identified by van den Oord et al. (2008) were only in the 
order of 10-5. The replication step of the analysis, however, then clearly confirmed the 
association. More research will also be needed to clarify the role of gender-specific 
SNPs in neuroticism and the possibility of age-varying genetic associations with 
neuroticism. In general, the genetic architecture of neuroticism is very complex and 
genes identified so far can only explain a small amount of the total genetic variance in 
neuroticism. Therefore, even larger sample sizes might be needed in future studies. 
This GWAS of neuroticism may aid in the identification of MDD susceptibility genes, 
as neuroticism has been proposed as an endophenotype for MDD. However, the 
impact of the genes identified has to be formally tested for MDD.
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Supplementary Table S1  Gene function and associated disorders.
SNP
Gene name
Chromosome
Position (bp)
Description gene
Associated disorder 
(SLEP; Sullivan Lab 
Evidence Project )
References of 
studies with LOD 
score ≥ 2
rs10930299
STK39
2 (q24.3)
168.525.248
This gene encodes a serine/
threonine kinase that is thought 
to function in the cellular stress 
response pathway. The kinase is 
activated in response to hypotonic 
stress, leading to phosphorylation 
of several cation-chloride-coupled 
cotransporters. The catalytically 
active kinase specifically activates 
the p38 MAP kinase pathway, and its 
interaction with p38 decreases upon 
cellular stress, suggesting that this 
kinase may serve as an intermediate 
in the response to cellular stress.
Bipolar disorder, autism
Buxbaum et al. 2001 (AUT). 
IMGSAC 2001 (AUT). Ramoz et al. 
2008 (AUT). Zandi et al. 2007 (BPD).
rs523604
CXCR5
11 (q23.3)
118.260.948
This gene was identified as a
gene specifically expressed in 
Burkitt's lymphoma and lymphatic 
tissues. The protein encoded 
by this gene is predicted to be a 
seven transmembrane G protein- 
coupled receptor and belongs to 
the CXC chemokine receptor family. 
Studies of this gene and its mouse 
conterpart strongly suggest the 
essential function of this gene in B 
cell migration and localization within 
specific anatomic compartments, 
such as follicles in lymph nodes as 
well as in spleen.
Autism, schizophrenia, nicotine 
dependence, ADHD
Arcos-Burgos et al. 2004 (ADHD). 
Lewis et al. 2003 (SCZ).
ADHD, attention deficit/hyperactivity disorder; AUT, autism; BPD, bipolar disorder;  
ED, eating disorder; MDD, major depressive disorder; SCZ, schizophrenia
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Supplementary Table S1  Gene function and associated disorders.
rs523604
CXCR5
11 (q23.3)
118.260.948
This gene was identified as a
gene specifically expressed in 
Burkitt's lymphoma and lymphatic 
tissues. The protein encoded 
by this gene is predicted to be a 
seven transmembrane G protein- 
coupled receptor and belongs to 
the CXC chemokine receptor family. 
Studies of this gene and its mouse 
conterpart strongly suggest the 
essential function of this gene in B 
cell migration and localization within 
specific anatomic compartments, 
such as follicles in lymph nodes as 
well as in spleen.
Autism, schizophrenia, nicotine 
dependence, ADHD
Arcos-Burgos et al. 2004 (ADHD). 
Lewis et al. 2003 (SCZ).
rs7000487
MTUS1 / KIAA1288
8 (p22)
17.586.826
This gene encodes a protein which
contains a C-terminal domain able 
to interact with the angiotension II 
(AT2) receptor and a large coiled-
coil region allowing dimerization. 
Multiple alternatively spliced 
transcript variants encoding different 
isoforms have been found for this 
gene. One of the transcript variants 
has been shown to encode a 
mitochondrial protein that acts as a 
tumor suppressor and partcipates in 
AT2 signaling pathways.
MDD, harm avoidance, ADHD, schizophrenia, 
bipolar disorder
Cloninger et al. 1998 (MDD). Blouin et al. 1998 
(SCZ). Gurling et al. 2001 (SCZ). Lewis et al. 2003 
(SCZ). Kaufmann et al. 1998 (SCZ). Suarez et al. 
2006 (SCZ). Cichon et al. 2001 (BPD). 
rs687848
MACF1
1 (p34.2)
39.691.821
The protein encoded by this gene 
belongs to the plakin family of 
cytoskeletal linker proteins. 
This protein family forms bridges 
between different cytoskeletal 
elements through specialized 
modular domains. The encoded 
protein is one of the largest size 
proteins identified in human 
cytoskeletal proteins. It has 
functional actin and microtubule 
binding domains, and it appears 
to stabilize actin at sites where 
microtubules and microfilaments 
meet. It may function in microtubule 
dynamics to facilitate actin-
microtubule interactions at the 
cell periphery and to couple the 
microtubule network to cellular 
junctions. 
MDD, schizophrenia, eating disorder
Camp et al. 2005 (MDD). Fallin et al. 2003 (SCZ). 
Sklar et al. 2004 (SCZ). Grice et al. 2002 (ED). 
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Supplementary Table S2  Gender-specific SNPs / genes in neuroticism 
    and association with psychiatric disorders
SNP
rs4897939
rs507757
rs2030006
rs11089788
rs331535
rs1976524
rs751355
rs2159132
rs6080106
rs165626
rs2179795
rs3822735
rs2044416
rs229747
rs2057553
Chromosome
and locus
19 (p13.3)
18 (p11.32)
5 (p15.33)
22 (q12.3)
11 (p15.4)
18 (p11.31)
18 (p11.22)
17 (p12)
20 (p12.1)
22 (q11.21)
1 (p35.3)
5 (p13.2)
5 (p13.2)
14 (q21.3)
6 (p12.3)
Position (bp)
252.619
572.838
2.777.582
3.501.047
4.433.275
4.512.661
9.418.420
13.946.164
15.977.837
19.284.760
29.514.905
35.835.751
36.016.941
44.266.229
45.308.653
Gene name
Intergenic
Intergenic
Intergenic
MYH9
Intergenic
Intergenic
Intergenic
COX10
MACROD2
Intergenic, 12.8 kb 
from MED15
PTPRU
SPEF2
UGT3A1
Intergenic
SUPT3H
OMIM#
160775
602125
611567
602454
610172
602947
Unadjusted
p-value
9,41E-05
8,48E-05
6,99E-05
5,99E-05
2,53E-05
3,38E-06
4,91E-05
8,16E-05
7,13E-05
8,47E-06
2,31E-05
9,82E-05
4,08E-05
9,38E-05
4,38E-05
* Z-score positive: males score higher than females. Z-score negative: males score lower than females.
# OMIM; Online Mendelian Inheritance in Man
## SLEP; Sullivan Lab Evidence Project
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Unadjusted
p-value
9,41E-05
8,48E-05
6,99E-05
5,99E-05
2,53E-05
3,38E-06
4,91E-05
8,16E-05
7,13E-05
8,47E-06
2,31E-05
9,82E-05
4,08E-05
9,38E-05
4,38E-05
Z-score for
interaction*
3,91
3,93
3,98
-4,01
-4,21
-4,65
4,06
3,94
3,97
-4,45
-4,23
3,9
4,1
-3,91
4,09
Description gene
Cytochrome c oxidase (COX), the terminal 
component of the mitochondrial respiratory 
chain, catalyzes the electron transfer from 
reduced cytochrome c to oxygen.
The protein encoded by this gene is a 
member of the protein tyrosine phosphatase 
(PTP) family. PTPs are known to be signaling 
molecules that regulate a variety of cellular 
processes. 
Disorder (SLEP##)
Schizophrenia, nicotine 
dependence, bipolar disorder, 
eating disorder
MDD (Middeldorp et al., 
2008), ADHD, autism, nicotine 
dependence, bipolar disorder, 
alzheimer
Schizophrenia, nicotine 
dependence, bipolar disorder
Schizophrenia, nicotine 
dependence
Schizophrenia, ADHD, autism
ADHD, schizophrenia, autism
MDD (Nash et al., 2004; Wray 
et al., 2008), schizophrenia, 
ADHD, nicotine dependence
128
chapter 6
Supplementary Table S2  Continued
SNP
rs6458435
rs7760112
rs3763190
rs1460198
rs521664
rs2441755
rs11149567
rs10514573
rs12922399
rs3814018
Chromosome
and locus
6 (p12.3)
6 (p12.3)
6 (p12.3)
18 (q21.2)
6 (p12.1)
10 (q21.3)
16 (q23.3)
16 (q23.3)
16 (q23.3)
1 (p21.3)
Position (bp)
45.330.652
45.417.610
45.455.622
48.466.647
52.930.496
67.835.273
82.004.528
82.011.352
82.023.539
94.859.366
Gene name
SUPT3H
SUPT3H + 
RUNX2
RUNX2
DCC
Intergenic
CTNNA3
CDH13
CDH13
CDH13
Intergenic
OMIM#
602947
600211
120470
607667
601364
601364
601364
Unadjusted
p-value
7,82E-05
5,08E-05
8,58E-05
9,37E-05
8,48E-05
2,78E-05
3,30E-05
6,64E-05
3,32E-05
8,24E-05
* Z-score positive: males score higher than females. Z-score negative: males score lower than females.
# OMIM; Online Mendelian Inheritance in Man
## SLEP; Sullivan Lab Evidence Project
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Unadjusted
p-value
7,82E-05
5,08E-05
8,58E-05
9,37E-05
8,48E-05
2,78E-05
3,30E-05
6,64E-05
3,32E-05
8,24E-05
Z-score for
interaction*
3,95
4,05
3,93
3,91
3,93
4,19
-4,15
-3,99
-4,15
3,94
Description gene
This gene is a member of the RUNX family of 
transcription factors and encodes a nuclear 
protein with an Runt DNA-binding domain. 
This protein is essential for osteoblastic 
differentiation and skeletal morphogenesis 
and acts as a scaffold for nucleic acids and 
regulatory factors involved in skeletal gene 
expression.
This gene is a member of the cadherin 
superfamily. The encoded protein is a calcium 
dependent cell-cell adhesion glycoprotein 
comprised of five extracellular cadherin 
repeats, a transmembrane region but, unlike 
the typical cadherin superfamily member, lacks 
the highly conserved cytoplasmic region. This 
particular cadherin is a putative mediator of 
cell-cell interaction in the heart and may act as 
a negative regulator of neural cell growth.
See above
See above
Disorder (SLEP##)
See above
MDD ( Nash et al., 2004; Wray 
et al., 2008), schizophrenia, 
ADHD, nicotine dependence
Schizophrenia, bipolar disorder, 
nicotine dependence
Schizophrenia, bipolar disorder, 
nicotine depencence, autism, 
alzheimer
ADHD, schizophrenia, autism, 
substance use disorder, smoking
See above
See above
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SNP
rs7613565
rs1518611
rs1518618
rs2056533
rs13262609
rs10484678
rs296171
rs962514
rs159977
rs3935541
rs346119
rs1947202
rs10520439
rs10520440
rs4951440
rs7545070
Chromosome
and locus
3 (q12.1)
2 (q12.2)
2 (q12.2)
3 (q13.31)
8 (24.22)
6 (q24.3)
5 (q33.2)
5 (q32.2)
5 (q33.2)
1 (q23.1)
4 (q34.3)
4 (q34.3)
4 (q34.3)
4 (q34.3)
1 (q32.3)
1 (q34.3)
Position (bp)
100.850.559
105.563.830
105.567.220
115.967.835
134.775.844
148.333.855
152.584.259
152.675.042
152.708.309
154.928.996
179.920.397
179.942.302
181.002.632
181.035.999
210.406.423
238.566.113
Gene name
COL8A1
Intergenic
Intergenic
ZBTB20
Intergenic
Intergenic
Intergenic
Intergenic
Intergenic
Intergenic
Intergenic
Intergenic
Intergenic
Intergenic
Intergenic
FMN2
OMIM#
120251
606025
606373
Unadjusted
p-value
2,79E-05
7,31E-05
3,16E-05
5,79E-05
3,20E-05
1,50E-05
8,37E-05
1,64E-05
2,82E-05
6,45E-05
6,85E-05
2,00E-05
1,37E-05
2,11E-05
6,51E-05
1,01E-05
* Z-score positive: males score higher than females. Z-score negative: males score lower than females.
# OMIM; Online Mendelian Inheritance in Man
## SLEP; Sullivan Lab Evidence Project
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Unadjusted
p-value
2,79E-05
7,31E-05
3,16E-05
5,79E-05
3,20E-05
1,50E-05
8,37E-05
1,64E-05
2,82E-05
6,45E-05
6,85E-05
2,00E-05
1,37E-05
2,11E-05
6,51E-05
1,01E-05
Z-score for
interaction*
4,19
-3,97
-4,16
4,02
-4,16
-4,33
3,94
4,31
4,19
-4
-3,98
-4,26
-4,35
-4,25
4
4,42
Description gene
This gene encodes one of the two alpha chains 
of type VIII collagen. The gene product is a 
short chain collagen and a major component 
of the basement membrane of the corneal 
endothelium.
Role in cytoskeletal organisation and/or 
establishment of cell polarity.
Disorder (SLEP##)
Schizophrenia, nicotine 
dependence
Autism, schizophrenia, nicotine 
dependence
Schizophrenia, bipolar disorder
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Major depressive disorder (MDD) is a highly prevalent multifactorial psychiatric 
disorder that aggregates in families with an estimated heritability of 35%-40% (Kendler 
et al., 2006b; Shih et al., 2004; Sullivan et al., 2000). Females are approximately twice 
as often affected with MDD as males (ratio 1.7: 1; Kessler et al., 1993). Symptom 
profiles differ markedly between individuals affected with MDD as do the age of 
onset of MDD, the severity of MDD, the course of the disease and the individuals’ 
response to antidepressant treatment. The presence of lifetime comorbid disorders is 
common in MDD (de Graaf et al., 2002b; Kessler et al., 2003) and adds to the clinical 
heterogeneity of MDD.
Besides the research into environmental factors predisposing to MDD, many 
researchers are currently seeking to unravel the genetic factors involved in disease 
etiology and the role of the interplay between environmental and genetic factors. 
Several interesting genetic loci, candidate genes and gene by environment interactions 
have been reported. Despite the large number of genetic studies conducted so far, 
no consistent picture has emerged, though. Inconsistencies in genetic findings are 
common and have to be resolved to gain a better understanding of the etiology of 
complex disorders.
As indicated above, factors thought to complicate genetic research are the clinical 
and genetic heterogeneity of MDD and the high rate of comorbidity. Because of this, I 
explored whether molecular genetic studies of MDD could be improved by redefining 
the MDD phenotype and by investigating which factors should be taken into account 
in MDD genetic research (see Table for overview of studies).
Chapters 2 and 3 interrogated whether familiality of MDD influenced the pattern of 
comorbid axis I disorders in MDD and whether gender differences existed in these 
patterns of comorbidity. It was also studied whether MDD characteristics, such as age 
of onset, disease course and severity, influenced the association between familiality 
of MDD and comorbidity.
In chapter 2, two different samples with MDD cases were included: a clinical sample 
(from the GenMood study) and a population-based sample (from the Netherlands 
Mental Health Survey and Incidence Study; NEMESIS). In the GenMood study, 
individuals with lifetime major depression and a familial vulnerability to depression 
(having at least one first-degree relative with a history of MDD) participated. From 
the population-based NEMESIS study, individuals with lifetime MDD were selected 
and divided into two subsamples: a sample having family members affected with 
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lifetime MDD (familial MDD: f-MDD) and a sample without affected first-degree 
family members (nonfamilial MDD: nf-MDD). All participants were phenotyped for 
lifetime MDD and lifetime comorbid disorders on the basis of a structured diagnostic 
interview, the Composite International Diagnostic Interview (CIDI; WHO-CIDI, 1998; 
World Health Organization, 1990). The clinical f-MDD sample and the population-
based f-MDD and nf-MDD samples were then compared with regard to the presence 
of lifetime comorbid disorders. The clinical f-MDD sample showed most comorbid 
disorders, followed by the population-based f-MDD sample. The population-based 
nf-MDD sample showed least lifetime comorbid disorders. The patterns of lifetime 
comorbidity appeared to be dependent on familiality. F-MDD in the population 
sample was associated with significantly more comorbid dysthymia and alcohol-
related disorders compared to the nf-MDD sample. Comparing the clinical and 
population-based f-MDD samples showed that significantly more comorbid anxiety 
disorders and significantly less alcohol use disorders were present in the clinical 
sample. The MDD characteristics (age of onset, disease course and severity) did 
not substantially alter these findings. As familiality of MDD was associated with the 
presence of specific comorbid disorders, the conclusion can be drawn that it is an 
important factor to take into account in research into MDD etiology, as well as in the 
phenotypic description of MDD and in MDD treatment.
In chapter 3, potential gender differences in comorbidity were investigated in the 
population-based f-MDD and nf-MDD samples. In general, females reported 
significantly more comorbid dysthymia and anxiety disorders (in particular 
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Table  Overview of studies
Chapter Study
2 and 3 Familiality of MDD, comorbidity, and gender
4 Genetic association study of the 5-HTTLPR polymorphism in 
 comorbid disorders in MDD and the role of gender
5 Meta-analysis of the BDNF gene and MDD; roles of gender, 
 ethnicity and age
6 Genome-wide association study of neuroticism and the 
 influence of gender
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agoraphobia, panic disorder, GAD and specific phobias), whereas males reported 
more comorbid alcohol-related disorders. For some of the comorbid disorders, the 
gender differences were dependent on a familial history of MDD. Independent of a 
familial history of MDD were panic disorders (more often present in females in both 
f-MDD and nf-MDD) and alcohol-related disorders (more often present in males in both 
f-MDD and nf-MDD). The gender differences in dysthymia and GAD (more apparent 
in females with f-MDD than in f-MDD males), and specific phobias and agoraphobia 
(more in females with nf-MDD than in nf-MDD males) were dependent on familiality 
of MDD. Again, taking the MDD characteristics into account did not substantially alter 
the gender differences in comorbidity. These findings imply that models to explain 
comorbidity may differ by gender and that familiality of MDD should be taken into 
account when analyzing gender differences in MDD comorbidity. This is important 
for a better understanding of both phenotypic expressions of the disorder and the 
etiology and segregation of comorbid disorders. As in chapter 2, the conclusion 
from chapter 3 is that it might be useful to use comorbid diagnoses to define more 
genetically homogeneous forms of MDD for molecular genetic studies. In addition, 
this chapter suggests that taking gender into account might be of importance.
The exploratory study described in chapter 4 gives an example of what can be 
achieved by using the guidelines laid down in the earlier two chapters. Here, the 
association between the 5-HTTLPR polymorphism in the serotonin transporter gene 
(5-HTT) and MDD was investigated. Multiple association studies of the 5-HTTLPR 
polymorphism with MDD have been performed to date, but with inconsistent results. 
The current exploratory study investigated MDD plus comorbid disorders in a sample 
of familial MDD cases, the clinical GenMood sample. The analyses were stratified for 
gender to test the hypothesis that gender-specific associations exist for the 5-HTTLPR 
polymorphism. Association studies taking comorbid disorders into account have not 
been commonly reported in MDD, thus far.
In this study, lifetime comorbid GAD, dysthymia and alcohol use disorders were 
assessed by use of the CIDI and blood was taken for DNA extraction. For each of the 
comorbid disorders, MDD cases with a particular comorbid disorder were compared 
to all MDD cases without that specific comorbidity. MDD characteristics age of onset, 
severity and disease course were optionally included as covariates, as these MDD 
characteristics were found to be associated with comorbidity (Kendler et al., 1996; 
Rush et al., 2005; Sullivan et al., 1998).
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In 83.7% of MDD subjects, lifetime comorbid disorders were present. Association 
analyses of the 5-HTTLPR polymorphism showed an association specifically for 
MDD plus dysthymia, in that significantly more comorbid dysthymia was present 
in subjects homozygous for the l-allele of the polymorphism. The gender-specific 
association analyses showed that comorbid alcohol use disorders were significantly 
less often present in female s-carriers than in females not carrying an s-allele. Taking 
into account MDD characteristics did not change these findings.
Although the study was limited with regard to power given a rather small sample size 
and does need replication, it indeed supports the hypothesis that narrowing down 
the MDD phenotype by defining familial status, stratifying by gender, and considering 
the psychiatric phenotype with its comorbid disorders to create more homogeneous 
subgroups may help to clarify the relationship of genetic factors with disease.
Chapter 5 was also set up to test the impact of a better definition of the MDD 
phenotype on genetic association studies. Here, a meta-analysis was performed on 
all available case-control association studies on the Val66Met variant of the gene 
encoding the brain-derived neurotrophic factor (BDNF) in relation to MDD. This meta-
analysis is one of the largest on BDNF to date, and the first to explore the effects of 
gender, ethnicity and age on the association between this gene and MDD. Ethnicity 
was taken into account since both the BDNF Met allele frequency and the prevalence 
of MDD strongly differ between Asians and Caucasians.
In total, fourteen studies were eligible for inclusion in the meta-analysis, including 
2,812 cases with current or last-year MDD and 10,843 controls. Odds ratios were 
calculated for Met versus Val alleles, Met/Met versus Val/Val, and Val/Met versus Val/
Val genotypes.
As expected from three earlier meta-analyses, the results showed no overall 
association of the Val66Met polymorphism with MDD. However, a gender-specific 
effect was observed in which male Met carriers were significantly more likely to be 
depressed compared to males without any Met alleles. The ethnicity-dependent 
analyses did not show an ancestry-dependent association of the polymorphism with 
depression. The data also suggested an age effect, with elderly patients showing 
stronger associations between the BDNF Val66Met variant and MDD. Thus, age 
might modify the relationship between the Met allele and MDD.
In conclusion, this study again confirms that a better specification of MDD can help 
to clarify the role of a gene in disease etiology. Furthermore, our results suggested 
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that the BDNF Val66Met polymorphism is of greater importance in the development 
of MDD in males than in females. The effects of gender and age require further 
research. In addition, large primary studies should be performed to confirm or refute 
these findings.
Chapter 6 describes an alternative approach to identify the molecular basis of complex 
disorders, in this case MDD, i.e. using an endophenotype of MDD. Endophenotypes 
are defined as measurable components that lie intermediate between genes and 
the disorder (Gottesman & Gould, 2003). The personality trait of neuroticism was 
investigated in this study. This trait meets the proposed criteria for an endophenotype 
for MDD and has already been successfully used in genetic studies (Sen et al., 2003; 
Shifman et al., 2008; van den Oord et al., 2008). New genes for neuroticism were 
sought to be identified here by means of a genome-wide association study (GWAS). 
In GWA analyses, the entire genome is examined for association with a phenotype 
of interest after subjects have been genotyped for 315,000 up to 1,000,000 single 
nucleotide polymorphisms (SNPs).
A population sample from the Nijmegen Biomedical Study (NBS) was used for this 
GWAS of neuroticism. The short version of the Eysenck Personality Questionnaire 
(EPQ-RSS) was applied as a self-report measure of neuroticism. We hypothesized 
that gender-specific SNPs would be apparent, given that females generally score 
higher on the neuroticism trait than males. After quality control procedures, 301,596 
autosomal single nucleotide polymorphisms (SNPs) were available for analysis with 
a total genotyping rate of 99.6%.
Four SNPs were found associated with neuroticism at a nominal p-value of <10-5 in 
the entire sample, all of them located within known genes. The most significant result 
was SNP rs10930299 located within the STK39 gene. The three other SNPs were 
rs523604, located within the CXCR5 gene; SNP rs7000487, located within MTUS1 
and SNP rs687848 located within the MACF1 gene. The latter two genes have been 
found in linkage regions for harm avoidance (Cloninger et al., 1998) and MDD (Camp 
& Cannon-Albright, 2005). However, none of the findings remained significant after 
Bonferroni correction for multiple testing.
Gender-specific analyses for the above-mentioned SNPs did not reveal significant 
gender-specific effects. However, in the overall gender-specific analyses, 41 SNPs 
achieved nominal p-values smaller than 10-4, of which 18 were located within known 
genes. These SNPs were most often associated with an increase in neuroticism 
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scores in males and a decrease in scores in females. Five of them, located within 
the COX10, SUPT3H and RUNX2 genes, were interesting with regard to MDD, as they 
lay in linkage regions for this disorder (Middeldorp et al., 2008b; Nash et al., 2004; 
Wray et al., 2008). Our gender findings did not show overlap with the other two GWA 
studies as no exploration of gender-specific SNPs had been performed (van den 
Oord et al., 2008) or no gender-specific SNPs had been observed (Shifman et al., 
2008).
Despite the findings being insignificant when strictly correcting for multiple testing, 
we consider the results as promising as we do have evidence for the involvement 
of several of the observed regions in harm avoidance, MDD and other psychiatric 
disorders. However, more research will be needed to clarify the role of gender-
specific SNPs in neuroticism. In general, the genetic architecture of neuroticism is 
very complex and genes identified so far can only explain a small amount of the 
total genetic variance in neuroticism. Therefore, replication in large samples is clearly 
needed before any conclusions can be drawn. This GWAS of neuroticism may aid in 
the identification of MDD susceptibility genes, as neuroticism has been proposed as 
an endophenotype for MDD. However, the impact of the genes identified has to be 
formally tested for MDD.
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The chapters in this thesis aimed at studying which factors could serve to improve 
the depression phenotype for molecular genetic studies. To achieve this, several 
approaches investigating different factors were used, of which some had not been 
included in previous genetic studies. In all these approaches the role of gender was 
studied given the large gender difference in MDD prevalence. Accurate phenotyping of 
MDD and other psychiatric disorders is essential to improve power of genetic linkage and 
association studies and hence, to obtain more insight in the genetics of MDD. In general, 
a better understanding of the phenotype of MDD is of importance not only for etiological 
(genetic) studies but also for the clinical assessment, treatment and prevention of MDD. 
The results of the studies in this thesis add knowledge to the complexity of the MDD 
phenotype, to the genetics of MDD and its endophenotype neuroticism.
Below, the role of gender in both the phenotypic expression of MDD and in genetic 
studies is discussed. Furthermore, the use of meta-analytic strategies, the role of the 
BDNF gene in MDD and the use of endophenotypes and of genome-wide association 
studies are discussed. Finally, suggestions for future research are given.
The role of gender
The chapters in this thesis have investigated and described the role of gender, either in 
relation to familiality of MDD, comorbidity in MDD or in genetic association studies of 
MDD and neuroticism. Although the etiology of MDD (and comorbid disorders) shows 
overlap between genders (see also the etiologic developmental models for MDD by 
Kendler et al. 2002; 2006a), gender-specific etiologic factors are likely to exist, too. In 
general, there are several factors that could contribute to gender differences, among 
others, gender-specific genetic processes such as X chromosome inactivation, genomic 
imprinting and sex-specific meiotic events, differences in hormone programming both 
prenatal and in adolescence, gender differences in exposure and/or susceptibility to 
stress or adversity, gender differences in cognitive and affective coping styles and the 
accessibility of social support (Rutter et al., 2003).
The findings of the first two studies suggest that the phenotypic expression of MDD is 
dependent on both gender and familiality. Different comorbid disorders were present 
in males and females, being partly dependent on familiality of MDD. This suggests 
that different etiological models might explain comorbidity across gender and familial 
status. 8
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The three chapters exploring the molecular genetics of the disease (the 5-HTTLPR 
association study, the BDNF meta-analysis and the GWAS of neuroticism), have 
shown a major role for gender in the genetic determinants of MDD and related 
endophenotypes. Briefly, in the association study of the 5-HTTLPR polymorphism 
and MDD comorbidity, the presence of different comorbid disorders was associated 
with the polymorphism in males and females. A role for gender in MDD genetics also 
appeared from the meta-analysis, as the BDNF gene increased MDD susceptibility 
in males only. Furthermore, the GWAS of the MDD endophenotype neuroticism 
revealed gender-specific genetic effects with most of the associated SNPs leading to 
an increase in neuroticism scores in males, but a decrease in females.
All these studies indeed confirm the existence of a gender-specific biology of 
depression and neuroticism, which highlights the importance of stratifying for gender 
in future (molecular) genetic studies. What should be stated here is that gender-
specific analyses are not only interesting for traits and diseases that are known to 
have prevalence differences in males and females, but it could also yield insight 
in possible gender-specific etiology in diseases that are equally prevalent in both 
genders. Insight in gender-specific etiological processes might aid in developing 
targeted treatment and preventive strategies to lower the incidence, prevalence and 
the burden of MDD.
Meta-analytic strategies in genetic studies
Results of genetic association studies of the BDNF Val66Met polymorphism and other 
genetic variants with depression and other psychiatric phenotypes have shown to 
be highly inconsistent (Egan et al., 2003; Gratacos et al., 2007; Hariri et al., 2003; 
Lang et al., 2005; Sen et al., 2003). An approach to gain more knowledge of genetic 
effects in complex disorders can be achieved by performing genetic meta-analyses. 
With meta-analytic techniques, discrepancies in genetic studies can be resolved as 
more precise estimates of effect can be determined due to increased statistical power 
(Munafo & Flint, 2004; Trikalinos et al., 2008). Three published meta-analyses of the 
BDNF gene had earlier shown negative results for association with MDD (Chen et al., 
2008; Gratacos et al., 2007; Lopez-Leon et al., 2008). However, I hypothesized that 
inclusion of additional characteristics of the patients, in this case gender, ethnicity and 
age might change this result. In original studies, samples are often too limited in size to 
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stratify for certain characteristics. In meta-analysis, however, stratification for gender, 
age and ethnicity could contribute to more homogeneity within groups without loss of 
too much power, and hence increase the homogeneity of the study population.
This meta-analysis confirmed the absence of a significant genetic association 
between the BDNF Val66Met polymorphism and MDD. However, I was able to show 
that the Val66Met polymorphism is of importance in the development of MDD in 
males only. The possible explanations for the gender-specific effect of the BDNF 
Met allele in MDD development have already been discussed before. No clear effect 
for ethnicity in relation to the Val66Met polymorphism emerged, but evidence for a 
role of age was found. Thus, this study proofs that the absence of an overall genetic 
association effect does not indicate that there is no association at all.
An interesting finding for age appearing from this meta-analysis was the stronger 
association with MDD in elderly Met allele carriers. A similar role for age had been 
described in another meta-analysis of BDNF in MDD (Chen et al., 2008). It is unknown 
whether this age effect is actually related to MDD as the BDNF gene has also 
been described in association with cognitive aging (Mattay et al., 2008). Knowing 
that BDNF appears to be involved in both cognitive aging and MDD complicates 
interpretation of possible age effects; is the more pronounced association of BDNF 
and MDD in elderly subjects related to the presence of MDD or is it related to natural 
cognitive decline in the elder age? Or does it go hand in hand, with cognitive decline 
leading to depression or vice versa? Age-varying genetic associations have also 
been observed in relation to obesity (Lasky-Su et al., 2008a) where the strength of 
the genetic effect of a SNP in the ROBO1 gene on obesity was age-dependent. It is 
suggested that if age-varying effects are not considered in the selection of samples 
and the analyses, genetic associations may be missed (Lasky-Su et al., 2008a). So 
far, firm conclusions cannot be drawn regarding this possible age effect; this needs 
to be explored in future studies.
Altogether, this study has shown that stratification for gender, age and ethnicity in 
meta-analytic studies could lead to clarification of results as more homogeneous 
samples are investigated.
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The role of the brain-derived neurotrophic factor gene
(BDNF)
Several studies have been performed to study the involvement of the BDNF Val66Met 
polymorphism gene in MDD (Egan et al., 2003; Gratacos et al., 2007; Hariri et al., 
2003; Lang et al., 2005; Sen et al., 2003). So far, this has revealed inconsistent 
results. Both alleles have been implicated in different disease processes (Gratacos 
et al., 2007) and mixed results have been put forward within depression phenotypes 
and related measurements. Despite these inconsistent results for the involvement 
of the Val66Met polymorphism in MDD and the negative results of three meta-
analytic studies, the “neurotrophic hypothesis” of depression (Duman, 2004) and a 
review paper by Martinowich et al. (2007) have described a role for the BDNF gene 
in depression. Some evidence has indicated that BDNF might have different and 
perhaps opposing roles in the brain stress and brain reward systems (Martinowich et 
al., 2007). In addition, studies at the level of genetic neuroimaging (see below) have 
suggested effects of the BDNF Val66Met polymorphism on the activity/structure of 
brain regions linked to MDD, such as the hippocampus and the amygdala (Egan 
et al., 2003; Frodl et al., 2007; Hariri et al., 2003; Hariri et al., 2005). Functional MRI 
studies showed poorer episodic memory (a symptom that is often observed in MDD 
patients) in Met allele carriers compared to Val/Val homozygotes (Egan et al., 2003). 
Further, lower hippocampal volumes (Frodl et al., 2007; Pezawas et al., 2004) and a 
reduced hippocampal engagement during memory tasks (Hariri et al., 2003) have 
been observed in Met allele carriers. As said before, BDNF is also implicated in the 
process of aging. This clearly illustrates that the BDNF gene might affect several 
psychiatric disorders as well as processes and structures in the healthy brain. This 
points to the idea that candidate genes for a particular disorder could also serve as 
interesting candidate genes for other disorders. Performing genetic research with 
similar candidate genes across disorders could yield more insight in the effects 
of genes on psychopathology in general. In addition, investigating associations 
of different candidate genes within one disorder and performing gene by gene 
interaction studies (see also Pezawas et al., 2008) could also contribute to a better 
understanding of the underlying mechanism of disease.
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A genome-wide association study of neuroticism
An alternative approach to identify the molecular basis of complex human disease 
phenotypes is the study of endophenotypes which is thought to resolve part of the 
phenotypic heterogeneity in complex psychiatric phenotypes (Gottesman & Gould, 
2003). The neuroticism personality trait meets the criteria for an endophenotype for 
MDD and has been regularly studied in genetic linkage and candidate gene studies 
(Du et al., 2000; Fullerton et al., 2003; Munafo et al., 2003; Nash et al., 2004; Sen 
et al., 2003), but only in a limited number of GWA studies (Shifman et al., 2008; van 
den Oord et al., 2008). Therefore, a GWAS of neuroticism was performed to identify 
new candidate genes for MDD, taking into account potential gender-specific genetic 
associations in this personality trait. In addition, this GWAS was compared to the 
earlier GWA studies of neuroticism (Shifman et al., 2008; van den Oord et al., 2008).
This GWAS of neuroticism identified four SNPs of interest, all located within known 
genes that have been described to be located within linkage regions for MDD, harm 
avoidance and/or other psychiatric phenotypes (Camp & Cannon-Albright, 2005; 
Cloninger et al., 1998). The other two GWAS (Shifman et al., 2008; van den Oord 
et al., 2008) identified different SNPs, located in other genes. Comparison of the 
GWA studies of neuroticism showed that there were no similarities in the top SNP 
findings. Conversely, the top SNPs in the Shifman et al. (2008) and van den Oord et 
al. (2008) studies did not show significant association findings for neuroticism in our 
study, either. Apparently, this hypothesis-free genetic approach did not lead to similar 
results in several GWA studies designed to measure the same personality trait.
There are two issues that can be discussed in this approach: 1) the use of 
endophenotypes in genetic studies and 2) the use of genome-wide association 
designs to detect genetic effects.
Regarding the first, when the concept of endophenotypes was introduced in 
psychiatric genetics, this approach was regarded as very promising. Endophenotypes 
were assumed to have a simpler genetic architecture than the complex psychiatric 
phenotypes and genes related to the endophenotypes should therefore be easier 
to detect and show larger effect sizes compared to those related to the complex 
clinical phenotypes (Flint & Munafo, 2007). Nowadays, a number of endophenotype 
studies have been performed and from a meta-analysis of the COMT gene in relation 
to several endophenotypes (Flint & Munafo, 2007) it appeared that effect sizes may 8
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actually not be larger than for complex phenotypes and that the explained variation 
was still relatively small. Nevertheless, a genetic linkage study by our own group, 
using endophenotypes to identify genes for ADHD, did suggest that this approach is 
more powerful in identifying disease susceptibility loci than the use of conventional 
clinical phenotypes or disease symptoms (Rommelse et al., 2008). Therefore, 
endophenotypes could aid in revealing internal disease pathways and contribute to 
the understanding of the genetic architecture of MDD. A challenging factor in this field 
is the study of how an endophenotype genetically relates to a complex phenotype. 
Therefore, it is interesting to investigate whether genome-wide studies of neuroticism 
and of depression would yield overlapping results.
Regarding the second issue, the use of genome-wide association designs to detect 
genetic effects, it might be too early to comprehensively evaluate its pros and cons as 
it is a relatively new approach. Though, a few are mentioned here. GWAS have been 
successful in finding genes for complex disorders. There have been already nearly 
100 genome-wide significant associations reported for common diseases and traits, 
including psychiatric disorders (Ferreira et al., 2008; Lasky-Su et al., 2008b; Manolio 
et al., 2008). In GWA studies, only a few of the 300,000 or more SNPs contribute to 
the trait or phenotype of interest with a relatively small effect. For example, in van den 
Oord et al. (2008), the four top SNPs only explained 0.25 to 0.40% of the total variation 
of neuroticism. Further, only a very limited number of SNPs do pass the correction 
tests for multiple testing. Overall, this does not contribute to a broad insight in the 
genetics of a particular trait. However, the top SNPs that do pass the multiple testing 
methods might give valuable information regarding candidate genes for the outcome 
of interest. Therefore, more insight in the mechanism of action and the biological 
processes of the candidate genes is needed. Overall, GWA findings can aid in the 
development of further research plans, such as the search to new candidate genes 
for neuroticism or any other trait.
Suggestions for further research
In this thesis, several phenotypic and genetic studies of MDD have been described 
with an emphasis on the role of gender, ethnicity, age, familiality and comorbidity. 
The implications for further research have partly been described above, but I will 
elaborate on them below. What did the different studies tell us?
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The first two studies recommended distinguishing subjects with familial MDD from 
subjects without familial MDD as we have shown that familial and nonfamilial MDD 
cases differ in the presence of lifetime comorbid disorders. An important factor that 
could improve knowledge of the segregation of MDD and related comorbid disorders 
is the assessment of psychiatric disorders in both probands and their relatives. It is 
largely unknown how psychiatric disorders in relatives influence psychopathology 
in probands. This is of importance given that e.g. a comorbid anxiety disorder in a 
mother might predispose a child to develop MDD (Olino et al., 2006).
Another important issue is the accuracy of family history methods for the assessment 
of familiality of MDD and other psychiatric disorders in first-degree relatives. Having 
a complete overview of the presence of MDD and associated comorbid disorders in 
family members might aid to better insights in the clustering of psychiatric disorders. 
Future research should focus on the presence and segregation of comorbid 
disorders in relatives, in addition to the psychopathology in probands, to evaluate 
which phenotypes are informative for genetic studies.
This thesis has also shown the influence of taking comorbid disorders into account in 
the MDD phenotype in genetic studies. In other psychiatric disorders, like ADHD, the 
benefits of performing genetic studies of single ADHD versus ADHD plus a comorbid 
disorder have already been described (Thapar et al., 2006; Zhou et al., 2008). In MDD 
research this is relatively new; additional studies could shed more light on this issue. 
For such studies, large samples with clearly defined phenotypes are necessary.
The benefits of performing meta-analytic genetic studies have already been proven 
(Lopez-Leon et al., 2008; Munafo & Flint, 2004; Schinka et al., 2004; Trikalinos et al., 
2008). It has been shown to be a good approach to detect valid genetic effects in 
psychiatric disorders and other traits, as sample sizes and power are larger than in 
original studies. However, a disadvantage is that each original study has its own sample 
selection strategy. The meta-analytic study in this thesis has shown that the absence 
of an overall genetic association effect does not necessarily indicate that there is no 
association at all. The association might only be observable in subgroups. Stratification 
for certain sample characteristics such as gender and age could give more insight in 
the data. Therefore, sample sizes that allow subgroup analyses are recommended.
Whereas meta-analytic strategies allow evaluation of known candidate genes, non-
hypothesis driven genome-wide studies are necessary to identify new candidates. 
In general, genome-wide association studies appeared a good means of identifying 8
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candidate genes of neuroticism, MDD and other traits and complex disorders. 
Findings of GWA studies could give direction to future candidate gene studies. 
The GWAS of neuroticism in this thesis has shown that gender-specific analyses 
could provide additional value. Again, power issues should be taken into account. 
Replication studies are necessary to confirm or refute earlier GWAS findings and 
are dependent on several factors; 1) sample recruitment, 2) sample size, 3) ethnic 
background and other demographic variables, 4) the method of phenotyping, 5) the 
choice of genotyping platforms and 6) the choice of software programs for analysis. 
Using replication samples that are grossly similar to the initial study sample on the 
above-mentioned grounds and having a similar mean age and gender distribution 
are recommended. An additional step in future GWAS should be the investigation of 
how certain SNPs or genes might contribute to disease pathology, i.e. it is important 
to obtain knowledge of the underlying biological mechanisms of the genes.
Whereas endophenotypes based on personality traits may be used to increase 
power of genetic studies aimed at identifying MDD candidate genes, as I showed 
in this thesis, a relatively new approach that could contribute even more insight into 
the genetics of MDD is the field of imaging genetics. Brain endophenotypes for 
psychiatric disorders, based on MRI designs measuring brain structure or activity, 
are used in order to detect the role of genetic factors (de Geus et al., 2008). The 
underlying assumption is that these neuroimaging phenotypes allow the estimation of 
genetic effects at neural system levels related to brain processes that are biologically 
closer to gene function than behavioral phenotypes are (de Geus et al., 2008; Mattay 
et al., 2008). Important candidate genes for genetic imaging are those impacting on 
neurotransmission metabolism, reuptake, release and receptor density and affinity, 
and those involved in brain morphogenesis and neurodevelopment (de Geus et al., 
2008). So far, genetic imaging studies have revealed interesting findings regarding 
the BDNF and 5-HTT genes (Aleman et al., 2008; de Geus et al., 2008). For example, 
an fMRI study in healthy female volunteers measuring amygdala activity in response 
to emotional and neutral stimuli showed higher amygdala activation in BDNF Met 
allele carriers in response to emotional stimuli in comparison to Val-homozygotes, 
which indicates involvement of the Met allele in emotional processing (Montag et 
al., 2008). A neuroimaging study investigating the 5-HTTLPR polymorphism yielded 
evidence for the s-allele to bias amygdala reactivity in the context of emotional tasks 
and suggested this polymorphism to be a susceptibility factor for MDD (Hariri et al., 
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2005). A large advantage of genetic imaging studies is that different measurements 
of brain function within a single subject, or the effect of a particular candidate gene 
on multiple brain systems can be obtained in a single session (Mattay et al., 2008). 
Furthermore, due to the higher power of these studies to detect genetic associations 
less subjects are needed than in conventional genetic association studies. On the 
other hand, due to the small samples, statistical power is often too low to stratify 
analyses for factors like age, gender or ethnicity. Incorporation of genetic imaging in 
current research could lead to better insights in disease etiology.
Another field that has not been explored in this thesis, but could be expected to 
give more insight in the etiology of MDD may be sought in incorporating the role of 
environmental factors in genetic studies (G x E interaction) as well as the investigation 
of epistasis (gene by gene interaction) between candidate genes.
The results of this thesis add to the discussion regarding the use of DSM and ICD 
handbooks in phenotyping subjects. These handbooks provide disease descriptions 
based on the presence or absence of particular symptoms. Overlap in symptoms 
between different psychiatric disorders is largely neglected and if subjects do not 
fulfill sufficient criteria for a certain disease they are not diagnosed, despite suffering 
or experiencing impairments in daily functioning. Another disadvantage of the current 
classification systems is that they do not provide insight in the etiology of psychiatric 
disorders, nor do they describe psychopathological processes. Therefore, they are 
not suitable for use as a guide in establishing phenotypes for genetic studies. More 
attention to the etiology of psychiatric disorders in these handbooks is essential 
as this might guide in treating the cause(s) of a disorder (instead of treating the 
consequences, e.g. symptoms).
Conclusion
Adequate phenotyping strategies are an important means in unraveling the genetic 
etiology and could guide in making samples for genetic studies more similar. The 
studies in this thesis have shown which factors act upon the MDD phenotype. Overall, 
gender, age, ethnicity, familiality of MDD and the presence of comorbid disorders 
appeared potential variables for both selection and stratification of samples. 8
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The approaches and factors to redefine and choose adequate MDD phenotypes 
for genetic studies of MDD that have been described in this thesis are to be 
recommended, but elaboration on these approaches is certainly necessary.
In molecular genetic studies of MDD, I would recommend to use samples with either 
familial MDD cases or nonfamilial MDD cases, and to clearly define the phenotype 
of interest. This aids in the inclusion of genetically more homogeneous forms of 
MDD. As gender appeared to be an important determinant in both the phenotypic 
expression of MDD and in genetic factors related to both MDD and neuroticism, I 
recommend to always take gender into account in depression research. Performing 
gender-specific analyses of susceptibility genes involved in familial and nonfamilial 
MDD with and without comorbid disorders will provide a better understanding of the 
expression of disorders and the clustering and etiology of comorbid disorders. To 
be able to do this, large sample sizes are needed that make stratification for gender 
and other variables possible without losing statistical power. For genetic studies, and 
especially for GWA studies, very large adequately powered sample sizes are needed 
and replication studies are necessary. To achieve this, consortium approaches and 
collaboration between researchers will be necessary.
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Iedereen weet wat een depressie of dipje is en iedereen heeft er wel eens last van. 
Iemand voelt zich somberder dan anders en heeft minder energie en/of zin om 
activiteiten te ondernemen. In de meeste gevallen gaat het dan om een dip en niet 
om een depressie in engere zin. In dit proefschrift gaat het over ernstige depressies 
(MDD) waarbij de aandoening voldoet aan de criteria van een classificatiesysteem om 
psychiatrische stoornissen vast te stellen (Diagnostic and Statistical Manual of Mental 
Disorders, ook wel DSM-IV genoemd) en waarbij sprake is van substantieel lijden.
Depressie is een van de meest voorkomende psychiatrische aandoeningen met een 
lifetime prevalentie (het percentage mensen dat ooit op enig moment in het leven een 
depressie heeft gehad) van 15 tot 17 procent. Het zorgt voor aanzienlijke ziektelast en 
sterfte. Daarnaast drukt de ziektelast zwaar op families en de maatschappij en brengt 
het hoge ziektekosten met zich mee. De Wereldgezondheidsorganisatie (WHO) heeft 
voorspeld dat in het jaar 2020 depressie een van de meest voorkomende ziekten is, 
zowel onder somatische als psychiatrische aandoeningen.
Bij vrouwen komen depressies vaker voor dan bij mannen (ratio 1.7; 1). Dit gender-
verschil in depressieprevalentie wordt wereldwijd gerapporteerd, maar de algemene 
prevalentie is niet overal even hoog. Zo worden in Aziatische culturen depressies 
aanzienlijk minder gerapporteerd (2 tot 3 procent) dan in westerse samenlevingen.
Symptomen die een depressie kenmerken zijn: interesseverlies, somberheid, een leeg 
of depressief gevoel, energieverlies en vermoeidheid, minder of juist meer eetlust hebben 
dan gewoonlijk, veel slapen of moeite hebben om in en door te slapen, het hebben van 
onterechte schuldgevoelens, verminderd concentratievermogen of besluitenloosheid 
en gedachten aan de dood of plannen tot zelfdoding. Deze symptomen komen in 
wisselende samenstellingen voor.
Een depressieve stoornis komt zelden geïsoleerd voor. Vaak hebben mensen met een 
depressie ook andere (comorbide) psychiatrische aandoeningen. De aanwezigheid van 
comorbide stoornissen is eerder regel dan uitzondering. Twee derde van de personen 
met een lifetime depressie heeft minstens één comorbide psychiatrische aandoening. 
Voornamelijk gegeneraliseerde angststoornissen (GAD) en andere angststoornissen, 
dysthymie en alcoholmisbruik en -afhankelijkheid komen veelvuldig voor. Ook in de 
prevalentie van comorbide stoornissen komen genderverschillen voor. Zo rapporteren 
vrouwen voornamelijk angststoornissen (zoals specifieke fobieën) en eetstoornissen, 
terwijl mannen voornamelijk middelenmisbruik en -afhankelijkheid rapporteren. 
Ook hebben vrouwen vaker dan mannen drie of meer comorbide stoornissen.
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Depressie is een multifactoriële aandoening met een complexe etiologie. Meerdere 
genen met een relatief klein effect spelen een rol in het ontstaan van depressie. 
Daarnaast kunnen omgevingsfactoren een risico vormen op de ontwikkeling van 
depressies, evenals interacties tussen genen en omgevingsinvloeden (G x E). 
Veel onderzoek naar de etiologie van depressie richt zich dan ook op het verkrijgen van 
inzicht in zowel genetische- en omgevingsfactoren als interacties tussen deze factoren.
Aan de hand van familie- en tweelingstudies is de erfelijkheid van depressie geschat 
op ongeveer 35 procent. Deze studies tonen aan dat eerstegraads familieleden van 
depressieve personen ongeveer een drie keer grotere kans hebben op de ontwikkeling 
van een depressie in vergelijking met personen waarbij geen depressie in de familie 
voorkomt. Studies naar verschil in erfelijkheid van depressie tussen mannen en 
vrouwen laten inconsistente resultaten zien; in enkele studies wordt een hogere 
erfelijkheid voor vrouwen gerapporteerd, terwijl in andere studies geen verschil wordt 
gevonden voor mannen en vrouwen. Over het algemeen wordt aangenomen dat 
mannen en vrouwen een deel van de genetische risicofactoren voor depressie delen, 
maar ook dat een deel genderspecifiek is.
Er bestaan verschillende methoden om genetisch onderzoek uit te voeren naar regio’s 
in het DNA en/of specifieke genen die mogelijk betrokken zijn bij depressie; dit zijn 
genetische koppelingstudies, ook wel linkage genoemd, en associatiestudies.
De linkage-methode is hypothesevrij. Bij linkage wordt gekeken of er binnen families 
sprake is van cosegregatie van een marker allel in het DNA met een specifieke 
aandoening. Als een bepaalde genetische marker vaker voorkomt bij familieleden die 
concordant zijn (beiden hebben de aandoening) dan bij familieleden die discordant 
zijn (hebben niet beiden deze aandoening) dan wordt gesproken van linkage tussen 
de marker en de ziekte; de genetische marker en de ziekte lijken gekoppeld voor te 
komen. Deze marker hoeft niet noodzakelijkerwijs de ziekteveroorzaker te zijn, het 
geeft een indicatie over de regio waarin het gen zich bevindt dat geassocieerd is 
met de ziekte. Om exacter te identificeren waar het met ziekte geassocieerde gen 
zich bevindt, kan aanvullend onderzoek worden verricht naar die specifieke regio. 
De huidige genetische koppelingstudies naar depressie laten geen eenduidig beeld 
zien; meerdere regio’s/loci zijn beschreven en enkele daarvan zijn gerepliceerd in 
andere onderzoeken. Sommige loci lijken in beide geslachten gerelateerd aan 
depressie, terwijl andere loci genderspecifiek lijken te zijn.
De tweede methode om moleculair genetisch onderzoek uit te voeren is associatie. 
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De associatiemethode omvat zowel kandidaatgen onderzoek als genome-wide 
associatie-onderzoek. Met deze designs kan onderzocht worden of er associaties 
bestaan tussen (functionele) genetische markers en een bepaalde ziekte.
Kandidaatgen onderzoek is gebaseerd op bevindingen uit eerdere linkage-, dier- of 
farmacologische studies (niet hypothesevrij). Varianten die mogelijk een rol spelen 
bij het ontstaan van depressie worden in kaart gebracht en bestudeerd. Zo is uit 
eerder onderzoek gebleken dat de neurotransmitter serotonine een rol speelt bij veel 
fysiologische functies zoals stemming en emotie, aandacht, slaap, eetlust, motoriek, seks 
en de hormoonhuishouding. Deze fysiologische functies zijn bij depressie veelal verstoord. 
Daarnaast zijn SSRI’s (antidepressiva die het serotonerge systeem beïnvloeden) effectief 
gebleken in het verminderen van depressieve klachten. Door deze bevindingen wordt 
een belangrijke rol toegekend aan de serotonerge neurotransmissie in de pathofysiologie 
van depressie. Een belangrijk kandidaatgen voor depressiegerelateerde fenotypen is het 
serotonine transporter gen (5-HTT). Dit gen (ook wel bekend als SLC6A4) bevindt zich 
op chromosoompositie 17q11.1-12. Een functioneel polymorfisme in de regulatieregio 
(promoter) van het 5-HTT gen is eerder in verband gebracht met depressie. Deze variant 
wordt aangeduid als het 5-HTTLPR polymorfisme. De korte variant (short allel; s) van 
dit polymorfisme is geassocieerd met verlaagde transcriptie en functie van serotonine 
in vergelijking met de lange variant (long allel; l). Dit leidt tot een lagere heropname van 
serotonine uit de synapsspleet waardoor onder andere de stemming en circadiane en 
neuroendocriene functies verstoord kunnen raken.
Een ander belangrijk kandidaatgen voor depressie is het brain-derived neurotrophic 
factor gen (BDNF). Het BDNF gen bevindt zich op chromosoom 11 (p13). BDNF is een 
neurotrofine en speelt een rol in de proliferatie, differentiatie en overleving van neuronale 
cellen en het reguleert synaptische plasticiteit en connectiviteit in de hersenen. BDNF 
komt in veel delen van de hersenen voor, voornamelijk in de hippocampus. Volgens 
de neurotrofe hypothese van depressie is een verminderde aanwezigheid van BDNF 
geassocieerd met de pathofysiologie van depressie. Ook is aangetoond dat het 
gebruik van antidepressiva leidt tot een toename van BDNF in de hippocampus. Een 
single-nucleotide polymorfisme (SNP) op exon 11 van het BDNF gen is voornamelijk in 
verband gebracht met depressie. Het gaat om een aminozuursubstitutie van valine in 
methionine op codon 66, vandaar de naam van deze SNP; Val66Met.
Voor beide kandidaatgenen zijn verscheidene moleculair genetische studies 
uitgevoerd naar associatie met depressie, maar deze leveren tot op heden 
inconsistente resultaten op. De meta-analyses naar deze varianten zijn ook 
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inconsistent. Wat betreft het 5-HTTLPR polymorfisme lijkt er overwegend bewijs te 
zijn dat het korte allel het risico op depressie vergroot, terwijl onzeker is of het BDNF 
Val dan wel BDNF Met allel een verhoogd risico geeft op depressie.
Met genome-wide associatiestudies (GWAS) kan hypothesevrij genetisch onderzoek 
uitgevoerd worden naar associatie tussen genetische markers en een ziektebeeld 
over het gehele genoom. Hiermee kunnen risicogenen voor depressie en andere 
aandoeningen worden geïdentificeerd. GWAS is een vrij nieuwe, veelbelovende 
methode. Er worden voor GWA-studies honderdduizenden markers geïdentificeerd 
van het menselijk DNA. Door deze grote hoeveelheden is de verwerking van het 
DNA erg kostbaar.
Op het moment van schrijven zijn er nog geen GWAS van depressie gepubliceerd, maar 
er zijn wel GWAS uitgevoerd naar een kwetsbaarheidsfactor voor depressie, namelijk 
neuroticisme. Neuroticisme is een persoonlijkheidstrek die de mate van emotionele 
instabiliteit en negatief affect weerspiegeld. Een hoge mate van neuroticisme geeft 
een grotere kans op de ontwikkeling van psychopathologie. Neuroticisme kent een 
geschatte erfelijkheid van 30 tot 60 procent en is voornamelijk een risicofactor voor de 
ontwikkeling van depressieve- en angststoornissen. Uit eerder gepubliceerd GWA-
onderzoek naar deze persoonlijkheidstrek zijn verschillende nieuwe kandidaatgenen 
naar voren gekomen. De betrokkenheid van deze genen in relatie tot depressie moet 
nader onderzocht worden.
Aangezien in de etiologie van depressie ongeveer 35 procent van de variantie wordt 
verklaard door erfelijkheid, spelen omgevingsfactoren ook een rol bij het ontstaan 
van depressie. Het gaat daarbij voornamelijk om unieke omgevingsfactoren 
(individu-specifieke omstandigheden en gebeurtenissen) en minder om gedeelde 
omgevingsfactoren (omstandigheden/gebeurtenissen waaraan familieleden in 
dezelfde mate blootgesteld zijn). Enkele voorbeelden van omgevingsrisicofactoren 
zijn traumata (seksueel misbruik, verlies van een ouder en andere stressvolle 
gebeurtenissen), huwelijksproblemen of gescheiden zijn, financiële problemen of het 
ervaren van weinig sociale steun vanuit de omgeving. Naar deze omgevingsfactoren 
in relatie tot bepaalde kandidaatgenen wordt onderzoek uitgevoerd. Deze gen-
omgeving interactie (G x E) studies zijn de laatste jaren in opkomst en laten enkele 
veelbelovende resultaten zien voor depressie. De gedachte is dat genen de 
gevoeligheid voor omgevingsfactoren kunnen beïnvloeden. G x E studies hebben 
aangetoond dat bepaalde omgevingsvariabelen in de aanwezigheid van een bepaald 
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genotype kan leiden tot het ontstaan van depressie, terwijl dezelfde omgevingsfactor 
niet tot een depressie hoeft te leiden in de afwezigheid van datzelfde genotype.
Kortom, verschillende interessante genetische regio’s, kandidaatgenen en gen-
omgeving interacties zijn beschreven. Maar ondanks het grote aantal genetische 
studies naar zowel depressie als gerelateerde psychiatrische ziektebeelden is er geen 
eenduidig beeld ontstaan over genetische factoren in de etiologie van depressie. 
Dit kan meerdere redenen hebben, onder andere:
-  Depressie is een multifactoriële aandoening; het kan veroorzaakt worden door 
zowel genetische als omgevingsinvloeden en interacties hiertussen,
-  Depressie is een polygenetische aandoening; het wordt veroorzaakt door een 
samenspel van meerdere genen en mogelijke interacties hiertussen,
-  Depressie is een diagnostisch heterogene aandoening; de ziekte manifesteert 
zich op uiteenlopende manieren, het ziektebeeld van depressie kan sterk variëren 
van persoon tot persoon,
-  Er is sprake van een hoge mate van comorbiditeit; vaak zijn er andere psychiatrische 
stoornissen aanwezig waardoor de uitkomstmaat van associatiestudies kan 
worden beïnvloed,
-  Depressie komt niet even vaak voor bij mannen en vrouwen, gender kan een rol 
spelen in etiologie,
-  Etniciteit kan een rol spelen; de prevalentie van depressie is mede afhankelijk 
van etnische afkomst. Daarnaast kunnen allelfrequenties verschillen tussen 
uiteenlopende etnische groepen.
De factoren die inconsistenties in genetisch onderzoek veroorzaken moeten in kaart 
gebracht worden om beter inzicht te verkrijgen in de etiologie van depressie. De studies 
in dit proefschrift zijn uitgevoerd om te bestuderen of moleculair genetische studies naar 
MDD verbeterd kunnen worden door het MDD fenotype te herdefiniëren en te onderzoeken 
met welke factoren rekening gehouden moet worden in genetisch onderzoek.
Hiertoe zijn de rol van familialiteit van depressie, de aanwezigheid van comorbiditeit bij 
depressie en moleculair genetische aspecten van depressie bestudeerd, met speciale 
aandacht voor de rol van gender binnen deze relaties. Meer specifieke doelen waren 
1) het onderzoeken of familialiteit van MDD gerelateerd is aan verschillende patronen 
van comorbiditeit in MDD en of deze patronen beïnvloed worden door gender, 2) het 
uitvoeren van een associatiestudie naar een kandidaatgen voor MDD in relatie tot 
MDD plus comorbide stoornissen, 3) meer inzicht verkrijgen in de rol van het BDNF 
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gen in relatie tot depressie en 4) het uitvoeren van een genome-wide associatiestudie 
naar neuroticisme dat een kwetsbaarheidsfactor vormt voor MDD.
Studies en resultaten proefschrift
Voor de hoofdstukken in dit proefschrift werden drie verschillende cohorten gebruikt.
Het eerste cohort is verzameld in het kader van een klinische studie naar de genetica 
van depressie, de GenMood studie. Personen met depressie in engere zin en met een 
familiale gevoeligheid voor depressie (minstens één eerstegraads familielid met een 
depressie in de voorgeschiedenis) werden geworven voor deelname aan deze studie. 
Voorwaarde was dat voorouders van Nederlandse afkomst waren. Personen die voldeden 
aan de inclusiecriteria werden gefenotypeerd op basis van een diagnostisch interview 
en temperamentsvragenlijsten. Daarnaast werd een (neuro)cognitieve testbatterij 
afgenomen, werden endocrinologische metingen uitgevoerd en zelfrapportage 
vragenlijsten over levensstijl en life-events ingevuld. Ook vond een bloedafname plaats 
voor genotypering. Familieleden van deze deelnemers werd gevraagd ook deel te 
nemen. Ongeveer 200 families zijn op deze wijze in kaart gebracht.
Het tweede cohort is een bevolkingscohort dat in het kader van de NEMESIS studie 
(Netherlands Mental Health Survey and Incidence Study) is verzameld door het 
Trimbos-instituut. NEMESIS is een studie naar de prevalentie, incidentie, het verloop 
en de determinanten van psychiatrische stoornissen in een representatieve groep 
Nederlandse volwassenen. De eerste meting, waaraan 7.076 individuen deelnamen, 
vond plaats in 1996. De gegevens van deze meting zijn gebruikt voor de studies in 
dit proefschrift. Uit deze meting werden personen met lifetime MDD geselecteerd en 
verdeeld in twee subgroepen: een groep personen waarvan minstens één familielid 
ook lifetime MDD had (familiale MDD: f-MDD) en een groep personen met lifetime 
MDD zonder aangedane eerstegraads familieleden (niet-familiale MDD: nf-MDD).
Het derde cohort is verzameld in het kader van de Nijmegen Biomedische 
Studie (NBS). Het doel van de NBS is het verkrijgen van prevalentiecijfers als 
referentie voor onderzoek bij patiënten. Er werd 22.000 inwoners van Nijmegen en 
omgeving gevraagd deel te nemen. Vragenlijsten over lichamelijke activiteit, roken, 
alcoholgebruik, vermoeidheid, doorgemaakte ziekten en medicijngebruik werden 
ingevuld. Tevens vond er een bloedafname plaats. Deze gegevens zijn verzameld 
tussen 2001 en 2003.
In de eerste studie (hoofdstuk 2) is onderzocht of patronen van comorbide as I 
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stoornissen anders zijn bij personen met een familiale depressie (f-MDD) dan bij 
personen zonder familiale depressie (nf-MDD). Ook werd bestudeerd of klinische 
kenmerken van depressie zoals de ontstaansleeftijd, de ernst en het beloop 
(eenmalige of terugkerende episoden) van invloed waren op patronen van 
comorbiditeit bij personen met f-MDD en nf-MDD. Hiervoor werden drie groepen 
met elkaar vergeleken, de nf-MDD en f-MDD populatiegroepen (NEMESIS) en de 
klinische f-MDD groep (GenMood).
Met behulp van een gestandaardiseerd diagnostisch interview (CIDI; Composite 
International Diagnostic Interview) werden depressie en comorbide stoornissen in 
kaart gebracht. Met logistische regressie-analyse werd gekeken naar de invloed van 
familialiteit op de aanwezigheid van comorbide stoornissen bij depressie.
Deze studie toonde aan dat in de klinische f-MDD groep de meeste comorbide 
stoornissen voorkwamen, gevolgd door de populatie f-MDD groep. De nf-MDD 
groep rapporteerde de minste comorbiditeit. Verder bleek dat personen met f-MDD 
andere comorbide stoornissen rapporteerden dan personen met nf-MDD. Zo 
kwamen dysthymie en alcoholgerelateerde stoornissen significant vaker voor in 
de populatie f-MDD groep dan in de nf-MDD groep. In de klinische f-MDD groep 
kwamen bijna alle comorbide stoornissen (met uitzondering van agorafobie en 
alcoholgerelateerde stoornissen) significant vaker voor dan in de nf-MDD groep. 
Vergelijking van de populatie f-MDD groep met de klinische f-MDD groep toonde aan 
dat voornamelijk angststoornissen (paniekstoornissen, sociale en specifieke fobieën, 
GAD en obsessief-compulsieve stoornissen) significant vaker voorkwamen in de 
klinische groep dan in de populatiegroep, terwijl alcoholgerelateerde stoornissen 
juist vaker voorkwamen in de populatiegroep. De klinische kenmerken van depressie 
(ontstaansleeftijd, ernst, beloop) bleken de aanwezigheid van comorbide as I 
stoornissen nauwelijks te beïnvloeden.
De bevinding dat familialiteit van depressie invloed heeft op de aanwezigheid van 
comorbide psychiatrische stoornissen is van belang voor inzicht in het depressie-
ziektebeeld, het effectief behandelen van deze groep en voor het opzetten van 
moleculair genetische studies.
In de tweede studie (hoofdstuk 3) werd bekeken of er genderverschillen in de 
prevalentie van comorbide as I stoornissen in de f-MDD en de nf-MDD populatie-
groepen (NEMESIS) bestaan. De aanwezigheid van comorbide stoornissen werd in 
kaart gebracht met het CIDI interview.
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De prevalentie van comorbide stoornissen was hoger in de f-MDD groep dan in 
de nf-MDD groep. Bij vrouwen kwamen significant meer comorbide dysthymie 
en angststoornissen voor (voornamelijk agorafobie, paniekstoornissen, GAD en 
specifieke fobieën), terwijl bij mannen met depressie voornamelijk comorbide 
alcoholgerelateerde stoornissen aanwezig waren.
Bij enkele comorbide aandoeningen bleken genderverschillen afhankelijk te zijn van 
familialiteit van depressie, terwijl bij andere comorbide stoornissen genderverschillen 
aanwezig waren onafhankelijk van de familialiteit van depressie. Zo rapporteerden 
vrouwen met f-MDD significant vaker comorbide dysthymie en GAD dan mannen 
uit dezelfde groep. Vrouwen met nf-MDD rapporteerden significant vaker comorbide 
specifieke fobieën en agorafobie dan nf-MDD mannen. De ontstaansleeftijd van 
depressie, het beloop van de aandoening en de ernst van de depressie beïnvloedden 
de genderverschillen in comorbide stoornissen niet.
Paniekstoornissen bleken onafhankelijk te zijn van familialiteit; zowel in de f-MDD 
als de nf-MDD groep kwam dit significant vaker voor bij vrouwen. Alcoholgebruik 
en -afhankelijkheid kwamen daarentegen significant vaker voor bij mannen in beide 
groepen.
Dit is de eerste studie die genderverschillen in comorbiditeitspatronen beschrijft 
in depressie met inachtneming van familialiteit van depressie. Hieruit blijkt dat de 
aanwezigheid van depressie in de familie van invloed is op de genderverschillen in 
de prevalentie van comorbiditeit. 
Deze bevindingen suggereren dat verklaringsmodellen voor comorbiditeit kunnen 
verschillen per gender en dat familialiteit van MDD in acht genomen moet worden 
als genderverschillen in comorbiditeit in MDD geanalyseerd worden. Tevens is dit 
van belang voor een beter begrip van de fenotypische expressie van psychiatrische 
stoornissen en voor meer inzicht in de etiologie en segregatie van comorbide 
stoornissen in mannen en vrouwen met en zonder familiale depressie. Ook voor 
behandel- en preventiedoeleinden is meer inzicht in de achtergrond van depressie 
met comorbiditeit van belang. Deze studie heeft implicaties voor de uitvoering van 
moleculair genetische studies. Mogelijk leidt de inclusie van comorbiditeit tot de 
definiëring van genetisch meer homogene typen van depressie. Tevens lijkt het van 
belang om gender te bestuderen.
In hoofdstuk 4 wordt een exploratieve associatiestudie beschreven waarin, zoals 
beschreven in de eerdere twee hoofdstukken, comorbiditeit in het MDD fenotype is 
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opgenomen. De associatie tussen het 5-HTTLPR polymorfisme in de promoter regio 
van het serotonine transporter gen (5-HTT) en de aanwezigheid van depressie met 
comorbide as I stoornissen werd onderzocht. In eerdere genetische associatiestudies 
is nauwelijks aandacht besteedt aan de aanwezigheid van comorbide stoornissen 
bij MDD.
Deze studie werd uitgevoerd in de klinische groep met familiale depressie (GenMood). 
Aan de hand van de CIDI werd de lifetime aanwezigheid van comorbide stoornissen 
vastgesteld (dysthymie, GAD en alcoholgerelateerde stoornissen) en bloed werd 
afgenomen voor DNA verwerking. De associatie tussen het 5-HTTLPR polymorfisme 
en depressie met een bepaalde comorbide stoornis werd in kaart gebracht. Hiertoe 
werden personen met MDD plus een bepaalde comorbide stoornis vergeleken 
met alle mensen met MDD zonder die bepaalde stoornis. De analyses werden 
gestratificeerd naar gender om de hypothese te toetsen dat er genderspecifieke 
associaties bestaan voor het 5-HTTLPR polymorfisme. De klinische kenmerken van 
MDD (ontstaansleeftijd, beloop, ernst) werden optioneel geïncludeerd als covariaten 
aangezien deze kenmerken geassocieerd bleken te zijn met comorbiditeit.
In deze f-MDD groep had 83.7 procent van de personen minstens één lifetime 
comorbide stoornis, voornamelijk GAD en dysthymie. De aanwezigheid van comorbide 
alcoholgerelateerde stoornissen was significant hoger in mannen dan vrouwen. 
Regressieanalyses toonden een associatie tussen het 5-HTTLPR polymorfisme en 
dysthymie; personen met een s-allel hadden significant minder vaak comorbide 
dysthymie dan mensen zonder s-allel. De genderspecifieke analyses toonden een 
associatie voor alcoholgerelateerde stoornissen waarbij vrouwelijke dragers van het 
s-allel significant minder vaak deze aandoening rapporteerden dan vrouwen zonder 
het s-allel. Uitvoering van dezelfde analyses zonder de klinische kenmerken van 
depressie veranderden de resultaten niet.
Ondanks de lage power van deze studie en de afwezigheid van replicatiestudies lijkt 
deze studie de hypothese te ondersteunen dat het verfijnen van het MDD fenotype 
met familiale status, het stratificeren naar gender en het includeren van comorbide 
stoornissen om meer homogene subgroepen te vormen, kan bijdragen aan meer 
inzicht in de relatie tussen genetische factoren en ziekte.
In hoofdstuk 5 wordt een meta-analyse beschreven naar de associatie van de 
Val66Met variant van het BDNF gen en depressie. Aan de hand van alle case-control 
associatiestudies naar deze variant (Val66Met) en depressie werd onderzocht of 
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geslacht, etniciteit en leeftijd een rol spelen in de relatie tussen dit kandidaatgen 
en depressie. De rol van etniciteit (Aziatisch versus Kaukasisch) werd onderzocht 
omdat zowel de prevalentie van depressie als de allel frequentie van het BDNF gen 
verschillend is in Aziaten (Met allel 40-50%) en Kaukasiërs (Met allel 25-32%).
Veertien van de 42 studies voldeden aan de inclusiecriteria voor deze meta-analyse. 
Dit resulteerde in 2.812 personen met een huidige depressie of een depressie in het 
afgelopen jaar en 10.843 niet-depressieve controles. Van alle studiegroepen werden 
zowel genotype (Met/Met, Val/Met en Val/Val) als allel (Met en Val) frequenties 
berekend voor de depressieve en controle personen. Hiermee werden odds ratios 
(ORs) berekend met het Val/Val genotype (of Val allel) als referentiegroep.
In de totale groep werd geen associatie tussen het Val66Met polymorfisme en MDD 
aangetoond. Dit komt overeen met de resultaten uit drie eerdere meta-analyses naar 
dezelfde variant. Een opvallende bevinding was echter dat de genderspecifieke 
analyses wel een associatie toonden met betrekking tot het BDNF gen. Het bleek 
dat mannen met een Met allel significant vaker depressies hadden dan mannen 
zonder Met allel. De resultaten suggereerden ook een effect voor leeftijd; oudere 
mensen toonden sterkere associaties tussen de Val66Met variant en depressie. 
Mogelijk beïnvloedt leeftijd de relatie tussen het Met allel en MDD. Daarentegen lieten 
de etniciteitspecifieke analyses geen significante associaties zien tussen de BDNF 
variant en depressie.
Deze meta-analyse is de grootste tot nu toe en de eerste die gender, etniciteit en 
leeftijd in beschouwing neemt. In eerdere, kleinere meta-analyses werden ook 
geen associaties gevonden tussen de BDNF variant en depressie. Dit laat zien dat 
de afwezigheid van een associatie tussen gen en ziekte niet inhoudt dat er geen 
genetische associatie is, deze kan namelijk aanwezig zijn in subgroepen.
De aanwezigheid van significante genderspecifieke associaties in de Val66Met 
variant in relatie tot depressie heeft implicaties voor toekomstig onderzoek, zoals 
het bestuderen van genderverschillen in genetische risicofactoren, in gen-omgeving 
interactie studies, en mogelijk voor het anders behandelen van mannen en vrouwen. 
Ook de rol van leeftijd in genetische studies moet nader bestudeerd worden.
Samengevat, deze meta-analyse laat zien dat een betere specificatie van het MDD 
fenotype de mogelijke rol van een gen in ziekte-etiologie kan verhelderen.
In hoofdstuk 6 wordt een genome-wide associatiestudie (GWAS) beschreven 
in relatie tot neuroticisme in de Nederlandse populatie. Neuroticisme is een 
samenvatting in het nederlands
195
persoonlijkheidstrek die wordt omschreven als emotionele instabiliteit, het hebben 
van een negatief affect en als predispositie voor het ervaren van angsten, depressie, 
schaamte en stress. Het is een kwetsbaarheidsfactor voor de ontwikkeling van 
depressie en andere psychiatrische ziektebeelden. Neuroticisme wordt gezien als 
een endofenotype voor MDD. Een endofenotype is een kwantificeerbaar kenmerk 
dat grotendeels genetisch bepaald is en gerelateerd is aan het klinische fenotype (de 
ziekte). De verwachting is dat endofenotypen beter te koppelen zijn aan genactiviteit 
omdat ze beter te definiëren zijn dan klinisch heterogene ziekten.
Met deze GWAS werd gezocht naar genen of SNPs (single nucleotide polymorphisms) 
die geassocieerd zijn met neuroticisme. Omdat vrouwen in het algemeen hoger 
scoren op neuroticisme dan mannen werd bekeken of er genderspecifieke SNPs 
waren in relatie tot deze persoonlijkheidstrek.
301.596 markers uit het DNA werden onderzocht in relatie tot de neuroticisme-score 
op een zelf in te vullen persoonlijkheidsvragenlijst; de verkorte versie van de Eysenck 
Personality Questionnaire (EPQ-RSS). De groep bestond uit 1.313 personen (49.6% 
mannen) van de Nijmegen Biomedische Studie (NBS). Vier SNPs werden geïdentificeerd 
die geassocieerd waren met neuroticisme (gelokaliseerd in de STK39, CXCR5, MTUS1 
en MACF1 genen). Na toepassing van een correctie omdat meerdere statistische 
testen werden uitgevoerd, bleken deze SNPs niet langer significant geassocieerd te 
zijn met neuroticisme. Aangezien de regio’s waarbinnen deze SNPs zich bevonden 
in eerdere studies geassocieerd bleken met onder andere depressie en bepaalde 
persoonlijkheidstrekken (harm avoidance) zijn ze interessant voor verder onderzoek.
De SNPs in bovengenoemde genen lieten geen overtuigende genderspecifieke 
resultaten zien. Daarentegen werden 41 andere genderspecifieke SNPs geïdentificeerd 
waarvan een aantal interessant bleken omdat ze gelokaliseerd zijn in genen 
(COX10, SUPT3H en RUNX2) die al eerder beschreven zijn in relatie tot depressie of 
gerelateerde maten. Over het algemeen bleken deze SNPs geassocieerd te zijn met 
een verhoging van de neuroticisme-score in mannen en een daling van de score 
in vrouwen. Vergelijking van deze genderresultaten met een eerder gepubliceerde 
GWAS naar neuroticisme liet geen overeenkomsten zien.
De genetische architectuur van neuroticisme is erg complex en de bevindingen van 
deze GWAS verklaren dan ook geen groot deel van de variantie in neuroticisme. 
De bevindingen zijn echter wel richtinggevend voor toekomstig onderzoek. 
Kandidaatgenstudies kunnen worden opgezet en replicatie in onafhankelijke 
studiegroepen kan plaatsvinden. Ondanks dat de resultaten insignificant werden nadat 
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de correctie voor multiple testing was toegepast, lijken het interessante regio’s te zijn 
aangezien in eerdere studies naar depressie en relateerde maten dezelfde regio’s 
beschreven zijn.
Deze GWAS toont het belang aan van het onderscheiden van mannen en vrouwen 
in genetische studies, maar meer studies zijn nodig om de rol van genderspecifieke 
SNPs in neuroticisme te verhelderen. Een belangrijke volgende stap in GWAS is meer 
inzicht verkrijgen in de biologische mechanismen die ten grondslag liggen aan de 
werking van de genen op psychopathologie. Deze GWAS naar neuroticisme kan 
bijdragen aan de identificatie van MDD kwetsbaarheidsgenen. Het is wenselijk om 
te onderzoeken welke SNPs en genen die geassocieerd zijn met neuroticisme ook 
associatie vertonen met depressie.
In de hoofdstukken 7 en 8 wordt vervolgens een samenvatting gegeven, worden 
de resultaten bediscussieerd en aanbevelingen gedaan voor toekomstig onderzoek 
naar depressie.
Conclusie
De studies in dit proefschrift laten zien dat meerdere factoren het depressie-fenotype lijken 
te beïnvloeden en van belang zijn in het detecteren van genetische associaties. Zo bleken 
gender, leeftijd, etniciteit, familialiteit en de aanwezigheid van comorbiditeit belangrijke 
variabelen in het samenstellen van de te onderzoeken groep en voor stratificatie binnen 
de statistische analyses. Een specificatie van het te onderzoeken fenotype leidt tot de 
inclusie van een genetisch meer homogene onderzoeksgroep.
Het uitvoeren van (genderspecifieke) analyses naar kwetsbaarheidsgenen voor familiale 
en niet-familiale depressies, met inachtneming van comorbide stoornissen, kan bijdragen 
aan een beter begrip van genetische fenotypen, de expressie van de aandoening en 
de clustering en etiologie van comorbide aandoeningen. Voor genetische studies, 
en voornamelijk voor GWA studies, zijn grote samples nodig, zodat stratificatie voor 
gender en andere variabelen niet leidt tot een verlies van statistische power. Daarnaast 
zijn replicatiestudies van belang. Samenwerkingsverbanden tussen consortia en 
onderzoeksgroepen en betere toegankelijkheid tot genetische data zouden hieraan 
kunnen bijdragen.
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